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I	
	
Preface	
“SOCRATES:	Well,	then,	let	us	see	in	what	way	the	self-existent	can	be	discovered	by	us;	that	
will	give	us	a	chance	of	discovering	our	own	existence,	which	otherwise	we	can	never	know.	
ALCIBIADES:	You	say	truly.	
SOCRATES:	Come,	now,	I	beseech	you,	tell	me	with	whom	you	are	conversing?	—	with	whom	
but	with	me?	
ALCIBIADES:	Yes.	
SOCRATES:	As	I	am,	with	you?	
ALCIBIADES:	Yes.	
SOCRATES:	That	is	to	say,	I,	Socrates,	am	talking?	
ALCIBIADES:	Yes.	
SOCRATES:	And	Alcibiades	is	my	hearer?	
ALCIBIADES:	Yes.	
SOCRATES:	And	I	in	talking	use	words?	
ALCIBIADES:	Certainly.	
SOCRATES:	And	talking	and	using	words	have,	I	suppose,	the	same	meaning?	
ALCIBIADES:	To	be	sure.	
SOCRATES:	And	the	user	is	not	the	same	as	the	thing	which	he	uses?	
ALCIBIADES:	What	do	you	mean?	
SOCRATES:	I	will	explain;	the	shoemaker,	for	example,	uses	a	square	tool,	and	a	circular	tool,	
and	other	tools	for	cutting?	
ALCIBIADES:	Yes.	
	
	
II	
	
SOCRATES:	But	the	tool	is	not	the	same	as	the	cutter	and	user	of	the	tool?	
ALCIBIADES:	Of	course	not.	
SOCRATES:	And	in	the	same	way	the	instrument	of	the	harper	is	to	be	distinguished	from	the	
harper	himself?	
ALCIBIADES:	It	is.	
SOCRATES:	Now	the	question	which	I	asked	was	whether	you	conceive	the	user	to	be	always	
different	from	that	which	he	uses?	
ALCIBIADES:	I	do.	
SOCRATES:	Then	what	shall	we	say	of	the	shoemaker?	Does	he	cut	with	his	tools	only	or	with	
his	hands?	
ALCIBIADES:	With	his	hands	as	well.	
SOCRATES:	He	uses	his	hands	too?	
ALCIBIADES:	Yes.	
SOCRATES:	And	does	he	use	his	eyes	in	cutting	leather?	
ALCIBIADES:	He	does.	
SOCRATES:	And	we	admit	that	the	user	is	not	the	same	with	the	things	which	he	uses?	
ALCIBIADES:	Yes.	
SOCRATES:	Then	the	shoemaker	and	the	harper	are	to	be	distinguished	from	the	hands	and	
feet	which	they	use?	
ALCIBIADES:	Clearly.	
SOCRATES:	And	does	not	a	man	use	the	whole	body?	
ALCIBIADES:	Certainly.	
SOCRATES:	And	that	which	uses	is	different	from	that	which	is	used?	
ALCIBIADES:	True.	
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SOCRATES:	Then	a	man	is	not	the	same	as	his	own	body?	
ALCIBIADES:	That	is	the	inference.	
SOCRATES:	What	is	he,	then?	
ALCIBIADES:	I	cannot	say.”	
(from	PLATONE,	Alcibiade	first,	F.	Adorno,	in	Opere	cit.,	vol.	V,	p.	81-83)	
What	is	a	man?	
Socrates	with	 the	word	 "man"	 includes/speaks	 of	 all	 he	 is	 concerned	with	 and	 puts	 great	
attention	to	the	thought	and	the	concept	of	soul.	Although	it	is	not	the	purpose	of	this	thesis	
to	deal	with	this	topic,	more	relevant	to	the	studies	of	metaphysics,	this	question	should	be	
kept	in	mind	and	used	as	a	background	guideline	along	this	work.		
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1.	State	of	the	art	
1.1	Microbiota	
1.1.1	The	super-organism	
In	 the	past	decades,	 the	 scientific	 community	has	made	progress	 in	 studying	not	only	 the	
physical	object	"human"	in	terms	of	its	innate	complexity	and	nature,	but	also	the	close	and	
fundamental	symbiosis	with	complex,	dynamic	communities	of	other	organisms.	
This	discovery	defined	a	new	realm	of	 individuality	called	a	 ‘super-organism’	or	 ‘holobiont’	
(Greek,	from	holos,	whole;	bios,	life;	-ont,	to	be;	whole	unit	of	life),	(Dheilly	2014;	Gilbert	2014)	
composed	of	host	cells	(or	human	body)	and	persistent	populations	of	symbionts	that	inhabit	
it	(de	Moreno	et	al.	2014).	These	complex,	ecological	symbiotic	communities	are	composed	
of	 commensal,	 symbiotic	 and	 pathogenic	 microorganisms,	 such	 as	 bacteria,	 fungi	 (mainly	
yeasts),	 protozoa,	 archaea,	 and	 viruses	 (mainly	 bacteriophages)	 (Ferranti	 et	 al.	2014).	 The	
whole	system	is	entitled	“microbiota”.		The	microbiota	is	located	at	different	sites	of	human	
body,	mainly	the	ones	exposed	to	the	outer	world,	(e.g.	gastrointestinal	tract,	skin,	oral	and	
nasal	 cavity,	 vagina	 and	 urogenital	 apparatus,	with	more	 than	 70%	 of	 all	microbes	 in	 the	
human	body	situated	 in	the	colon).	 It	 is	estimated	that	the	number	of	the	microorganisms	
residing	in	the	gastrointestinal	tract	is	likely	10	times	higher	than	the	number	of	somatic	cells	
composing	the	whole	body	(approximately	100	trillion	(Sandrini	et	al. 2015).	They	add	1.5-2	
kg	to	the	total	body	weight	and	their	gene	content,	called	microbiome,	is	about	150-200	times	
larger	than	that	of	the	human	genome	(Gilbert 2014).	
In	conclusion,	the	"super-organism"	is	the	new	subject	to	be	investigated	in	order	to	answer	
the	question	"what	 is	a	man?"	and	the	 topic	has	 to	be	approached	by	using	 the	“complex	
systems	theory”.	
	
	
2	
	
A	“complex	system”	is	defined	as	the	structure	in	which	individual	parts	are	affected	by	short-
range	 interactions	which	 lead	 to	 changes	 in	 the	overall	 system.	The	 inability	 to	 study	as	a	
whole	system,	leaves	us	with	one	preferential	option:	studying	the	local	changes	and	short-
range	interactions	in	order	to	establish	the	general	rules	that	govern	the	whole	system,	always	
keeping	 in	 mind	 the	 quote	 by	 French	 philosopher	 Edgar	 Morin	 "in	 complex	 systems,	
unpredictability	and	paradox	are	always	present	and	some	things	will	remain	unknown."	(La	
connaissance	de	la	connaissance,	1989).	
1.1.2	The	intestinal	microbial	ecosystem 
The	discovery	of	the	numerous	microorganisms	strictly	interacting	with	the	human	body	led	
to	numerous	questions	pertaining	to	the	influence	that	gut	microbiota	(composed	of	mostly	
anaerobic	bacteria)	might	have	on	the	physiology	of	the	human	organism.	The	gut	microbiota	
is	 potentially	 expressing	 around	 4	million	 distinct	 genes.	Most	 of	 these	 genes	 encode	 for	
proteins	(i.e.	enzymes)	involved	in	the	digestion	of	food	and	metabolic	reactions	essential	for	
host	homeostasis.	This	 complex	 system	could	be	compared	 to	a	bioreactor	 that	generates	
molecules	 interacting,	 both	 directly	 and	 indirectly,	 with	 immune-system,	 epigenome	 and	
metabolism	 of	 the	 host	 (Li	 et	 al.	 2008).	 Extensive	 research	 in	 this	 field	 together	with	 the	
advancement	of	high-throughput	technologies,	helped	elucidating	significantly	the	influence	
of	intestinal	microbial	ecology	(IME)	on	human	physiology.	This	influence	is	evident	in	many	
different	processes,	from	the	modulation	of	the	effects	that	ingested	food	has	on	host’s	health	
(Bourassa et	al. 2016)	to	the	direct	influence	on	host’s	gene	expression	(Forsythe	and	Kunze	
2013).		
1.1.3	Inter-personal	microbiota	variability		
IME	 influences	human	processes	 that	determines	also	our	behaviour	and	the	 fundamental	
aspects	 of	 our	 personality	 (Cryan	 and	 Dinan	 2012),	 leading	 to	 an	 obvious	 but	 important	
question:	if	the	microbiota	is	so	fundamental	for	the	human	physiology,	how	conserved	is	its	
composition	over	time	and	between	different	people?	
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There	 is	 an	 extraordinary	 interpersonal	microbiota	 variability	within	 the	 human	 gut.	 Each	
individual	has	a	unique	microbiota	composed	of	distinct	combination	of	microorganisms.	This	
observation	 led	 to	 the	 hypothesis	 that	 each	 individual	 possesses	 a	 unique	 microbiota	 in	
composition,	like	a	microbial	‘fingerprint’.	This	diversity	arises	from	all	the	diverse	factors	that	
can	affect	the	development	and	stability	of	the	microbiota,	such	as	host	genetics	(Goodrich	et	
al. 2014),	physiological	status,	pathologies,	environment,	diet	and	lifestyle	(Schippa	and	Conte	
2016).	In	fact,	while	serial	gut	microbiota	samples	coming	from	the	same	organism	typically	
show	 similar	 microbiota	 composition	 over	 time,	 the	 similarity	 in	 microbiota	 composition	
among	gut	samples	from	different	organisms	is	significantly	lower.	According	to	the	study	of	
Tojo	et	al.,	more	than	80%	of	individuals	maintains	the	same	microbiota	composition	during	
life,	which	can	be	used	as	a	unique	identifying	marker	(Tojo	et	al. 2014).	The	observation	that	
less	than	50%	of	bacterial	taxa	at	the	species	level	are	shared	between	monozygotic	twins	is	
another	 proof	 of	 the	 microbiota	 originality	 (Tojo	 et	 al. 2014). Despite	 the	 considerable	
variability	 in	 the	 composition	 of	 the	 gut	 microbiota	 between	 individuals,	 the	 core	 set	 of	
redundant	 genes,	 among	 different	 bacterial	 species,	 remains	 stable	 over	 years.	 This	
‘functional	core’	 is	 indispensable	 for	basic,	house-keeping	metabolic	activities	and	remains	
quite	similar	between	individuals	(Schippa	and	Conte	2016).	
1.1.4	Personalized	responses	based	on	microbiota		
The	variability	of	microbiota	observed	between	individuals	is	a	consequence	of	different	host	
responses	 to	 the	 external	 stimuli	 like	 therapeutic	 treatment,	 diet	 and	 lifestyle.	 Intestinal	
microbiota	 can	 be	 considered	 an	 optimal	 target	 for	 therapeutic	 manipulation	 due	 to	 its	
accessibility.	The	therapeutic	manipulation	could	be	performed	by	simple	procedures	such	as	
addition	of	probiotic	microorganisms	in	the	diet,	use	of	specific	antibiotic	molecules,	or	the	
modulation	of	nutritional	sources.	
It	has	been	observed	that	the	gut	commensals	are	able	to	modify	drugs	through	a	variety	of	
bio-transformation	processes,	such	as	hydrolysis	and	reduction,	significantly	 impacting	also	
on	 the	 efficacy	 of	 therapeutic	 treatments	 (Iida	 et	 al.	 2013).	 The	 dietary	 habits	 have	 the	
dominant	 role	 in	 shaping	 the	 IME.	 There	 is	 evidence	 indicating	 that	 different	 glycaemic	
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responses	given	by	different	individuals	to	the	identical	meals	are	associated	with	differences	
in	 microbiota	 composition	 (Suez	 et	 al. 2014).	 Specifically,	 the	 metabolic	 functions	 of	 the	
intestinal	 microbiota	 of	 a	 single	 subject	 regulate	 food	 processing	 and	 therefore	 nutrient	
availability.	Significant	changes	in	microbiota	composition	affect	the	reactions	that	transform	
ingested	 food	 into	 nutrients	 available	 for	 the	 absorption.	 Based	 on	 these	 observations,	
nutritional	science	should	take	into	account	also	the	connection	between	dietary	intervention	
and	microbiota.	This	correlation	has	been	confirmed	by	several	cases.	For	instance,	the	study	
performed	 by	 Hazen	 and	 colleagues	 (Koeth et	 al. 2013)	 demonstrated	 a	 cause-effect	 link	
between	 the	 gut	 microbiome,	 red	 meat	 consumption	 and	 atherosclerosis.	 The	 authors	
showed	that	specific	gut	bacteria	transform	L-carnitine,	a	nutrient	abundant	in	red	meat,	into	
trimethylamine	(TMA),	which	is	a	rapidly	absorbed	volatile	molecule,	subsequently	converted	
to	the	atherogenic	molecule	TMAO	by	liver	flavin	monooxygenases.	The	abundance	of	TMA-
producing	bacteria	is	variable	among	people	and	largely	depends	on	the	dietary	pattern.	In	
fact,	the	same	study	showed	a	reduced	ability	to	convert	carnitine	into	TMA	and	then	TMAO	
by	vegetarians	compared	to	omnivore	people	(Hu	et	al.	2000).	Then,	the	consumption	of	red	
meat	may	promote	cardiovascular	diseases	particularly	in	people	with	increased	susceptibility	
due	to	a	specific	microbiome	profile.	
Regarding	 the	 needs	 to	 personalize	 universal	 dietary	 recommendations,	 a	 recent	 study	
showed	the	microbiome-dependent	induction	of	glucose	intolerance	caused	by	consumption	
of	non-caloric	artificial	sweeteners	(Suez	et	al. 2014).	In	a	pilot	prospective	study,	it	was	shown	
that	even	short-term	consumption	of	non-caloric	artificial	sweeteners	may	increase	glucose	
intolerance	 in	 a	 subpopulation	 of	 human	 individuals	 that	 possess	 a	 peculiar	 intestinal	
microbiota	structure.	These	data	suggest	that	general	recommendations	for	the	reduction	of	
sugar	consumption	via	the	widespread	use	of	non-caloric	artificial	sweeteners	may	be	harmful	
for	some	people.		
1.1.5	The	concept	of	‘enterotype’	
Nowadays,	 the	 importance	 of	 the	 role	 of	 the	 microbiota	 for	 human	 health	 has	 become	
evident.	The	wealth	of	knowledge	acquired	during	the	last	15	years	by	the	research	on	the	
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intestinal	microbiota	and	microbiome	has	been	used	to	define	proper	biomarkers	of	health	
and	disease	through	the	definition	of	microbial	co-occurrence	patterns.	In	this	context,	the	
concept	of	“enterotypes”	was	proposed	(Arumugam	et	al.	2011).	The	enterotypes	are	classes	
of	gut	microbiotas	distinguished	according	to	the	abundance	of	specific	bacterial	groups.	 It	
has	been	suggested	that	the	human	gut	microbiota	fall	into	three	distinct	enterotypes	defined	
by	differential	representation	of	genera.	Enterotype	I	is	rich	in	Bacteroides	and	other	bacteria	
belonging	to	Bacteroidetes	phyla	that	take	energy	above	all	from	protein	and	carbohydrates	
fermentation.	 Enterotype	 II	 is	 enriched	 in	Prevotella	 and	Desulfovibrio,	which	 are	 bacteria	
specialized	in	the	degradation	of	complex	dietary	fibers.	Enterotype	III	is	rich	in	Ruminococcus	
and	 Akkermansia	 that	 are	 mucin	 degradation	 bacteria	 (Arumugam	 et	 al.	 2011).	 The	
enterotypes	described	so	far	appear	to	be	continent,	ethnicity,	age	and	gender	independent.	
Furthermore,	notably,	only	a	habitual	long	term	diet	can	influence	the	foundation	of	a	specific	
enterotype	(Wang	et	al.	2015).	
However,	the	actual	existence	of	the	enterotypes	is	controversial;	for	instance,	almost	two-
thirds	of	the	Russian	faecal	samples	analysed	in	a	recent	study	were	not	dominated	by	either	
Prevotella	or	Bacteroides	genera,	but	contained	novel	community	structures	that	were	not	
observed	 in	non-Russian	metagenomes	 (Tyakht	et	al.	 2013).	 This	notion	challenges	 current	
microbiota	subdivision,	suggesting	probably	the	existence	of	other	enterotypes.	Nonetheless,	
there	 are	 also	 studies	 that	 contest	 these	 findings,	 supporting	 a	 continuous	 gradient	 of	
dominant	taxa	rather	than	distinct	clusters	(Schippa	and	Conte	2014).	
1.1.6	Intra-subject	evolution	of	the	gut	microbiota		
Human	beings	constantly	evolve	during	their	life	span.	Since	the	bacterial	communities	live	in	
close	 interaction	 with	 the	 host,	 a	 question	 arises	 about	 how	 host	 variation	 impacts	 the	
development	of	bacterial	communities.	The	differences	observed	in	the	microbiota	structures	
among	individuals	and	during	life	in	a	single	subject	cannot	be	determined	by	different	diet	
habits	only	and,	therefore,	remain	at	least	partly	unexplained.	Microorganisms	first	colonize	
the	host	during	the	transition	from	the	in	utero	environment	to	the	mother’s	vagina,	which	
changes	its	IME	just	before	birth	(Biasucci	et	al.	2008).	The	study	by	Dominguez-Bello	et	al.	
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(2010)	showed	that	the	microbiota	of	newborns	differs	drastically	depending	on	the	type	of	
childbirth	 (natural	 or	 caesarean).	 It	 has	 been	 proposed	 that	 the	 new-born	 microbiota	
resembles	 the	 mother’s	 vaginal	 or	 skin	 microbiota	 depending	 on	 the	 first	 bacteria	
communities	that	the	new-born	encounters	during	the	delivery	(Dominguez-Bello	et	al.	2010).	
Therefore,	there	exists	a	similarity	between	mother’s	and	newborn’s	microbiota	promoted	by	
the	 vertical	 transmission	 of	 bacteria	 (faecal-oral,	 oral–oral	 and	 skin-oral	 routes)	 from	 the	
mother	to	the	newborn	(Adlerberth	and	Wold	2009).	The	study	by	Palmer	and	collaborators	
showed	that	the	earliest	gut	colonisers	are	generally	facultative	anaerobes,	followed	by	strict	
anaerobes.	 Palmer	 advanced	 the	 hypothesis	 that	 the	 intestinal	 microbiota	 is	 strongly	
influenced	by	maternal	communities	(Palmer	et	al.	2007).		
1.1.7	Macronutrients	and	microbiota	
Nutritional	components	(macro/micronutrients)	are	not	only	important	for	the	host	nutrition,	
but	also	for	shaping	the	microbiota	(Wu et	al. 2011).			
The	major	macronutrients	implicated	in	the	gut	microbiota	modulation	are	the	carbohydrates.	
The	complex	polysaccharidic	fibers	that	are	not	absorbed	by	the	proximal	intestine	represent	
the	principal	source	of	energy	for	the	 intestinal	microbes	(Conlon	and Bird 2014).	 	The	gut	
bacterial	 communities	 produce	 carbohydrate-active	 enzymes	 (CAZymes)	 that	 facilitate	 the	
degradation/fermentation	of	a	vast	range	of	(otherwise	non-degradable)	carbohydrates,	with	
production	of	organic	acids	and	other	nutrients	used	by	the	host	and	the	surrounding	bacteria	
(Gill	et	al. 2006).	The	most	important	catabolites	of	this	process	for	host’s	physiology	are	the	
short	chain	fatty	acids	(SCFAs),	especially:	acetate,	butyrate	and	propionate	(Tojo	et	al.	2014).	
Proteins	are	another	macronutrients	that	influence	microbial	growth.	Dietary	proteins	serve	
as	the	major	source	of	nitrogen	(including	ammonia)	for	colonic	microbial	growth	(Schippa	
and	Conte	 2014).	Notably,	 diets	 that	 promote	microbial	 protein	 synthesis	 (and	 the	 use	 of	
ammonia	as	N	source),	efficiently	redirect	systemic	N	excretion	from	kidneys	to	faecal	stream,	
resulting	beneficial	for	renal	health.	(Conlon	and Bird 2014).	Conversely,	protein	fermentation	
increases	the	formation	of	putrefactive	products	and,	consequently,	the	generation	of	gases	
(Backus	 et	 al.	 2002).	 Also,	 many	 end-products	 of	 protein	 fermentation	 (e.g.	 ammonia,	
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hydrogen	sulphides,	amines,	phenols,	thiols	and	indoles)	have	been	shown	to	have	cytotoxic,	
genotoxic	and	carcinogenic	effects	in	vitro	and	in	animal	models	(Amstberg	et	al.	1980,	Backus	
et	al.	2002)	
Dietary	fats	may	influence	the	gut	microbiota	indirectly	through	bile	acids,	although	the	exact	
mechanism	of	this	interaction	is	not	completely	understood.	For	instance,	it	was	shown	that	
members	of	the	intestinal	microbiota	produce	the	enzyme	7	α-dehydroxylase	transforming	
the	 primary	 into	 secondary	 bile	 acids	 such	 as	 deoxycholic	 acid,	 which	 exerts	 hepatotoxic	
effects	(Yoshimoto	et	al.	2013).	It	is	also	known	that	the	excess	of	lipids	in	the	diet	increases	
intestinal	permeability,	 leading	to	enhanced	translocation	of	bacterial	 lipopolysaccharide	in	
the	 bloodstream	 (Conlon	 and Bird 2014,	 Moreira	 et	 al. 2012).	 Further	 investigations	 are	
required	 to	 clarify	 the	 interaction	 between	 fats	 introduced	 with	 the	 diet,	 bile	 acids	 and	
microbiota	modifications.	
1.1.8	Short	chain	fatty	acids	(SCFAs)		
Acetate,	propionate	and	butyrate	are	the	major	SCFAs	present	in	the	colon,	accounting	for	
90%	of	the	total	SCFAs	produced,	with	molar	ratios	approximately	of	60:25:15.	Other	minor	
organic	acids	produced	include	lactate,	succinate,	valerate,	pyruvate,	and	formate.	Branched-
chain	 SCFAs	 (e.g.,	 isobutyrate	 and	 isovalerate)	 are	 formed	 during	 the	 fermentation	 of	
branched	chain	amino	acids	(Wong	et	al. 2006).	
In	 the	caecum	and	colon	 the	 fermentation	 is	very	 intense,	 leading	 to	a	high	production	of	
SCFAs,	 pH	 reduction	 (range	 5-6)	 and	 rapid	 bacterial	 growth.	 In	 the	 distal	 colon	 the	
fermentation	process	almost	stops	due	to	the	lack	of	substrates,	leading	to	a	higher	pH	and	
putrefactive	processes.	
The	 SCFAs	 have	 many	 important	 functions	 in	 the	 host	 physiology.	 i)	 Butyric	 acid	 for	
consistency	 serves	 as	 the	 principal	 source	 of	 energy	 for	 colonocyte	 differentiation	 and	
apoptosis,	 and	 therefore	 it	 is	 essential	 for	 maintaining	 mucosal	 integrity	 and	 protection	
against	 colon	 cancer	 (Brinkworth	 et	 al. 2009).	 Furthermore,	 butyrate	modulates	 intestinal	
inflammation	responses	and	regulates	glucose	metabolism	through	the	hormone	glucagon-
like	 peptide-1.	 ii)	 Propionic	 acid	 positively	 influences	 the	 growth	 of	 hepatocytes	 and	 it	 is	
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considered	 an	 additional	 source	 of	 energy	 for	 the	 host	 (used	mainly	 for	 the	 synthesis	 of	
glucose	 and	 lipids).	 iii)	 Acetic	 acid	 has	 a	 positive	 effect	 on	 the	 development	 of	 peripheral	
tissues,	in	particular	in	muscles	(Conlon	and Bird 2014).	Moreover,	SCFAs	modulate	glucose	
and	cholesterol	metabolisms	and	stimulate	the	absorption	of	calcium,	magnesium	and	iron	
(Wong	et	al. 2006).	
1.1.9	Probiotics	and	prebiotics	
It	has	been	proposed	that	the	observed	differences	in	the	intestinal	microbiota	composition	
of	Western	country	people	compared	to	people	 in	developing	countries	and	rural	areas	of	
Africa	 and	 South	 America,	 are	 plausibly	 due	 to	 the	 industrialization	 processes	 in	 food	
manufacturing,	 as	 all	 foodstuff	 nowadays	 is	 processed	 in	 order	 to	 increase	 shelf-life,	
decreasing	at	the	same	time	the	presence	of	microorganisms.	In	comparison,	the	diet	of	our	
forefather	consisted	of	 fermented	foods	 (fermentation	was	a	widespread	method	for	 food	
conservation),	that	was	also	a	way	to	introduce	considerable	quantities	of	different	bacteria,	
increasing	 the	 overall	 microbial	 diversity	 in	 the	 intestine.	 Of	 note,	 nowadays	 the	 overall	
microbiome	richness	is	also	low	in	people	living	in	the	urban	areas	of	the	Western	world,	as	a	
possible	consequence	of	a	general	distancing	from	natural	environments	with	a	consequential	
little	 exposure	 to	 soil,	 animals,	 and	 associated	 microbes	 (Ferranti	 et	 al.	 2014).	 These	
environmental	and	lifestyle	changes	in	the	Western	world	have	created	a	need	to	reintegrate	
live	 bacteria	 that	 are	no	 longer	 introduced	with	 the	diet.	 In	 this	 context,	 strong	 industrial	
interests	arose	to	implement	the	knowledge	on	and	production	of	probiotics.	
The	term	probiotic,	meaning	“for	life,”	is	derived	from	the	Latin	word	(pro,	“in	favour	of”)	and	
the	 Greek	 word	 (bios,	 “life”).	 The	 word	 “probiotic”	 was	 first	 used	 in	 1965	 to	 describe	
“substances	 secreted	 by	 one	 microorganism	 which	 stimulates	 the	 growth	 of	 another”	 in	
antithesis	 with	 the	 term	 antibiotic	 (Lilly	 and	 Stillwell	 1965).	 Almost	 10	 years	 later,	 Parker	
(Parker	1974)	proposed	a	different	definition	of	probiotic	(“organisms	and	substances	which	
contribute	 to	 intestinal	 microbial	 balance”)	 which	 is	 not	 far	 from	 the	 currently	 accepted	
definition:	 “Live	microorganisms	 which	 when	 administered	 in	 adequate	 amounts	 confer	 a	
health	benefit	on	the	host”	(FAO	May	2002,	FAO/WHO).		
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Probiotic	 microorganisms	 have	 been	 demonstrated	 to	 possess	 several	 health	 promoting	
properties.	 Probiotics	 may	 exert	 a	 regulatory	 effect	 on	 the	 intestinal	 epithelial	 barrier	 in	
different	ways,	for	instance	through	a	direct	action	on	the	intestinal	epithelium,	by	stimulating	
the	synthesis	and	secretion	of	mucin	by	the	goblet	cells.	Probiotic	microorganisms	may	also	
antagonize	pathogens	by	competing	for	the	adhesion	to	epithelial	surfaces,	or	through	the	
production	of	antimicrobial	molecules	Probiotic	microbes	can	moreover	improve	the	stability	
of	 tight-junctions,	 reducing	 the	 epithelial	 permeability	 and	 possible	 translocation	 of	
pathogenic	agents	and	their	products.	(Patel	RM	and	Lin	2010).	In	addition,	several	probiotic	
strains	 have	 been	 demonstrated	 to	modulate	 the	 host	 immune	 system	 (Ashraf	 and	 Shah	
2014).	
Besides	the	administration	of	live	bacteria,	gut	homeostasis	also	benefits	from	diet	integration	
with	prebiotics	molecules.	A	prebiotic	is	defined	as	“a	substrate	that	is	selectively	utilized	by	
host	 microorganisms	 conferring	 a	 health	 benefit.”	 (Gibson	 et	 al.	 2017).	 The	 concept	 of	
prebiotics	 has	 attracted	 increasing	 attention,	 stimulating	 both	 scientific	 and	 industrial	
interest.	However,	several	food	components,	especially	oligosaccharides	and	polysaccharides,	
have	 been	 claimed	 to	 possess	 prebiotic	 activity	 even	 though	 a	 scientific	 demonstration	 is	
missing	(Roberfroid	2007).	Not	all	dietary	carbohydrates	are	prebiotics,	and	there	are	specific	
criteria	for	classifying	a	food	ingredient	as	a	prebiotic.	According	to	Gibson	et	al.	(2014),	these	
criteria	are:		
a)	Non-digestibility:	testing	of	prebiotic	resistance	to	gastric	acidity,	hydrolysis	by	mammalian	
enzymes,	and	gastrointestinal	absorption.		
b)	Fermentation	by	the	colonic	microbiota.	
c)	Selective	stimulation	of	growth	and/or	activity	of	intestinal	bacteria.		
1.2	Microbiome	data	analysis	
The	step	that	allowed	the	progression	in	the	scientific	research	on	microbial	ecosystems	was	
the	introduction	of	next-generation	sequencing	technologies	(NGS).	NGS	allowed	for	fast	and	
low-cost	 DNA	 sequencing,	 permitting	 the	 generation	 of	 millions	 of	 sequences.	 Deep	
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sequencing	 analysis	 enables	 characterization	 of	 microbial	 communities	 in	 different	
environments	 without	 the	 need	 of	 culture-based	 methods	 increasing	 enormously	 the	
information	obtained	from	complex	microbial	ecosystems	
A	critical	issue	of	the	microbiota	study	is	the	correct	analysis	and	interpretation	of	the	data.	
The	data	produced	in	the	microbiota	studies	has	several	biases	due	to	the	complexity	of	this	
system	 and	 due	 to	 the	 technology	 used.	 These	 aspects	 of	 the	 data	 analysis	 in	microbiota	
research	are	discussed	in	the	next	paragraphs.	
1.2.1	Next	generation	sequencing	technologies	
NGS	 technologies	 come	 from	 the	 Sanger	method	 based	 on	 the	 selective	 incorporation	 of	
chain-terminating	 dideoxynucleotides	 in	 the	 first	 automatic	 sequencing	 machine	 was	
produced	 by	 Applied	 Biosystems	 in	 1987;	 (Liu	 et	 al. 2012).	 Currently,	 there	 are	 several	
platforms	available	 for	 sequencing.	 Each	one	has	 advantages	 and	disadvantages	 regarding	
generation	of	largest	total	throughput	per	run,	read	length,	accuracy	and	time.	In	the	studies	
included	in	the	present	PhD	thesis	two	different	sequencing	platforms	have	been	used:	Ion	
PGM	from	Ion	Torrent	and	Illumina's	MiSeq.	
The	output	data	originating	from	NGS	consist	of	hundreds	of	thousands	of	reads,	which	can	
be	counted	as	a	discrete	number	of	counts.	The	analysed	samples	will	express	their	diversity	
qualitatively	and	quantitatively	in	terms	of	diversity	in	the	sequence	of	bases	and	library	size.	
In	this	context,	statistics	has	a	pivotal	importance	to	properly	manage	and	interpret	the	data	
generated	by	the	different	NGS	approaches.	
1.2.2	Amplicon	sequencing	
NGS	has	been	used	to	characterize	the	human	intestinal	microbiota.	PCR	amplification	of	the	
16S	rRNA	gene	is	considered	the	most	suitable	way	to	define	the	taxonomic	composition	of	
the	bacteria	in	a	metagenomic	sample.	The	16S	rRNA	gene	is	a	region	of	the	bacterial	genomes	
that	 includes	 both	 very	 conserved	 and	 variable	 sequences.	 Conventionally,	 only	 specific	
regions	of	16S	rRNA	gene	are	sequenced	 in	microbiomics.	 In	fact,	due	to	the	 length	of	the	
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whole	 gene	 (about	 1.5	 kb),	 sequencing	 the	 full	 gene	 would	 lead	 to	 decreased	 depth	 of	
sequence	coverage,	making	it	more	difficult	to	detect	the	rare	taxa	present	in	the	sample.	
Specifically,	 the	 16S	 rRNA	 gene	 contains	 nine	 hypervariable	 regions	 (Vn),	which	 possess	 a	
sequence	divergence	that	permit	the	potential	discrimination	of	bacterial	taxa	to	the	level	of	
species.	Not	all	the	Vn	have	different	sequences	among	different	species.	In	fact,	some	species	
can	 be	 distinguished	 only	 by	 one	 of	 the	 nine	 Vn.	 Schloss	 (2010)	 reported	 that	 the	 use	 of	
different	variable	regions	influences	the	richness	and	evenness	of	communities	(Schloss	2010).	
Since	the	usage	of	any	specific	Vn	of	the	16S	rRNA	gene	has	advantages	and	disadvantages,	
some	 researchers	opt	 to	 sequence	more	 than	one	variable	 region	 simultaneously	 to	 get	 a	
clearer	view	of	the	composition	of	the	microbiome.		According	to	the	study	of	Shah	et	al.,	the	
V1–V3	or	V1–V4	regions	should	be	targeted	for	microbiome	sequencing,	although	the	choice	
should	be	made	by	taking	into	account	the	aim	of	the	experiment	and	at	the	nature	of	samples	
(Shah	et	al. 2011).	
Another	issue	is	given	by	the	primers	used	for	the	amplification	of	the	16S	rRNA	gene	region. 
Even	though	these	primers	are	considered	“universal”	(or,	more	correctly,	pan-bacterial),	they	
preferentially	anneal	on	the	16S	rRNA	gene	of	certain	taxa	over	others,	resulting	in	the	over-
representation	of	specific	taxa.	Another	bias	is	introduced	by	the	fact	that	the	16S	rRNA	gene	
is	present	in	multiple	copies	in	the	bacterial	genome	(Acinas	et	al.	2004)	leading	to	the	over-
representation	of	 the	abundance	of	 certain	 taxa.	 Furthermore,	 in	 certain	bacterial	 species	
(e.g.,	extremophiles;	[Acinas	et	al.	2004]),	the	sequences	of	the	multiple	16S	rRNA	genes	in	
the	same	genome	diverge,	resulting	in	the	overestimation	of	the	taxonomic	diversity.	
1.2.3	Taxonomic	association	
The	sequencing	process	produces	an	output	file	containing	all	DNA	sequences	obtained,	which	
are	conventionally	called	“reads”.	The	reads	are	associated	to	an	identification	code	(called	
barcode)	used	to	pair	each	sequence	to	a	unique	sample.	The	pairing	phase	leads	to	the	reads	
count,	 in	which	each	sample	has	a	precise	pool	of	sequences	that	expresses	the	numerical	
data	 of	 16S	 rRNA	 gene	 copies	 present	 in	 the	 metagenomic	 DNA;	 next,	 the	 taxonomic	
association	is	performed.	Each	read	is	compared	by	a	Bayesian	taxonomic	classifier	with	the	
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16S	rRNA	gene	sequences	present	in	a	database	in	order	to	be	associated	to	a	specific	bacterial	
species.	Important	considerations	have	to	be	taken	in	account	to	perform	this	bioinformatics	
step.	 Sequencing	 errors	 can	 lead	 to	minor	 different	 amplicon	 sequences	 within	 a	 species	
creating	an	overestimation	of	bacterial	diversity.	To	limit	this	bias,	the	reads	are	aligned	based	
on	their	similarity	and	grouped	in	clusters.	Typically,	97%	similarity	is	used	as	a	cut-off	for	the	
approximate	 clustering	 with	 species-level	 resolution,	 that	 corresponds	 to	 the	 operational	
taxonomic	units	(OTUs)	(Goebel	and	Stackebandt	1994).	Based	on	the	number	of	clustered	
sequences	present	 in	the	sample,	 it	 is	possible	to	extrapolate	the	richness	of	the	biological	
sample,	even	if	the	clusters	are	not	associated	to	a	taxonomy	at	this	point.	This	phase	is	called	
“OTU	 picking”.	 Two	 approaches	 can	 be	 adopted	 to	 determinate	 the	 OTUs.	 (i)The	 most	
common	one	is	“de	novo	OTU	picking”.	In	this	approach,	all	reads	are	compared	to	each	other	
and	grouped	into	OTUs	based	on	their	similarity.		(ii)	The	second	approach	is	named	“reference	
picking”.	Here,	the	sequences	are	compared	to	a	database	and	clustered	into	OTUs	based	on	
their	similarity	to	a	known	sequence	in	the	database.		
Each	approach	had	pros	and	cons.	For	example,	the	de	novo	picking	includes	more	erroneous	
sequences	than	the	reference	picking.	At	the	same	time	de	novo	OTU	picking	does	not	discard	
any	sequence	and	it	is	not	limited	by	the	quality	of	the	database	used	for	the	annotation.	Even	
though	 reference	 picking	 is	 quicker	 and	 creates	 less	 errors,	 this	 approach	 has	 the	
disadvantages	 of	 discarding	 many	 potentially	 valid	 sequences	 due	 to	 factors	 such	 as	
mismatches	in	the	database.		
The	annotation	of	the	OTUs	is	the	last	step	in	the	bioinformatics	pipeline.	For	this	step,	one	
sequence	 is	 selected	 per	 each	 cluster	 and	 compared	 with	 the	 sequences	 in	 a	 16S	 rRNA	
database	in	order	to	assign	the	taxonomy	to	each	specific	OTU	cluster.			
1.2.4	Biodiversity	determination	
The	biodiversity	of	 the	microbiota	can	be	analysed	 through	several	different	methods,	 the	
most	commonly	used	being	the	alpha	and	beta	diversity	indexes.	
The	alpha	diversity	indexes	are	defined	by	two	different	parameters:	the	richness	index	and	
the	diversity	index.	The	richness	index	indicates	the	number	of	different	bacteria	present	in	a	
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sample	and	it	is	determined	by	the	number	of	OTUs	present	in	the	sample	(e.g.,	Chao1	index)	
(Chao,	1984).	The	diversity	index	combines	richness	with	the	uniformity	of	distribution	of	the	
different	bacteria	in	a	sample	(evenness).	Diversity	index	is	commonly	determined	by	using	
the	Simpson	diversity	index	and	the	Shannon	diversity	index	(Li	et	al.	2008).	In	general,	the	
alpha	diversity	indexes	measure	the	intra-sample	diversity.		
The	beta	diversity	 indexes	measure	 the	biodiversity	by	evaluating	 the	 similarities	between	
different	group	of	samples.	The	beta	diversity	accounts	for	the	presence	or	absence	of	OTUs,	
their	abundance	and	their	phylogeny;	therefore,	in	this	analysis,	an	addition	or	removal	of	a	
samples	will	change	the	final	outcome.	More	specifically,	the	beta	diversity	indexes	are	based	
on	 a	multivariate	 analysis	 (Ramette 2007).	 The	 bacterial	 profiling	 defines	 each	 sample	 in	
analysis.	Each	sample,	which	is	characterized	by	a	large	range	of	variables	derived	from	the	
bacterial	profiling,	is	compared	to	the	other	samples,	creating	a	distance	matrix	based	on	the	
grade	of	dissimilarities.	The	distance	matrix	considers	the	phylogeny	as	well	as	the	abundance	
of	the	bacteria.		
The	 output	 of	 the	 beta	 diversity	 analysis	 is	 a	 square	matrix	 that	 determines	 the	 distance	
between	samples.	This	matrix	is	called	distance	matrix.	The	UniFrac	distance	analysis,	which	
also	 consider	 the	 phylogenetic	 information	 of	 the	 ecosystem	 under	 study,	 is	 the	 most	
frequently	used	algorithm	to	build	the	distance	matrix.	The	UniFrac	distance	analysis	can	be	
performed	in	two	ways:	(i)	by	generating	distance	matrix	only	based	on	similarity	between	the	
bacteria	present	in	the	samples	without	considering	their	abundance	(Unweighted	UniFrac);	
(ii)	by	including	both	similarity	and	abundance	of	the	bacteria	(Weighted	UniFrac)	(Lozupone	
et	al. 2011).	
The	final	results	of	the	beta	diversity	are	represented	in	a	graph	where,	conventionally,	the	
samples	are	plotted	in	multidimensional	Euclidean	space.	The	abscissa	separates	the	points	in	
the	space	and	refers	to	the	first	principal	coordinate	(PC);	the	ordinate	is	the	second	PC.	Each	
PC	is	associated	with	a	percentage	value	which	describes	the	variation	explained	by	the	axes.	
A	maximum	of	three	PCs	should	be	used	per	analysis.	The	principal	coordinates	analysis	(PCoA)	
and	the	principal	composition	analysis	(PCA)	are	the	most	common	multivariate	analyses	used	
to	 obtain	 the	 coordinates	 used	 to	 represent	 samples	 in	 the	 graph.	 PCoA	 derives	 from	 a	
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dissimilarity	matrix	that	emphasizes	the	most	abundant	OTUs	present	in	the	samples.	On	the	
other	hand,	PCA	gives	more	importance	to	the	OTUs	that	have	a	greater	variance	between	
samples.	It	is	still	controversial	which	is	the	best	approach	between	PCoA	and	PCA	to	evidence	
biologically	relevant	differences	between	groups.	
In	addition,	the	analysis	of	similarity	based	on	distance	metric	like	ANOSIM	can	be	also	used	
to	establish	significant	differences	in	the	microbiota	composition	between	groups	of	samples	
(Clarke	1993).	
1.2.5	Feature-comparison	methods		
The	output	of	the	sequencer	is	a	list	of	sequences	(reads)	that	could	be	analysed	as	counts	
data	or	compositional	data.	It	is,	however,	uncertain	if	it	is	more	appropriate	considering	reads	
as	counts	or	compositional	data.	If	reads	are	considered	compositional	data,	they	cannot	be	
analysed	by	the	use	of	the	statistical	analyses	that	assume	independence	of	the	data	because	
the	reads	are	not	actually	independent.	DNA	fragments	prior	to	sequencing	are	immobilized	
on	the	sequencing	chip.	The	area	available	 for	sequence	 immobilization	 is	 limited	allowing	
only	 for	a	 small	 fraction	of	 the	 fragments	present	 in	 the	 sample	 to	actually	be	bound	and	
sequenced.	 On	 the	 other	 hand,	 if	 considered	 as	 counts	 data,	 reads	 correspond	 to	 gene	
expression	data.	In	this	work,	the	reads	are	taken	in	consideration	like	counts	data,	therefore	
the	sequences	of	a	samples	are	independent	from	each	other.	
Another	feature	of	the	sequencer’s	output	is	the	different	library	size	for	each	sample.	The	
library	size	is	the	quantity	of	good	quality	reads	that	are	generated	for	a	single	sample.		
The	methods	to	analyse	the	differences	between	samples	take	into	account	the	independence	
of	the	data.	They	are	mainly	three:		
a)	Counts	table	transformation	in	relative	amount	of	OTU.	Where	the	sum	of	all	the	OTUs	for	
each	sample	will	equal	to	1;	
b)	The	rarefying	method;	(Hughes	et	al.	2005)	
c)	The	Differential	gene	expression	analysis	(DESeq2)	normalization;	(Anders and Huber 2010).
	
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The	 first	method	 reports	 the	 relative	abundance	of	 the	 reads	number	per	 sample	without	
regard	to	the	“compositional”	 feature	of	the	data.	The	second	method	 is	based	on	sample	
rarefying;	in	specific,	first,	the	minimum	library	size	is	established	(rarefying	level)	and,	then,	
the	reads	are	randomly	selected	for	each	sample	until	the	number	of	read	per	each	sequence	
equals	to	the	rarefying	level.	At	this	point,	the	data	are	normalized	by	a	linear	normalization	
method.	This	principle	does	not	apply	to	DESeq2	normalization,	which	is	a	method	evolved	
from	the	gene	expression	statistical	theory.	
Poisson	distribution	is	often	used	to	model	the	gene	expression	data.	The	Poisson	distribution	
is	 based	 on	 the	 assumption	 that	 the	mean	 and	 variance	 of	 the	 data	 are	 the	 same.	 If	 this	
assumption	is	not	met,	an	extension	of	the	Poisson	model	needs	to	be	applied.	This	extension	
of	the	model	provides	for	the	addition	of	the	dispersion	factor	Q.	The	Gamma-Poisson	model,	
also	called	the	negative	binomial	(NB)	model,	includes	this	dispersion	factor.	NB	is	used	to	test	
if	 the	 difference	 in	 expression	of	 different	OTUs	 is	 significant.	 To	 control	 the	 rate	 of	 false	
positive	genes,	it	is	necessary	to	recognize	the	factor	Q	>	0	and	to	estimate	its	value.	Many	
false	 positive	 OTUs	 appear	 significantly	 differentially	 expressed	 between	 experimental	
conditions	under	the	assumption	of	a	Poisson	distribution	(Q	=	0)	but,	nevertheless,	they	are	
not	significant	in	tests	that	account	for	the	larger	variance	as	in	the	16S	rRNA	sequencing.	With	
respect	 to	 the	 previously	 described	methods,	 the	 use	 of	 NB	model	 solves	 both	 the	 deep	
differences	of	the	library	size	and	the	lack	of	dispersion	factor	that	causes	the	overestimation	
of	the	OTU	variations.	
1.2.6	Correlation	and	regression	models				
The	analyses	described	above	allow	only	 for	 identification	of	OTUs	differentially	 abundant	
between	 different	 groups	 of	 samples	 (representing	 different	 conditions),	 but	 they	 do	 not	
provide	any	information	about	the	causing	factors	leading	to	this	differential	abundance.	In	
order	 to	 speculate	on	 the	potential	 causes	at	 the	origin	of	observed	microbiota	variations	
(differential	 OTU	 abundances),	 the	 correlation	 analysis	 may	 be	 performed	 between	
differentially	abundant	OTUs	and	different	biological	parameters	potentially	involved	in	this	
variation.	Due	to	the	compositional	nature	of	NGS	data,	the	correlation	analysis	requires	the	
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fulfilment	of	different	assumptions.	First,	data	need	to	be	normalized	and	false	positives	need	
to	be	eliminated	or	reduced	as	much	as	possible.	Kendall	rank	based	correlation	analysis	is	the	
most	 appropriate	 for	 this	 purpose	 because	 this	 statistical	 test	 uses	 a	 system	 of	 data	
perturbation	that	improves	identifying	and	removal	of	false	positive	correlations.	This	specific	
correlation	analysis	allows	for	the	establishment	of	an	interdependence	link	between	a	single	
OTU	and	a	biological	(e.g.	physiological	or	immunological)	parameter	linked	to	a	sample	group.	
Next,	the	regression	analysis	is	used	to	further	establish	if	the	variation	of	a	certain	biological	
parameter	leads	to	differential	OTU	abundance	in	a	direct	or	indirect	manner.	To	this	end,	a	
linear	model	 is	computed	to	estimate	the	 influence	of	a	specific	biological	parameter	over	
differential	 OTU	 abundance.	 If	 the	 obtained	 R2	 value	 is	 close	 to	 1,	 this	 indicates	 that	 the	
parameter	is	a	good	predictor	for	the	differential	OTU	abundance.	
1.3	References	
• Acinas	SG,	Marcelino	LA,	Klepac-Ceraj	V,	Polz	MF.	(2004).	Divergence	and	redundancy	
of	16S	rRNA	sequences	in	genomes	with	multiple	rrn	operons.	J	Bacteriol.	186(9):2629-
35.		
• Adlerberth	I,	Wold	AE.	(2009).	Establishment	of	the	gut	microbiota	in	Western	infants.	
Acta	Paediatr.	98(2):229-38.		
• Amaral	FA,	Sachs	D,	Costa	VV,	Fagundes	CT,	Cisalpino	D,	Cunha	TM,	Ferreira	SH,	Cunha	
FQ,	 Silva	 TA,	 Nicoli	 JR,	 Vieira	 LQ,	 Souza	 DG,	 Teixeira	 MM.	 (2008).	 Commensal	
microbiota	is	fundamental	for	the	development	of	inflammatory	pain.	Proc	Natl	Acad	
Sci	U	S	A.	105(6):2193-7.	
• Amstberg	 G,	 Drochner	W,	Meyer	 H.	 (1980).	 Influence	 of	 food	 composition	 on	 the	
intestinal	flora	of	the	dog.	Nutrition	of	the	dog	and	cat.	Pergamon	Press,	181–188.	
• Anders	S,	Huber	W.	(2010).	Differential	expression	analysis	for	sequence	count	data.	
Genome	Biol.	11(10):R106.		
• Arumugam	M,	Raes	J,	Pelletier	E,	Le	Paslier	D,	Yamada	T,	Mende	DR,	Fernandes	GR,	
Tap	 J,	 Bruls	 T,	 Batto	 JM,	Bertalan	M,	Borruel	N,	 Casellas	 F,	 Fernandez	 L,	Gautier	 L,	
Hansen	T,	Hattori	M,	Hayashi	T,	Kleerebezem	M,	Kurokawa	K,	Leclerc	M,		Levenez	F,	
	
	
17	
	
Manichanh	C,	Nielsen	HB,	Nielsen	T,	Pons	N,	Poulain	J,	Qin	J,	Sicheritz-Ponten	T,	Tims	
S,	Torrents	D,	Ugarte	E,	Zoetendal	EG,	Wang	J,	Guarner	F,	Pedersen	O,	de	Vos	WM,	
Brunak	 S,	 Doré	 J;	 MetaHIT	 Consortium,	 Antolín	 M,	 Artiguenave	 F,	 Blottiere	 HM,	
Almeida	M,	Brechot	C,	Cara	C,	Chervaux	C,	Cultrone	A,	Delorme	C,	Denariaz	G,	Dervyn	
R,	 Foerstner	 KU,	 Friss	 C,	 van	 de	 Guchte	 M,	 Guedon	 E,	 Haimet	 F,	 Huber	 W,	 van	
Hylckama-Vlieg	 J,	 Jamet	 A,	 Juste	 C,	 Kaci	 G,	 Knol	 J,	 Lakhdari	 O,	 Layec	 S,	 Le	 Roux	 K,	
Maguin	E,	Mérieux	A,	Melo	Minardi	R,	M'rini	C,	Muller	J,	Oozeer	R,	Parkhill	J,	Renault	
P,	Rescigno	M,	Sanchez	N,	Sunagawa	S,	Torrejon	A,	Turner	K,	Vandemeulebrouck	G,	
Varela	 E,	 Winogradsky	 Y,	 Zeller	 G,	 Weissenbach	 J,	 Ehrlich	 SD,	 Bork	 P.	 (2011).	
Enterotypes	of	the	human	gut	microbiome.	Nature.	473(7346):174-80.		
• Ashraf	R,	Shah	NP.	(2014).	Immune	system	stimulation	by	probiotic	microorganisms.	
Crit	Rev	Food	Sci	Nutr.	54(7):938-56.	
• Backus	RC,	Puryear	LM,	Crouse	BA,	Biourge	VC,	Rogers	QR.	(2002).	Breath	hydrogen	
concentrations	 of	 cats	 given	 commercial	 canned	 and	 extruded	 diets	 indicate	
gastrointestinal	microbial	activity	vary	with	diet	type.	Journal	of	Nutrition	132,	1763S–
1766S.	
• Berggren	AM,	Nyman	EM,	Lundquist	I,	Björck	IM.	(1996).	Influence	of	orally	and	rectally	
administered	propionate	on	cholesterol	and	glucose	metabolism	 in	obese	 rats.	Br	 J	
Nutr.	76(2):287-94.	
• Biasucci	G,	Benenati	B,	Morelli	 L,	Bessi	 E,	Boehm	G.	 (2008).	Cesarean	delivery	may	
affect	the	early	biodiversity	of	intestinal	bacteria.	J	Nutr.	138(9):1796S-1800S.		
• Bik	HM,	Porazinska	DL,	Creer	S,	Caporaso	JG,	Knight	R,	Thomas	WK.	(2012).	Sequencing	
our	 way	 towards	 understanding	 global	 eukaryotic	 biodiversity.	 Trends	 Ecol	 Evol.	
27(4):233-43.	
• Bourassa	MW,	Alim	I,	Bultman	SJ,	Ratan	RR.	(2016).	Butyrate,	neuroepigenetics	and	
the	gut	microbiome:	Can	a	high	fiber	diet	improve	brain	health?	Neurosci	Lett.	625:56-
63.			
• Brinkworth	GD,	Noakes	M,	Clifton	PM,	Bird	AR.	 (2009).	Comparative	effects	of	very	
low-carbohydrate,	high-fat	and	high-carbohydrate,	low-fat	weight-loss	diets	on	bowel	
	
	
18	
	
habit	 and	 faecal	 short-chain	 fatty	 acids	 and	 bacterial	 populations.	 Br	 J	 Nutr.	
101(10):1493-502.		
• Chao	A.	(1984).	Nonparametric	Estimation	of	the	Number	of	Classes	in	a	Population.	
Scandinavian	Journal	of	Statistics	11(4):265-270.	
• Clarke	 KR.	 (1993).	 Non-parametric	 multivariate	 analyses	 of	 changes	 in	 community	
struc-	ture.	Aust.	J.	Ecol.	18,	117–143.	
• Conlon	MA,	Bird	AR.	 (2014)	The	 impact	of	diet	 and	 lifestyle	on	gut	microbiota	and	
human	health.	Nutrients.	7(1):17-44.		
• Cryan	 JF,	 Dinan	 TG.	 (2012).	 Mind-altering	 microorganisms:	 the	 impact	 of	 the	 gut	
microbiota	on	brain	and	behaviour.	Nat	Rev	Neurosci.	13(10):701-12.		
• de	Moreno	de	LeBlanc	A,	LeBlanc	JG.	(2014).	Effect	of	probiotic	administration	on	the	
intestinal	 microbiota,	 current	 knowledge	 and	 potential	 applications.	 World	 J	
Gastroenterol.	20(44):16518	28.		
• de	Vos	WM,	de	Vos	EA.	(2012)	Role	of	the	intestinal	microbiome	in	health	and	disease:	
from	correlation	to	causation.	Nutr	Rev.	70	Suppl	1:S45-56.	
• Dheilly	 NM.	 (2014).	 Holobiont-Holobiont	 interactions:	 redefining	 host-parasite	
interactions.	PLoS	Pathog.	10(7):e1004093.	
• Dominguez-Bello	MG,	Costello	EK,	Contreras	M,	Magris	M,	Hidalgo	G,	Fierer	N,	Knight	
R.	(2010).	Delivery	mode	shapes	the	acquisition	and	structure	of	the	initial	microbiota	
across	multiple	body	habitats	in	newborns.	Proc	Natl	Acad	Sci	U	S	A.	107(26):11971-5.		
• FAO	May	(2002),	FAO/WHO.	Guidelines	for	the	evaluation	of	probiotics	in	food.	Report	
of	 a	 Joint	 FAO/WHO	Working	 Group	 on	 Drafting	 Guidelines	 for	 the	 Evaluation	 of	
Probiotics	in	Food;	Canada.	
• Ferranti	EP,	Dunbar	SB,	Dunlop	AL,	Corwin	EJ.	(2014).	20	things	you	didn't	know	about	
the	human	gut	microbiome.	J	Cardiovasc	Nurs.	29(6):479-81.		
• Forsythe	P,	Kunze	WA.	(2013).	Voices	from	within:	gut	microbes	and	the	CNS.	Cell	Mol	
Life	Sci.	70(1):55-69.		
• Gargari	G,	Taverniti	V,	Balzaretti	S,	Ferrario	C,	Gardana	C,	Simonetti	P,	Guglielmetti	S.	
(2016).	 	 Consumption	 of	 a	 Bifidobacterium	 bifidum	 Strain	 for	 4	Weeks	Modulates	
	
	
19	
	
Dominant	Intestinal	Bacterial	Taxa	and	Faecal	Butyrate	in	Healthy	Adults.	Appl	Environ	
Microbiol.	82(19):5850-9.		
• Gibson	GR,	Probert	HM,	Loo	JV,	Rastall	RA,	Roberfroid	MB.	(2014).	Dietary	modulation		
of	the	human	colonic	microbiota:	updating	the	concept	of	prebiotics.	Nutr	Res	Rev.	
17(2):259-75.		
• Gibson	 GR,	 Hutkins	 R,	 Sanders	 ME,	 Prescott	 SL,	 Reimer	 RA,	 Salminen	 SJ,	 Scott	 K,	
Stanton	 C,	 Swanson	 KS,	 Cani	 PD,	 Verbeke	 K,	 Reid	 G.	 (2017).	 Expert	 consensus	
document:	The	International	Scientific	Association	for	Probiotics	and	Prebiotics	(ISAPP)	
consensus	statement	on	the	definition	and	scope	of	prebiotics.	Nat	Rev	Gastroenterol	
Hepatol.	14(8):491-502.	
• Gilbert	 SF.	 (2014).	 Symbiosis	 as	 the	 way	 of	 eukaryotic	 life:	 the	 dependent	 co-
origination	of	the	body.	J	Biosci.	39(2):201-9.	
• Epub	2017	Jun	14.	Review.	PubMed	PMID:	28611480.	
• Gill	SR,	Pop	M,	Deboy	RT,	Eckburg	PB,	Turnbaugh	PJ,	Samuel	BS,	Gordon	JI,	Relman	DA,	
Fraser-Liggett	CM,	Nelson	KE.	(2006).	Metagenomic	analysis	of	the	human	distal	gut	
microbiome.	Science.	312(5778):1355-9.		
• Goebel	 BM,	 Stackebrandt	 E.	 (1994).	 Cultural	 and	 phylogenetic	 analysis	 of	 mixed	
microbial	 populations	 found	 in	 natural	 and	 commercial	 bioleaching	 environments.	
Appl	Environ	Microbiol.	60(5):1614-21.		
• Goodrich	JK,	Waters	JL,	Poole	AC,	Sutter	JL,	Koren	O,	Blekhman	R,	Beaumont	M,	Van	
Treuren	 W,	 Knight	 R,	 Bell	 JT,	 Spector	 TD,	 Clark	 AG,	 Ley	 RE.	 (2014).	 Human	
geneticsshape	the	gut	microbiome.	Cell.	159(4):789-99	
• Hu	 FB,	 Rimm	 EB,	 Stampfer	 MJ,	 Ascherio	 A,	 Spiegelman	 D,	 Willett	 WC.	 (2000).	
Prospective	study	of	major	dietary	patterns	and	risk	of	coronary	heart	disease	inmen.	
Am	J	Clin	Nutr.	72(4):912-21.		
• Hughes	JB,	Hellmann	JJ.	(2005).	The	application	of	rarefaction	techniques	tomolecular	
inventories	of	microbial	diversity.	Methods	Enzymol.397:292-308.		
• Iida	 N,	 Dzutsev	 A,	 Stewart	 CA,	 Smith	 L,	 Bouladoux	 N,	Weingarten	 RA,	Molina	 DA,	
Salcedo	R,	 Back	 T,	 Cramer	 S,	Dai	 RM,	Kiu	H,	 Cardone	M,	Naik	 S,	 Patri	AK,	Wang	E,	
	
	
20	
	
Marincola	FM,	Frank	KM,	Belkaid	Y,	Trinchieri	G,	Goldszmid	RS.	 (2013).	Commensal	
bacteria	 control	 cancer	 response	 to	 therapy	 by	 modulating	 the	 tumor	
microenvironment.	Science.	342(6161):967-70.		
• Kane	 AV,	 Dinh	 DM,	 Ward	 HD.	 (2015).	 Childhood	 malnutrition	 and	 the	 intestinal	
microbiome.	Pediatr	Res.	77(1-2):256-62.	
• Koeth	RA,	Wang	Z,	Levison	BS,	Buffa	JA,	Org	E,	Sheehy	BT,	Britt	EB,	Fu	X,	Wu	Y,	Li	L,	
Smith	JD,	DiDonato	JA,	Chen	J,	Li	H,	Wu	GD,	Lewis	JD,	Warrier	M,	Brown	JM,	Krauss	
RM,	 Tang	 WH,	 Bushman	 FD,	 Lusis	 AJ,	 Hazen	 SL.	 (2013).	 Intestinal	 microbiota	
metabolism	of	L-carnitine,	a	nutrient	in	red	meat,	promotes	atherosclerosis.	Nat	Med.	
19(5):576-85.		
• Li	K,	Bihan	M,	Yooseph	S,	Methé	BA.	(2012).	Analyses	of	the	microbial	diversity	across	
the	human	microbiome.	PLoS	One.	7(6):e32118.		
• Li	M,	Wang	B,	Zhang	M,	Rantalainen	M,	Wang	S,	Zhou	H,	Zhang	Y,	Shen	J,	Pang	X,	Zhang	
M,	Wei	H,	Chen	Y,	Lu	H,	Zuo	J,	Su	M,	Qiu	Y,	Jia	W,	Xiao	C,	Smith	LM,	Yang	S,	Holmes	E,	
Tang	H,	Zhao	G,	Nicholson	JK,	Li	L,	Zhao	L.	(2008).	Symbiotic	gut	microbes	modulate	
human	metabolic	phenotypes.	Proc	Natl	Acad	Sci	U	S	A.	105(6):2117-22.		
• Lilly	 D,	 Stillwell	 R.	 (1965).	 Probiotics:	 Growth-Promoting	 Factors	 Produced	 By	
Microorganisms.	Science.	147(3659):747-8.		
• Liu	L,	Li	Y,	Li	S,	Hu	N,	He	Y,	Pong	R,	Lin	D,	Lu	L,	Law	M.	(2012).	Comparison	of	next-
generation	sequencing	systems.	J	Biomed	Biotechnol.	2012:251364.	
• Liu	Z,	Wang	W,	Huang	G,	Zhang	W,	Ni	L.	(2016).	In	vitro	and	in	vivo	evaluation	of	the	
prebiotic	effect	of	raw	and	roasted	almonds	(Prunus	amygdalus).	Journal	of	the	science	
of	food	and	agriculture	96:	1836-43.		
• Lozupone	C,	Lladser	ME,	Knights	D,	Stombaugh	J,	Knight	R.	(2011).	UniFrac:	an	effective	
distance	metric	for	microbial	community	comparison.	ISME	J.	5(2):169-72.	
• Moreira	AP,	Texeira	TF,	Ferreira	AB,	Peluzio	Mdo	C,	Alfenas	Rde	C.	(2012).	Influence	of	
a	high-fat	diet	on	gut	microbiota,	intestinal	permeability	and	metabolic	endotoxaemia.	
Br	J	Nutr.	108(5):801-9.		
	
	
21	
	
• Palmer	C,	Bik	 EM,	DiGiulio	DB,	Relman	DA,	Brown	PO.	 (2007).	Development	of	 the	
human		infant	intestinal	microbiota.	PLoS	Biol.	5(7):e177.	Epub	2007	Jun	26.	
• Parke	RB.	(1974).	Probiotics,	the	other	half	of	the	antibiotics	story.	Animal	Nutrition	
Health,	vol.	29,	pp.	4–8.	
• Patel	RM.	and	Lin	PW.	(2010).	Developmental	biology	of	gut-probiotic	interaction.	Gut	
Microbes.	1(3):	186–195.	
• Ramette	A.	(2007).	Multivariate	analyses	 in	microbial	ecology.	FEMS	Microbiol	Ecol.	
62(2):142-60.		
• Sandrini	S,	Aldriwesh	M,	Alruways	M,	Freestone	P.	(2015).	Microbial	endocrinology:	
host-bacteria	communication	within	the	gut	microbiome.	J	Endocrinol.	225(2):R21-34.		
• Schippa	S,	Conte	MP.	 (2014).	Dysbiotic	events	 in	gut	microbiota:	 impact	on	human	
health.	Nutrients.	6(12):5786-805.		
• Schloss	 PD.	 (2010)	 The	 effects	 of	 alignment	 quality,	 distance	 calculation	 method,	
sequence	filtering,	and	region	on	the	analysis	of	16S	rRNA	gene-based	studies.	PLoS	
Comput	Biol.	6(7):e1000844	
• Shah	N,	Tang	H,	Doak	TG,	Ye	Y.	(2011).	Comparing	bacterial	communities	inferred	from	
16S	 rRNA	 gene	 sequencing	 and	 shotgun	 metagenomics.	 Pac	 Symp	 Biocomput.	
2011:165-76.	
• Suez	J,	Korem	T,	Zeevi	D,	Zilberman-Schapira	G,	Thaiss	CA,	Maza	O,	Israeli	D,	Zmora	N,	
Gilad	S,	Weinberger	A,	Kuperman	Y,	Harmelin	A,	Kolodkin-Gal	I,	Shapiro	H,	Halpern	Z,	
Segal	E,	Elinav	E.	(2014).	Artificial	sweeteners	induce	glucose	intolerance	by	altering	
the	gut	microbiota.	Nature.	514(7521):181-6.		
• Tojo	R,	Suárez	A,	Clemente	MG,	de	los	Reyes-Gavilán	CG,	Margolles	A,	Gueimonde	M,	
Ruas-Madiedo	 P.	 (2014).	 Intestinal	 microbiota	 in	 health	 and	 disease:	 role	 of	
bifidobacteria	in	gut	homeostasis.	World	J	Gastroenterol.	20(41):15163-76.	
• Tyakht	AV,	Kostryukova	ES,	Popenko	AS,	Belenikin	MS,	Pavlenko	AV,	Larin	AK,	Karpova	
IY,	Selezneva	OV,	Semashko	TA,	Ospanova	EA,	Babenko	VV,	Maev	IV,	Cheremushkin	
SV,	Kucheryavyy	YA,	Shcherbakov	PL,	Grinevich	VB,	Efimov	OI,	Sas	EI,	Abdulkhakov	RA,	
Abdulkhakov	 SR,	 Lyalyukova	 EA,	 Livzan	MA,	 Vlassov	 VV,	 Sagdeev	 RZ,	 Tsukanov	VV,	
	
	
22	
	
Osipenko	MF,	Kozlova	IV,	Tkachev	AV,	Sergienko	VI,	Alexeev	DG,	Govorun	VM.	(2013).	
Human	gut	microbiota	community	structures	in	urban	and	rural	populations	in	Russia.	
Nat	Commun.	2013;4:2469.		
• Wang	 WL,	 Xu	 SY,	 Ren	 ZG,	 Tao	 L,	 Jiang	 JW,	 Zheng	 SS.	 (2015).	 Application	 of	
metagenomics	in	the	human	gut	microbiome.	World	J	Gastroenterol.	21(3):803-14.	
• Wong	 JM,	 de	 Souza	 R,	 Kendall	 CW,	 Emam	 A,	 Jenkins	 DJ.	 (2006).	 Colonic	 health:	
fermentation	and	short	chain	fatty	acids.	J	Clin	Gastroenterol.	40(3):235-43.		
• Wu	GD,	Chen	J,	Hoffmann	C,	Bittinger	K,	Chen	YY,	Keilbaugh	SA,	Bewtra	M,	Knights	D,	
Walters	WA,	Knight	R,	Sinha	R,	Gilroy	E,	Gupta	K,	Baldassano	R,	Nessel	L,	Li	H,	Bushman	
FD,	 Lewis	 JD.	 (2011).	 Linking	 long-term	 dietary	 patterns	 with	 gut	 microbial	
enterotypes.	Science.	334(6052):105-8.		
• Xu	Z,	Knight	R.	(2015).	Dietary	effects	on	human	gut	microbiome	diversity.	Br	J	Nutr.	
113	Suppl:S1-5.		 	
	
	
23	
	
2.	Aim	of	the	PhD	work	
The	 aim	 of	 this	 PhD	 work	 was	 the	 characterization	 of	 the	 intestinal	 microbial	 ecosystem	
through	bioinformatic	and	statistical	analyses	of	the	microbiomics	data	originated	from	three	
studies	 carried	 out	 on	 different	 human	 populations:	 healthy	 (non-diseased)	 adults,	
hyperlipidemic	and	normo-lipidemic	children	and	adolescents,	and	subjects	with	diagnosed	
irritable	bowel	syndrome	(IBS).	
Specifically,	the	three	studies	presented	in	this	PhD	theses	were	as	follows:		
• Probiotic	crossover	intervention	study:	A	randomized,	double-blind,	crossover,	placebo-
controlled	 intervention	 study	 was	 carried	 out	 to	 determine	 the	 impact	 of	 a	
Bifidobacterium	bifidum	strain	on	the	IME	of	adult	healthy	volunteers.		
• Children’s	dyslipidemia	single	arm	intervention	study:	 In	this	trial,	the	IME	of	children	
and	adolescents	with	primary	hyperlipidemia	(a	risk	 factor	 for	cardiovascular	diseases)	
was	 compared	 with	 the	 IME	 of	 control	 (normo-lipidemic)	 group.	 In	 addition,	 the	
modulatory	effect	of	the	regular	intake	of	hazelnuts	on	hyperlipidemic	subjects’s	IME	was	
examines	in	order	to	evaluate	if	the	modulation	of	IME	by	hazelnuts	ameliorates	the	lipid	
profile.	
• Irritable	 bowel	 syndrome	 (IBS)	 observational	 study:	 The	 aim	 of	 this	 trial	 was	 the	
characterization	of	the	IME	in	human	subjects	affected	by	IBS.	The	characterization	was	
performed	 through	 the	 analysis	 of	 the	 bacterial	 communities	 present	 in	 the	 faecal	
samples	collected	during	a	multicentre	intervention	trial	(Cremon	et	al.,	2017).	Irritable	
bowel	syndrome	is	the	most	common	gastrointestinal	disorder	in	western	countries.	IBS	
is	conventionally	classified	in	four	different	subtypes	based	on	bowel	clinical	symptoms:	
constipation,	 diarrhoea,	 alternating	 constipation	 and	 diarrhoea,	 and	 unsubtyped	 IBS.	
Clinical	and	 immunological	data	collected	during	the	trial	were	used	to	 investigate	the	
potential	correlations	between	the	IME	characteristic	for	a	specific	IBS	subtypes	and	the	
physiological	and	clinical	parameters	of	the	host,	including	bowel	symptoms,	faecal	levels	
of	IgA	and	cytokines,	and	depression/anxiety	scores.	
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3.	Results	
3.1	Consumption	of	a	Bifidobacterium	bifidum	
Strain	 for	 4	 Weeks	 Modulates	 Dominant	
Intestinal	Bacterial	Taxa	and	Faecal	Butyrate	in	
Healthy	Adults	
3.1.1	Introduction	
The	 prevailing	 notion	 that	 the	 deliberate	 intake	 of	 viable	 cells	 of	 certain	 microorganisms	
through	 food	 and	 supplements	 may	 be	 beneficial	 for	 health	 underlies	 the	 worldwide	
commercial	 success	 of	 probiotic	 products.	 Probiotics	 have	 been	 defined	 as	 “live	
microorganisms	that,	when	administered	in	adequate	amounts,	confer	a	health	benefit	on	the	
host”	(Hill	C.	et	al.	2014).	Therefore,	a	positive	consequence	on	consumer	health	is	an	intrinsic	
feature	of	any	formulation	that	 is	considered	a	probiotic.	Accordingly,	the	European	Union	
considers	the	term	probiotic	a	health	claim	per	se	(“reference	to	probiotic/prebiotic	implies	a	
health	benefit”	[Food	Safety	Authority	of	Ireland]).	However,	although	numerous	studies	have	
demonstrated	 the	 efficacy	 of	 different	 probiotic	 preparations	 in	 a	 number	 of	 pathological	
conditions	 (Sanders	 ME.	 et	 al.	 2013),	 the	 potential	 benefits	 associated	 with	 probiotic	
consumption	by	the	general	(healthy)	population	remain	unclear	(Kristensen	NB.	et	al.	2016).	
The	lack	of	a	clear	cause-and-effect	relationship	between	probiotic	intake	and	health	benefits	
for	the	general	consumer	 is	the	most	frequent	reason	stated	by	the	European	Food	Safety	
Authority	(EFSA)	for	the	rejection	of	all	health	claims	requested	for	probiotics.	
The	intestinal	microbiota	has	been	proposed	as	an	additional	organ	of	the	human	body	that	
performs	numerous	functions,	ranging	from	vitamin	production	and	immunomodulation	to	
improvement	 of	 nutrient	 bioavailability	 and	 competitive	 exclusion	 against	 potential	
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detrimental	 microorganisms	 (Goulet	 O.	 2015).	 Therefore,	 modification	 of	 the	 intestinal	
microbial	 ecosystem	 (IME)	 may	 potentially	 induce	 functional	 changes	 that	 affect	 host	
physiology	(Goulet	O.	2015)	and	is	generally	recognized	by	certain	health	agencies	(e.g.,	Italian	
Ministry	of	Health	and	Health	Canada	Federal	Department)	as	the	primary	element	supporting	
probiotic	efficacy.	Studies	that	describe	and	demonstrate	the	ability	of	specific	probiotics	to	
impact	the	IME	of	healthy	consumers,	however,	remain	limited	(Ferrario	C.	et	al.		2014,	Veiga	
P.	et	al.	2014).	Contradictory	results	have	also	been	obtained	(Derrien	M.	et	al.	2015),	possibly	
owing	to	differences	in	the	microbial	strain	used,	the	number	of	viable	cells	administered,	and	
the	 product	 formulation.	 Furthermore,	 the	 deep	 complexity	 and	 profound	 variability	 of	
microbiota	composition	among	subjects	can	hinder	the	recognition	of	actual	modifications.	As	
a	consequence,	the	impact	of	a	probiotic,	dietary,	or	pharmacologic	intervention	on	the	IME	
can	be	studied	only	by	adopting	sensitive	analytical	tools,	such	as	16S	rRNA	gene	profiling,	and	
an	appropriate	trial	design.	
We	therefore	performed	an	intervention	trial	with	a	crossover	design	and	used	16S	rRNA	gene	
profiling	 together	with	 short-chain	 fatty	 acid	 (SCFA)	 quantification	 in	 faecal	 samples	 from	
healthy	 adults	 to	 investigate	 the	 impact	 on	 the	 IME	 of	 a	 product	 containing	 a	 single	
Bifidobacterium	bifidum	strain.	The	strain	was	selected	as	a	representative	of	a	species	that	
has	been	reported	to	possess	numerous	host	interaction	properties	(Turroni	F.	et	al.	2014),	
including	marked	adhesion	to	enterocytes	(Guglielmetti	S.	et	al.	2013,	Turroni	F.	et	al.	2013),	
immunomodulation	 (Turroni	F.	et	al.	2013,	Guglielmetti	S.	et	al.	2014),	and	metabolism	of	
mucin	and	human	milk	oligosaccharides	(Wada	J.	et	al.	2008,	Duranti	S.	et	al.	2015).	
3.1.2	Materials	and	methods	
3.1.2.1	Participants	
Thirty-eight	healthy	human	volunteers	(21	women	and	17	men;	age,	24	to	54	years;	mean,	31	
years)	 participated	 in	 the	 study,	 named	 PROBIOTA-Bb:	 “Effect	 of	 the	 probiotic	 strain	
Bifidobacterium	bifidum	Bb	on	the	faecal	microbiota	of	healthy	adults.”	All	patients	provided	
written	informed	consent,	and	the	study	protocol	was	approved	by	the	Ethics	Committee	for	
Research	 of	 the	Università	 degli	 Studi	 di	Milano	 (opinion	 37/12,	 19	December	 2012).	 The	
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procedures	were	carried	out	 in	accordance	with	the	approved	trial	synopsis.	The	following	
inclusion	criteria	were	adopted	 for	 the	enrollment	of	participants:	age	between	18	and	55	
years,	good	general	health,	and	a	signed	consent	form.	The	following	exclusion	criteria	were	
adopted:	antibiotic	therapy	during	the	1	month	prior	to	the	first	visit,	 intentional	 intake	of	
probiotic	or	prebiotic	products	1	month	before	the	first	visit,	viral	or	bacterial	enteritis	during	
the	 2	months	 before	 the	 first	 visit,	 presence	 of	 gastrointestinal	 disorders	 (e.g.,	 diarrhoea,	
inflammatory	bowel	disease,	or	irritable	bowel	syndrome),	pregnancy	or	breastfeeding,	and	
recent	or	presumed	episodes	of	alcoholism	or	drug	addiction.	Participants	in	the	study	were	
prohibited	 from	 eating	 probiotic	 foods	 and	 supplements	 and	 any	 foods	 or	 supplements	
enriched	in	prebiotic	compounds.	Traditional	yogurt	was	allowed.	
3.1.2.2	Experimental	design	
The	PROBIOTA-Bb	study	was	a	randomized,	double-blind,	and	placebo-controlled	crossover	
trial	with	two	parallel	groups	(Figure	1).	The	study	consisted	of	a	4-week	prerecruitment	(run-
in)	phase,	followed	by	random	assignment	of	participants	to	group	A	(n	=	16)	or	group	B	(n	=	
19).	The	group	A	protocol	included	a	4-week	probiotic	treatment	(one	capsule	every	day	for	4	
weeks	 in	 addition	 to	 habitual	 diet),	 followed	 by	 a	 4-week	 washout	 period	 and	 a	 4-week	
placebo	phase.	Group	B	followed	the	opposite	sequence,	with	placebo,	washout,	and	then	
probiotic	treatment.	Participants	received	written	and	oral	instructions	to	store	the	capsules	
at	room	temperature,	to	avoid	exposure	of	the	capsules	to	heat	sources,	and	to	consume	one	
capsule	every	day	in	the	morning	at	least	15	min	before	breakfast	with	natural	(not	sparkling)	
water	(alternatively,	to	consume	the	capsule	in	the	evening	at	least	3	h	after	the	last	meal	of	
the	day).	No	research	has	tested	which	mode	of	administration	is	better,	ingesting	probiotics	
on	an	empty	stomach	or	with	meals.	In	this	study,	we	decided	to	invite	volunteers	to	consume	
capsules	on	an	empty	stomach	because	food	intake	may	vary	enormously	from	meal	to	meal	
and	 from	 subject	 to	 subject,	 differently	 affecting	 cell	 transit	 through	 the	 stomach	 and	
therefore	diversely	influencing	probiotic	activity.	
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Figure	1.	Schematic	of	study	design	and	flow.	
The	study	consisted	of	five	visits:	before	the	run-in	period	(visit	V0),	before	and	after	the	first	
treatment	(V1	and	V2,	respectively),	and	before	and	after	the	second	treatment	(V3	and	V4,	
respectively)	 (Figure	 1).	 During	 each	 consultation,	 participants	 completed	 a	 short	 food	
frequency	 questionnaire	 that	 was	 specifically	 prepared	 to	 include	 a	 section	 for	 items	
considered	potential	sources	of	prebiotic	fibers.	In	addition,	participants	compiled	a	weekly	
Bristol	stool	chart	to	report	their	bowel	habits.	
3.1.2.3	Products	used	in	the	trial	
The	probiotic	preparation	consisted	of	gelatin	uncoated	capsules	filled	with	Bifidobacterium	
bifidum	Bb	isolated	from	the	stool	from	a	healthy	adult	woman	and	available	in	the	culture	
collection	of	the	section	of	Food	Microbiology	and	Bioprocesses	at	the	Department	of	Food,	
Environmental	and	Nutritional	Sciences	(University	of	Milan).	Viable	and	total	bacterial	cell	
counts	were	performed	approximately	1	week	before	 the	beginning	of	 the	 trial	on	several	
randomly	selected	capsules.	Viable	counts	were	performed	by	serial	dilutions	and	plating	on	
de	Man-Rogosa-Sharpe	(MRS)	agar	plates	with	the	addition	of	0.05%	cysteine-HCl.	After	72	h	
of	anaerobic	incubation	at	37°C,	we	calculated	that	each	capsule	contained	1.3	×	109	±	0.1	×	
109	CFU.	Total	bacterial	cell	counts,	which	were	performed	by	cytofluorimetry	(BD	Accuri	C6;	
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Becton	Dickinson	Italia,	Milan,	Italy)	upon	SYBR	green	cell	labeling,	revealed	that	each	capsule	
contained	 3.8	 ×	 109	 bacterial	 cells	 per	 capsule.	 The	 capsules	 also	 contained	maltodextrin,	
cellulose	powder,	dextrose,	 a	 separating	agent	 (magnesium	salts	of	 edible	 fatty	 acid),	 and	
silica.	Placebo	capsules	were	identical	and	were	filled	with	maltodextrin	instead	of	dry	powder	
probiotic	bacteria.	This	 trial	was	registered	at	www.isrctn.com/search?q=ISRCTN56945491	
under	trial	no.	ISRCTN56945491.	
3.1.2.4	Collection	of	faecal	samples	and	extraction	of	metagenomic	
DNA	
A	faecal	sample	was	collected	from	each	participant	in	a	sterile	plastic	pot	no	more	than	24	h	
before	visits	V1,	V2,	V3,	and	V4.	According	to	the	recommendations	for	“storage	conditions	of	
intestinal	microbiota	matter	in	metagenomic	analysis”	(Cardona	S.	et	al.	2012),	participants	
were	asked	to	preserve	the	sample	at	room	temperature	until	delivery	to	the	laboratory.	At	
delivery,	 stool	 specimens	 were	 immediately	 stored	 at	 −80°C	 until	 metagenomic	 DNA	
extraction,	which	was	performed	within	14	days	by	means	of	a	QIAamp	DNA	stool	minikit	
(Qiagen,	 Valencia,	 CA),	 according	 to	 the	 manufacturer's	 specifications,	 adopting	 a	
temperature	of	95°C	in	step	three	to	maximize	bacterial	cell	lysis.	
3.1.2.5	Profiling	of	faecal	microbiota	composition	
The	 bacterial	 community	 structure	 of	 faecal	 samples	 was	 determined	 by	 16S	 rRNA	 gene	
profiling,	 as	 previously	 described	 (Milani	 C.	 et	 al.	 2013).	 In	 brief,	 a	 DNA	 fragment	
encompassing	the	variable	region	V3	of	the	16S	rRNA	gene	was	amplified	from	metagenomic	
DNA	 with	 the	 primers	 Probio_Uni	 (5ʹ-CCTACGGGRSGCAGCAG-3ʹ)	 and	 Probio_Rev	 (5ʹ-
ATTACCGCGGCTGCT-3ʹ)	 and	 was	 sequenced	 by	 means	 of	 Ion	 Torrent	 PGM	 sequencing	
technology	(Life	Technologies,	Carlsbad,	CA).	Specifically,	emulsion	PCR	was	performed	using	
the	Ion	OneTouch	200	template	kit	version	2	DL	(Life	Technologies,	Guilford,	CT),	according	to	
the	manufacturer's	 instructions.	Amplicon	 library	 sequencing	was	performed	on	316	Chips	
using	the	Ion	sequencing	200	kit	(Life	Technologies).	The	sequencing	runs	were	multiplexed,	
and	barcode	sequences	were	used	to	discriminate	the	samples.	Sequence	reads	were	then	
analyzed	using	the	bioinformatic	pipeline	Quantitative	Insights	Into	Microbial	Ecology	(QIIME)	
	
	
30	
	
version	1.7.0	 (Caporaso	JG.	et	al.	2010)	with	the	GreenGenes	database	updated	to	version	
13.5.	Bacterial	 relative	abundances	 in	each	 faecal	 sample	were	 reported	at	 the	 taxonomic	
levels	of	phylum,	class,	order,	family,	and	genus.	
3.1.2.6	Quantification	of	faecal	SCFAs	
SCFAs	were	quantified	in	the	faecal	samples	from	25	out	of	27	subjects	who	completed	the	
intervention	 trial.	 The	 remaining	 two	 subjects	 were	 excluded	 from	 the	 analysis	 due	 to	
insufficient	 faecal	material	 availability.	 Faecal	 samples	were	 extracted	 according	 to	 Huda-
Faujan	et	al.	(Huda-Faujan	N.	et	al.	2010),	with	some	modifications.	In	detail,	stool	specimens	
(100	mg)	were	suspended	in	2	ml	of	0.001%	HCOOH	and	vortexed	for	1	min.	The	suspension	
was	centrifuged	at	1,000	×	g	for	2	min	at	4°C,	and	the	supernatant	was	recovered.	The	residue	
was	extracted	again,	as	described	above.	The	supernatants	were	combined,	and	the	volume	
was	adjusted	to	5	ml	with	a	solution	of	0.001%	HCOOH	in	water.	All	extracts	were	stored	at	
−20°C.	Before	ultraperformance	 liquid	chromatography–high-resolution-mass	 spectrometry	
(UPLC-HR-MS)	 analysis,	 samples	were	 diluted	 1:100	 in	 0.001%	HCOOH	 and	 centrifuged	 at	
3,000	×	g	for	1	min.	
UPLC-HR-MS	analysis	was	carried	out	on	an	Acquity	UPLC	separation	module	(Waters,	Milford,	
MA,	 USA)	 coupled	 with	 an	 Exactive	 Orbitrap	 MS	 with	 an	 HESI-II	 probe	 for	 electrospray	
ionization	(Thermo	Scientific,	San	Jose,	CA,	USA).	The	ion	source	and	interface	conditions	were	
as	follows:	spray	voltage,	−3.0	kV,	sheath	gas	flow	rate,	35	arbitrary	units;	auxiliary	gas	flow	
rate,	10	arbitrary	units;	temperature,	120°C;	and	capillary	temperature,	320°C.	A	1.8-μm	HSS	
T3	column	(150	by	2.1	mm;	Waters)	was	used	for	separation	at	a	flow	rate	of	0.2	ml/min.	The	
eluents	 were	 0.001%	 HCOOH	 in	 MilliQ-treated	 water	 (solvent	 A)	 and	 CH3OH:CH3CN	 (1:1	
[vol/vol],	 solvent	 B).	 A	 5-μl	 aliquot	 of	 the	 sample	 was	 separated	 by	 the	 UPLC	 using	 the	
following	elution	gradient:	0%	B	for	4	min,	0	to	15%	B	in	6	min,	15	to	20%	B	in	5	min,	20%	for	
13	 min,	 and	 then	 return	 to	 initial	 conditions	 in	 1	 min.	 The	 column	 and	 samples	 were	
maintained	at	30	and	15°C,	respectively.	The	UPLC	eluate	was	analyzed	in	full-scan	MS	in	the	
range	m/z	50	to	130.	The	resolution	was	set	at	50	K,	the	automatic	gain	control	(AGC)	target	
was	 1E6,	 and	 the	 maximum	 ion	 injection	 time	 was	 100	 ms.	 The	 ion	 with	m/z	 91.0038,	
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corresponding	 to	 the	 formic	 acid	 dimer	 [2M-H]−,	 was	 used	 as	 the	 lock	 mass.	 The	 mass	
tolerance	 was	 2	 ppm.	 The	 MS	 data	 were	 processed	 using	 Xcalibur	 software	 (Thermo	
Scientific).	Analytical-grade	SCFAs	were	used	as	standards	(Sigma-Aldrich,	Milan,	Italy).	Five-
point	 external	 calibration	 curves	were	 adopted	 to	 quantify	 pyruvic,	 lactic,	 succinic,	 acetic,	
propionic,	 butyric,	 isobutyric,	 valeric,	 and	 isovaleric	 acids	 in	 faecal	 samples.	 SCFA	
concentrations	were	expressed	in	milligrams	per	kilogram	of	wet	feces.	
3.1.2.7	Statistics	
Statistical	analyses	were	performed	using	the	R	statistical	software	(version	3.1.2).	To	measure	
valid	 outcomes,	 only	 participants	 with	 100%	 compliance	 with	 the	 treatments	 and	 the	
experiment	protocol	were	included	in	the	analysis	(per-protocol	analysis).	The	numerical	value	
of	0	was	given	to	any	taxon	that	was	undetected	in	a	specific	sample	to	allow	a	comparison.	
Because	of	the	necessary	crossover	design	for	significant	results,	 intention-to-treat	analysis	
was	not	performed.	Differences	between	the	effects	on	microbiota	composition	of	probiotic	
and	placebo	treatments	were	evaluated	by	analyzing	the	data	with	nonparametric	Wilcoxon-
Mann-Whitney	test	with	Benjamini-Hochberg	correction	using	paired	data.	In	particular,	we	
performed	two	separated	statistical	analyses:	in	the	first	analysis,	we	compared	data	for	each	
taxon	before	versus	after	probiotic	intake;	in	the	second,	data	from	the	same	subjects	were	
compared	 before	 versus	 after	 placebo.	 This	 analysis	 allowed	 us	 to	 decide	 whether	 the	
population	 distributions	 were	 identical	 without	 assuming	 them	 to	 display	 a	 normal	
distribution.	A	nonparametric	test	derived	from	the	Shapiro-Francia	test	was	performed	for	
the	composite	hypothesis	of	normality.	The	P	value	was	computed	from	the	formula	given	by	
Royston	(Royston	P.	1993).	Repeated-measures	analysis	of	variance	(ANOVA)	was	used	when	
the	data	were	consistent	with	the	assumption	of	a	parametric	test	for	normal	distribution.	
Statistical	significance	was	set	at	a	P	value	of	≤0.05,	and	mean	differences	with	0.05	<	P	≤	0.10	
were	accepted	as	trends.	To	group	subjects	 into	enterotypes,	the	tutorial	by	the	European	
Molecular	Biology	Laboratory	(EMBL)	was	used	(http://enterotype.embl.de/).	With	respect	
to	differences	in	the	absolute	quantity	of	SCFAs,	the	subjects	were	clustered	using	a	Jensen-
Shannon	 divergence	 (JSD)	 distance	 and	 the	 Partitioning	Around	Medoids	 (PAM)	 algorithm	
based	 on	 the	 SCFA	 concentration.	 Moreover,	 the	 treatment	 response	 was	 evaluated	 by	
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performing	the	Wilcoxon-Mann-Whitney	test	with	Benjamini-Hochberg	correction	using	the	
paired-data	test.	
Accession	number(s).	Sequence	reads	have	been	deposited	in	NCBI's	Sequence	Read	Archive	
(ENA)	under	accession	no.	PRJEB11694.	
3.1.3	Results	
3.1.3.1	Study	compliance	and	questionnaire	analyses	
All	participants	tolerated	the	capsules	well,	and	no	adverse	events	were	reported.	Participants	
maintained	their	usual	dietary	habits	during	the	study,	and	no	significant	differences	in	the	
intake	of	potentially	prebiotic	foods	were	observed.	The	only	registered	modifications	were	
related	 to	 slight	 seasonal	 differences	 in	 the	 availability	of	 fruits	 and	 vegetables	 (the	 study	
began	 in	 June	 and	 ended	 in	 October).	 Participants'	 adherence	 to	 the	 study	 protocol	 was	
assessed	based	on	capsule	counts	and	faecal	sample	collection,	and	compliance	was	higher	
than	 95%.	 In	 total,	 38	 participants	 were	 assessed	 for	 eligibility,	 and	 35	 participants	 were	
randomly	assigned;	27	participants	 (77%)	 concluded	 the	 study,	with	14	participants	 in	 the	
randomization	group	A	(6	females	and	8	males)	and	13	participants	in	group	B	(7	women	and	
6	men).	 The	 drop-out	 rate	 of	 volunteers	who	 began	 the	 first	 treatment	was	 20%	 (n	 =	 7),	
consistent	 with	 the	 literature	 (Ferrario	 et	 al.	 2014),	 and	 apparently	 justified	 by	 the	 strict	
exclusion	criteria	and	quite	long	duration	of	the	study	(four	months).	No	significant	changes	
in	stool	consistency	and	evacuation	frequency	were	noted	according	to	the	analysis	of	data	
reported	in	stool	diaries	(data	not	shown).	
3.1.3.2	16S	rRNA	gene	profiling	revealed	that	the	faecal	microbiota	
composition	was	markedly	varied	among	the	participants	in	the	
PROBIOTA-Bb	study	
A	total	of	15,845,061	filtered	high-quality	sequence	reads	were	generated	(average,	135,428	
reads	per	sample),	with	a	mean	±	standard	deviation	(SD)	length	of	179	±	4	bp.	Rarefaction	
curves	indicated	that	most	faecal	microbiota	diversity	had	been	covered	(see	Figure	S1A	 in	
the	supplemental	material).	We	identified	a	total	of	93	bacterial	 families	and	190	bacterial	
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genera, with	a	minimum	number	of	23	families	and	38	genera	and	a	maximum	of	65	families	
and	125	genera	per	faecal	sample.	Only	17	genera	were	detected	in	all	subjects	at	the	4	time	
points	(8.9%	of	all	detected	genera),	and	47	genera	were	present	in	at	least	one	sample	for	all	
subjects	(approximately	25%	of	all	detected	genera). 
Subsequently,	microbiota	profiling	data	were	stratified	by	enterotyping	based	on	the	relative	
abundances	of	the	bacterial	genera	(Arumugam	et	al.	2011).	The	microbiota	compositions	of	
all	samples	in	this	study	were	clustered	in	two	groups	(Silhouette	index	[SI]	=	0.25;	see	Figure	
S2	 in	 the	 supplemental	 material)	 resembling	 the	 Bacteroides-dominant	 (Ba)	 and	 the	
Prevotella-dominant	 (Pr)	 enterotypes	 (Arumugam	 et	 al.	 2011).	 During	 the	 study,	 8	 of	 27	
subjects	changed	enterotypes;	specifically,	we	observed	11	shifts	from	one	enterotype	to	the	
other	(accounting	for	the	14.7%	of	all	possible	shifts),	with	3	during	the	probiotic	intervention,	
5	 in	 the	 placebo	 treatment,	 and	 3	 in	 the	 washout	 phase	 (Figure	 S2B).	 Therefore,	 the	
treatments	 did	 not	 affect	 the	 affiliation	of	 subjects	 to	 enterotypes.	 Interestingly,	 bacterial	
richness	differed	significantly	between	the	two	enterotype	clusters:	the	α-diversity	estimated	
by	the	Chao1	index	was	significantly	higher	in	the	Ba	group	than	in	the	Pr	group	of	samples	
(see	Figure	S3	in	the	supplemental	material).	
The	analyses	described	below	were	conducted	to	identify	the	effects	induced	by	the	probiotic	
intake	on	faecal	microbial	ecology	and	were	restricted	to	the	participants	who	received	the	
intended	interventions	in	accordance	with	the	protocol	(per-protocol	analysis).	
3.1.3.3	B.	bifidum	intake	did	not	modify	the	α-	and	β-diversities	of	the	
faecal	microbiota	
The	effect	of	the	probiotic	intervention	was	first	investigated	with	respect	to	the	modification	
induced	by	B.	bifidum	intake	on	the	richness	and	evenness	of	the	operational	taxonomic	units	
(OTUs)	 in	 each	 sample	 (α-diversity)	 and	 the	 intersample	 relationship	 of	 the	 bacterial	
compositions	 (β-diversity).	According	 to	both	parametric	 (repeated-measures	ANOVA)	 and	
nonparametric	(Wilcoxon	text)	statistics,	the	intake	of	B.	bifidum	did	not	significantly	affect	
the	intrasample	biodiversity	as	measured	by	the	Chao1	and	Shannon	coefficients	(predictors	
of	taxonomic	richness	and	evenness;	Figure	S1A	and	B	in	the	supplemental	material)	or	the	
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intersample	diversity	determined	by	principal-coordinate	analysis	(PCoA)	based	on	weighted	
and	unweighted	UniFrac	distances	(measure	of	β-diversity;	Figure	S1C).	
3.1.3.4	Probiotic	intervention	with	B.	bifidum	modified	the	relative	
abundance	of	dominant	taxa	in	the	faecal	microbiota	
The	Wilcoxon	test	with	Benjamini-Hochberg	correction	was	used	to	identify	the	bacterial	taxa	
(from	 phylum	 to	 genus)	 that	 were	 significantly	 affected	 by	 the	 probiotic	 or	 placebo	
treatments.	This	nonparametric	statistical	analysis	revealed	that	B.	bifidum	Bb	intake	had	a	
greater	 impact	 than	 placebo	 on	 the	 relative	 abundance	 of	 OTUs	 (see	 Table	 S1	 in	 the	
supplemental	 material).	 In	 detail,	 the	 probiotic	 intervention	 induced	 the	 significant	
modification	of	25	taxa,	whereas	only	13	taxa	were	different	after	placebo.	More	importantly,	
only	1	OTU	that	changed	during	the	placebo	treatment	had	a	relative	abundance	above	1%	
(undefined	members	of	 the	Bacteroidales	order,	 from	1.10	to	0.46%;	P	=	0.036;	Table	S1),	
whereas	probiotic	intake	significantly	modulated	the	abundance	of	several	dominant	taxa	of	
the	 faecal	 microbiota,	 including	 the	 families	 Prevotellaceae	 (mean	 value	 of	 the	 relative	
abundances	from	14.18	to	11.97%;	P	=	0.041),	Rikenellaceae	(from	3.99	to	5.92%;	P	=	0.010),	
and	Ruminococcaceae	(from	12.21	to	15.27%;	P	=	0.039),	and	the	genus	Prevotella	(from	14.16	
to	11.96%;	P	=	0.034)	(Figure	2;	see	also	Table	S1).	
	
Figure	 2.	Relative	 abundance	of	 dominant	 bacterial	 families	 in	 faecal	 samples	 significantly	
modified	 by	 the	 probiotic	 treatment.	 Data	 are	 shown	 as	 Tukey	 box	 plots.	 Statistically	
significant	 differences	 are	 according	 to	 the	Wilcoxon-Mann-Whitney	 test	 with	 Benjamini-
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Hochberg	correction;	*,	P	<	0.05.	
The	statistical	strength	of	the	observed	differences	between	the	effects	induced	by	the	two	
treatments	is	corroborated	by	the	comparison	of	OTU	relative	abundances	before	treatments	
(i.e.,	for	samples	collected	at	V1	and	V3;	Figure	1).	The	Wilcoxon	test	revealed	that	only	three	
OTUs	 with	 relative	 abundances	 of	 less	 than	 1%	 were	 significantly	 different	 between	 the	
placebo	and	probiotic	pretreatment	phases	(see	Table	S1	in	the	supplemental	material).	
We	did	not	find	a	significant	modulation	of	the	genus	Bifidobacterium	by	probiotic	treatment,	
suggesting	that	the	intake	of	a	billion	B.	bifidum	cells	was	not	enough	to	affect	the	relative	
abundance	of	the	entire	genus.	On	the	contrary,	we	found	that	the	relative	abundance	of	the	
reads	 associated	 with	 the	 B.	 bifidum	 species	 increased	 importantly	 upon	 probiotic	
consumption,	changing	from	a	median	below	the	detection	limit	to	0.005%.	In	contrast,	during	
placebo	 treatment,	 the	 relative	 abundance	of	B.	 bifidum	 reads	 decreased	 from	0.002%	 to	
below	the	detection	limit.	
Finally,	we	also	observed	that	the	 impact	of	the	probiotic	 intervention	on	enterotypes	was	
greater	on	the	Pr	group	of	samples	(see	Table	S2	in	the	supplemental	material);	this	result,	
however,	may	have	been	merely	a	reflection	of	the	change	in	Prevotella	levels.	
3.1.3.5	Probiotic	intervention	modulated	the	faecal	levels	of	butyrate	
We	quantified	the	concentration	of	SCFAs	in	faecal	samples	by	UPLC-HR-MS	(see	Table	S3	in	
the	 supplemental	material).	 Statistical	 analyses	 (repeated-measures	 ANOVA	 and	Wilcoxon	
test)	 revealed	that	neither	the	probiotic	nor	placebo	 intervention	significantly	affected	the	
levels	of	SCFAs	quantified	in	all	faecal	samples	(see	Table	S4	in	the	supplemental	material).	
Subsequently,	 we	 clustered	 subjects	 by	 PCoA	 based	 on	 the	 concentrations	 of	 the	 most	
abundant	 faecal	 SCFAs,	 i.e.,	 acetate,	 butyrate,	 and	 propionate.	 According	 to	 the	 highest	
Silhouette	coefficient	of	clustering	prediction	 (SI	=	0.43),	we	separated	the	samples	 in	 two	
groups	 (Figure	 3A),	 which	 do	 not	 correspond	 to	 enterotype	 clusters.	 SCFA	 group	 H	 was	
characterized	 by	 higher	 concentrations	 of	 acetate,	 butyrate,	 isovalerate,	 propionate,	
succinate,	and	valerate	than	the	second	group	(SCFA	group	L;	Figure	3B).	Furthermore,	SCFA	
group	H	 exhibited	 significantly	 lower	 acetate/butyrate	 and	 acetate/propionate	 ratios	 than	
	
	
36	
	
SCFA	group	L	(Figure	3C).	Subsequently,	we	investigated	whether	the	intervention	affected	
faecal	levels	of	taxa	and	SCFAs	in	the	two	groups.	We	did	not	find	significant	modifications	of	
taxon	relative	abundance	upon	probiotic	or	placebo	treatment	in	the	SCFA	groups	(see	Table	
S5	 in	 the	supplemental	material).	On	 the	contrary,	we	determined	 that	 the	probiotic	 (but,	
notably,	not	the	placebo)	treatment	induced	a	significant	change	in	the	faecal	level	of	butyrate	
in	both	SCFA	groups	(Figure	3D;	see	also	Table	S3	in	the	supplemental	material).	Specifically,	
the	median	of	butyrate	levels	increased	from	5.2	to	8.2	mg	kg−1	of	wet	feces	in	group	L	and	
dropped	from	17.9	to	12.0	mg	kg−1	of	wet	feces	in	group	H,	erasing	the	significant	difference	
initially	existing	in	the	levels	of	this	SCFA	between	the	groups	(Figure	3D).	None	of	the	other	
SCFAs	were	significantly	affected	by	the	treatments	(Table	S3).	
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Figure	3.	Short-chain	fatty	acid	(SCFA)	cluster	analysis.	(A)	Principal-coordinate	analysis	(PCoA;	
the	 first	 two	 principal	 components	 are	 shown);	 clustering	 was	 based	 on	 the	 faecal	
concentrations	of	acetate,	butyrate,	and	propionate	using	JSD	distance	and	the	Partitioning	
around	Medoids	(PAM)	algorithm.	(B)	Tukey	box	plots	representing	the	proportion	of	main	
faecal	 SCFAs	 in	 groups	 H	 (displaying	 higher	 concentrations	 of	 SCFAs)	 and	 L	 (lower	 SCFA	
concentrations).	 (C)	 Tukey	box	plots	of	 the	 ratios	between	 the	 three	main	 faecal	 SCFAs	 in	
groups	H	 and	 L.	 (D)	 Tukey	 box	 plots	 representing	 the	 effect	 of	 the	 probiotic	 and	 placebo	
intervention	 on	 butyrate	 levels	 in	 SCFA	 groups	 H	 and	 L.	 Asterisks	 are	 according	 to	 the	
Wilcoxon-Mann-Whitney	 test	 (with	 paired	 data,	 when	 possible)	 with	 Benjamini-Hochberg	
correction	 to	 determine	 statistically	 significant	 differences	 between	 groups	 (B	 to	 D)	 and	
before	and	after	the	probiotic	treatment	(D).	*,	P	<	0.05;	**,	P	<	0.01;	***,	P	<	0.001;	n.s.,	no	
significant	difference.	
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3.1.4	Discussion	
The	 PROBIOTA-Bb	 trial	 was	 undertaken	 to	 contribute	 to	 the	 elucidation	 of	 the	 probiotic	
potential	 of	 strain	 of	 the	 species	 Bifidobacterium	 bifidum,	 which	 is	 a	 specialized	 human	
commensal	 possessing	 a	 large	 arsenal	 of	 host	 interaction	 properties	 (Turroni	 et	 al.	 2014).	
Specifically,	we	 studied	 the	 impact	 of	B.	 bifidum	 Bb	on	 the	 intestinal	microbial	 ecology	of	
healthy	 adults.	 Strain	 Bb	 was	 isolated	 from	 the	 feces	 from	 a	 healthy	 adult	 woman	 and,	
according	to	in	silico	analysis	of	its	draft	genome	(our	unpublished	data),	possesses	the	genetic	
determinants	 known	 to	 support	 the	B.	 bifidum-host	 interaction,	 including	 genes	 encoding	
sortase-dependent	pili	(Turroni	et	al.	2013),	mucin-metabolizing	enzymes	(Turroni	et	al.	2011),	
human-milk	oligosaccharide	hydrolases	(Ashida	H.	et	al.	2009),	BopA	outer	surface	lipoprotein	
(Guglielmetti	et	al.	2008),	and	Tal	transaldolase	(González-Rodríguez	et	al.	2015).	In	this	study,	
we	used	capsules	containing	approximately	one	billion	viable	Bb	cells,	which	corresponds	to	
the	 minimal	 daily	 dosage	 recommended	 for	 probiotics	 by	 the	 Italian	 Ministry	 of	 Health	
(Ministero	della	Salute	2013).	
16S	rRNA	gene	profiling	revealed	considerable	variation	of	the	faecal	microbiota	composition	
of	 the	 volunteers	 enrolled	 in	 the	 PROBIOTA-Bb	 trial,	 consistent	 with	 previous	 studies	
(Yatsunenko	et	al.	2012,	Davenport	et	al.	2014).	These	interindividual	differences	support	the	
choice	of	the	crossover	design,	in	which	individual	participants	serve	as	their	own	controls,	
resulting	in	the	reduction	of	interindividual	variation.	
To	 characterize	 the	 wide	 interindividual	 variability	 of	 the	 faecal	 microbiota,	 we	 clustered	
samples	according	to	common	features	in	the	taxonomic	composition.	In	light	of	the	theory	
suggesting	 that	 intestinal	 microbiota	 variation	 is	 generally	 stratified	 and	 not	 continuous	
(Arumugam	et	al.	2011),	we	adopted	the	enterotype	classification	to	cluster	the	data	collected	
during	the	PROBIOTA-Bb	study,	according	to	the	relative	abundance	of	bacterial	genera.	The	
proposed	 approach	 for	 enterotyping	 is	 subject	 to	 limitations.	 In	 particular,	 enterotyping	
reflects	 overconfidence	 in	 the	 assumption	 of	 discrete	 enterotypes	 without	 consistent	
evidence	to	refute	the	simpler	hypothesis	of	continuous	variation	of	the	microbiota	(Knights	
et	al.	2014).	The	existence	of	discrete	structures	for	gut	microbiota	has	not	been	convincingly	
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demonstrated	(Gorvitovskaia	et	al.	2016)	and	represents	a	crucial	assumption	in	applying	an	
appropriate	 prediction	 model.	 Nonetheless,	 we	 used	 the	 original	 tutorial	 to	 define	
enterotypes	(http://enterotype.embl.de/enterotypes.html)	in	the	present	study,	because	it	
has	been	demonstrated	to	be	useful	to	correlate	the	gut	microbial	community	structure	with	
host	 biomarkers	 and	 diet	 (Wang	 et	 al.	 2014,	 Vandeputte	 et	 al.	 2016).	 In	 our	 study,	
enterotyping	 clustered	 the	microbiota	 taxonomic	 structures	 of	 the	 faecal	 samples	 in	 two	
groups	corresponding	to	the	most	common	enterotypes	of	healthy	adult	populations,	namely,	
the	Bacteroides-dominant	(Ba)	and	the	Prevotella-dominant	(Pr)	enterotypes	(Arumugam	et	
al.	2011,	Vandeputte	et	al.	2016).	
In	our	trial,	the	α-	and	β-diversities	were	not	significantly	affected	by	probiotic	intervention.	
In	a	recent	intervention	study	that	was	performed	adopting	the	same	trial	design	(Ferrario	et	
al.	2014),	the	administration	of	capsules	containing	the	probiotic	strain	Lactobacillus	paracasei	
DG	did	not	modify	the	α-diversity	of	participants'	faecal	samples,	but,	in	contrast	to	the	results	
of	 this	 study,	 induced	 a	 significant	 change	 in	 the	β-diversity	 in	 terms	of	weighted	UniFrac	
distances.	 Kim	 et	 al.	 (Kim	 et	 al.	 2013)	 did	 not	 observe	 significant	 alterations	 in	 α-	 and	 β-
diversities	following	the	consumption	of	various	probiotic	products;	however,	a	very	limited	
number	 of	 subjects	 per	 group	 (only	 three)	 were	 used	 in	 that	 study.	 Furthermore,	 no	
alterations	in	α-	and	β-diversities	were	observed	in	the	faecal	microbiota	of	1-	to	2-year-old	
children	following	the	consumption	of	probiotic	milk	containing	Lactobacillus	rhamnosus	GG	
(LGG),	 Lactobacillus	 acidophilus	 La-5,	 and	 Bifidobacterium	 animalis	 subsp.	 lactis	 Bb-12	
(Dotterud	et	al	2015).	Other	 intervention	trials	 investigating	the	effect	of	probiotics	on	the	
intra-	and	interindividual	biodiversities	of	the	gut	microbiota	in	healthy	subjects	have	not	been	
reported.	Taken	together,	these	data	confirm	the	literature	(although	limited)	suggesting	that	
probiotic	intake	may	be	an	insufficiently	weak	perturbation	to	modify	the	α-	and	β-diversities	
of	 the	 intestinal	 microbiota	 of	 healthy	 adults.	 This	 hypothesis	 is	 plausible	 in	 light	 of	 the	
recognized	stability	throughout	adulthood	and	the	reported	resilience	of	the	human	intestinal	
microbiota	to	short-term	dietary	changes	(Lozupone	et	al.	2012).	
This	study	revealed	that	the	intervention	with	strain	Bb	affected	the	relative	abundances	of	
several	dominant	taxa	of	the	intestinal	microbiota;	specifically,	the	families	Ruminococcaceae	
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and	 Rikenellaceae	 increased,	 whereas	 Prevotellaceae	 decreased.	 Remarkably,	
Ruminococcaceae,	 Prevotellaceae,	 and	 Rikenellaceae	 (together	 with	 Lachnospiraceae	 and	
Bacteroidaceae)	have	been	identified	by	metatranscriptomics	as	the	predominant	families	of	
the	active	microbiota	(Gosalbes	et	al.	2011).	
Ruminococcaceae	 is	 a	 family	 of	 obligate	 anaerobes	 that	 include	 bacteria	 (e.g.,	
Faecalibacterium,	Ruminiclostridium,	 and	Ruminococcus	 spp.)	 that	may	degrade	numerous	
polysaccharides	in	the	lower	gastrointestinal	tract,	such	as	starch,	cellulose,	and	xylan,	and	
produce	SCFAs	(Flint	et	al.	2008).	The	expansion	of	Ruminococcaceae	in	centenarians	has	been	
reported,	 with	 a	 positive	 correlation	 with	 high-fiber	 diets	 (Wang	 et	 al.	 2015)	 and	 after	
intervention	with	resistant	starch	(Salonen	et	al.	2014).	Furthermore,	in	the	study	by	Martínez	
et	 al.,	Ruminococcaceae	were	more	dominant	 in	 normoweight	 than	obese	 individuals	 and	
negatively	correlated	with	markers	of	inflammation	(Martínez	et	al.	2012).	A	lower	abundance	
of	this	taxon	was	associated	with	exaggerated	Toll-like	receptor	2	(TLR-2)	responses	and	an	
increased	risk	of	developing	IgE-associated	eczema	in	infants	(West	et	al.	2015).	The	relative	
abundance	of	Ruminococcaceae	was	also	lower	in	acute-chronic	liver	failure	patients	(Chen	et	
al.	2015);	in	the	same	study,	a	negative	correlation	of	Ruminococcaceae	with	tumor	necrosis	
factor	alpha	(TNF-α)	and	interleukin	6	(IL-6)	and	endotoxemia	was	also	observed.	Finally,	two	
recent	 studies	 reported	 that	Ruminococcaceae	 are	diminished	 in	 the	guts	of	 inflammatory	
bowel	disease	(IBD)	patients,	particularly	those	with	ileal	Crohn's	disease	(Willing	et	al.	2010,	
Morgan	et	al.	2012).	Therefore,	a	number	of	observations	suggest	that	Ruminococcaceae	are	
commonly	associated	with	a	healthy	gut	microbiota	and	may	exert	a	protective	role	on	host	
health.	
A	 couple	 of	 studies	 have	 also	 suggested	 a	 potential	 positive	 role	 for	 Rikenellaceae,	 a	
Bacteroidales	family	significantly	enhanced	by	probiotic	treatment	with	strain	B.	bifidum	Bb.	
Specifically,	Rikenellaceae	 family	members	were	depleted	 in	patients	who	had	chronic	HIV	
infection	relative	to	HIV-uninfected	controls	(Dinh	et	al.	2015)	and	suppressed	in	IBD	patients	
relative	to	healthy	controls	(Morgan	et	al.	2012,	Scaldaferri	et	al.	2015).	Conversely,	one	study	
reported	a	higher	abundance	of	Ruminococcaceae	and	Rikenellaceae	and	a	decrease	in	the	
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abundance	 of	Prevotellaceae	 in	 the	 terminal	 ileum	microbiota	 of	 subjects	with	 ankylosing	
spondylitis	(AS)	compared	with	healthy	controls	(Costello	et	al.	2015).	
In	 our	 study,	 the	 probiotic	 intervention	 reduced	 the	 relative	 abundance	 of	 the	 family	
Prevotellaceae	and,	particularly,	the	genus	Prevotella.	The	relative	richness	of	Prevotella	spp.	
and	Prevotellaceae	is	frequently	modulated	following	dietary	interventions	(Clemente-Postigo	
et	al.	2013,	Karl	et	al.	2015)	and,	in	general,	by	lifestyle	modifications,	suggesting	that	these	
microorganisms	 represent	active	and	 rapidly	 reacting	 components	of	 the	human	 intestinal	
microbiota	 (Gosalbes	 et	 al.	 2011).	Notably,	Prevotella	 spp.	 are	 the	dominant	 colonizers	 of	
agrarian	 societies	 and	are	 associated	with	 long-term	diets	 rich	 in	plant	 carbohydrates	 and	
fibers,	whereas	the	abundance	of	Bacteroides	spp.	is	increased	in	individuals	from	urbanized	
societies	and	is	associated	with	diets	high	in	animal	fat	and	proteins	(Wu	et	al.	2011,	De	Filippo	
et	al.	2010).	Although	all	subjects	enrolled	in	the	present	study	lived	in	an	urbanized	European	
area	(Lombardia	region),	Prevotella	was	the	dominant	genus	in	approximately	30%	of	study	
participants	(8	of	27	subjects	at	V1).	This	high	prevalence	of	Prevotella	in	the	population	under	
study	may	potentially	be	explained	by	the	higher-than-average	fruit	and	vegetable	(and	thus	
fiber	and	starch)	intake	of	Italian	subjects	(De	Filippis	et	al.	2015).	
A	few	studies	have	suggested	that	the	abundance	of	Prevotellaceae/Prevotella	(Bacteroidetes	
phylum)	 is	 inversely	 associated	with	 the	 relative	 richness	 of	Ruminococcaceae	 (Firmicutes	
phylum).	For	 instance,	 increased	Ruminococcaceae	have	been	proposed	to	compensate	for	
lower	 levels	 of	 Prevotellaceae	 in	 Parkinson's	 disease	 patients	 (Scheperjans	 et	 al.	 2015).	
Conversely	to	Ruminococcaceae,	Prevotellaceae	have	been	observed	to	be	overrepresented	
in	obese	people	 (Zhang	et	al.	2009).	 Furthermore,	although	 typically	associated	with	plant	
carbohydrate	consumption,	enriched	abundance	of	Prevotella	has	also	been	linked	to	the	high	
consumption	of	L-carnitine-containing	foods,	such	as	red	meat	(Koeth	et	al.	2014).	
Notably,	 several	 studies	 also	 suggested	 a	 potential	 role	 of	 Prevotellaceae	 as	 intestinal	
pathobionts.	 The	 family	 Prevotellaceae	 was,	 in	 fact,	 demonstrated	 to	 elicit	 a	 strong	
inflammatory	 response	 in	 the	 guts	 of	mice	 (Elinav	 et	 al.	 2011)	 and	 is	 overrepresented	 in	
patients	with	 ulcerative	 colitis	 (Lucke	 et	 al.	 2006).	 An	 increase	 in	Prevotella	 spp.	was	 also	
reported	in	the	intestinal	lumen	microbiota	of	colorectal	cancer	patients	(Chen	et	al.	2012)	
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and	 in	 children	diagnosed	with	 irritable	bowel	 syndrome	 (Rigsbee	et	al.	2012).	 Finally,	 the	
species	 Prevotella	 copri	 was	 identified	 as	 strongly	 correlated	 with	 disease	 in	 new-onset	
untreated	rheumatoid	arthritis	patients	(Scher	et	al.	2013).	However,	increased	abundance	of	
P.	 copri	 has	 also	 been	 associated	 with	 dietary	 fiber-induced	 improvement	 in	 glucose	 and	
insulin	 responses	 (Kovatcheva-Datchary	 et	 al.	 2015).	 In	 addition,	 low	Prevotellaceae	 levels	
have	been	reported	 in	patients	with	type	1	diabetes	(Brown	et	al.	2011)	and	children	with	
autism	 (Kang	 et	 al.	 2013).	 However,	 a	 subsequent	 study	 involving	 a	 larger	 population	 of	
autistic	children	reported	the	opposite	result	(i.e.,	a	significant	increase	in	Prevotella	spp.	[Son	
et	 al.	 2015]).	 In	 conclusion,	 the	 scientific	 literature	 is	 far	 from	 a	 final	 and	 unambiguous	
understanding	of	the	role	of	a	specific	taxon	in	host	health;	plausibly,	the	same	bacterial	taxa	
of	the	gut	microbiota	may	exert	opposite	effects	on	the	host	(health	preserving	versus	health	
threatening),	depending	on	physiological	background.	This	variability	 is	particularly	true	for	
Prevotella	 spp.,	which	appear	 to	be	critical	bacteria	 for	healthy	microbiota	 that	have	been	
linked	 to	 plant-rich	 diets	 but	 also	 to	 chronic	 inflammatory	 conditions	 (Ley	 et	 al.	 2016).	 In	
addition,	 genera	 such	 as	 Prevotella	 include	 numerous	 species	 that	 possess	 wide	 genetic	
diversity	 and	 strain	 differences	 within	 species,	 which	 may	 at	 least	 partially	 explain	 the	
observed	differences	in	interactions	between	Prevotella	and	its	host	(Ley	et	al.	2016).	
Modification	of	the	intestinal	microbiota	structure	may	potentially	lead	to	alterations	of	the	
gut	levels	of	SCFAs,	which	are	microbial	metabolic	products	exerting	a	number	of	effects	on	
host	physiology	(den	Besten	et	al.	2013).	Diet	(probiotics	included)	may	modify	the	level	of	
SCFAs	 in	 the	 intestinal	 lumen	 by	 affecting	 their	 uptake/utilization	 by	 host	 and	 intestinal	
microbes	or	by	changing	the	relative	abundance	of	specific	butyrate-producing	bacteria.	 In	
our	 study,	 we	 observed	 the	 modification	 of	 Clostridiales	 bacteria	 of	 the	 family	
Ruminococcaceae,	 which	 are	 among	 the	 primary	 producers	 of	 SCFAs	 and,	 in	 particular,	
butyrate	in	the	human	large	intestine.	We	therefore	quantified	the	concentrations	of	SCFAs	
in	faecal	samples	by	UPLC-HR-MS.	We	observed	that	subjects	could	be	clustered	into	groups,	
H	and	L,	according	to	the	levels	of	the	three	most	abundant	SCFAs.	Group	H	was	characterized	
by	higher	concentrations	of	several	SCFAs,	including	butyrate,	than	those	in	group	L.	Notably,	
we	 observed	 that	 the	 probiotic	 treatment	 induced	 a	 significant	 change	 in	 butyrate	 levels,	
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which	decreased	in	group	H	and	increased	in	L.	Notably,	this	modification	was	not	observed	
with	placebo	treatment.	A	similar	effect	on	faecal	butyrate	levels	was	also	observed	during	an	
intervention	study	with	the	probiotic	strain	Lactobacillus	paracasei	DG	(Ferrario	et	al.	2014).	
In	light	of	literature	suggesting	that	excessive	intestinal	butyrate	may	be	detrimental	in	certain	
physiological	 conditions,	 such	 as	 irritable	 bowel	 syndrome	 (IBS)	 or	 metabolic	 syndrome	
(Bourdu	et	al.	2005,	Payne	et	al.	2011),	although	considered	improbable	by	some	researchers	
(Conlon	et	al.	2015),	we	recently	postulated	the	potential	existence	of	an	optimal	butyrate	
concentration	range	in	the	human	intestine	(Ferrario	et	al.	2014,	Guglielmetti	and	Riso	2015).	
In	this	context,	the	hypothesis	can	be	made	that	probiotics	might	be	used	to	decrease	high	
butyrate	 concentrations	 or	 increase	 low	 butyrate	 concentrations	 to	 maintain	 butyrate	
homeostasis	 in	 healthy	 people,	 potentially	 preventing	 disorders	 associated	 with	 altered	
butyrate	levels	(Guglielmetti	and	Riso	2015).	
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3.1.5	Supplementary	material	
	
Figure	S1.	Analyses	of	the	overall	faecal	microbiota	diversity	in	(panels	A	and	C)	and	among	
(panel	B)	the	Probiota-Bb	faecal	samples.	A,	bacterial	richness	estimated	through	rarefaction	
curves	using	Chao1	coefficient	as	α-diversity	predictors.	B,	biodiversity	according	to	Chao1	
coefficient	of	α-diversity,	before	and	after	 the	 treatments.	C,	Principal	Coordinate	Analysis	
(PCoA)	 based	on	Weighted	Unifrac	 expressing	 the	β-diversity	 of	 samples.	Axes	 of	 the	 two	
panels	are	the	two	most	informative	components	explaining	the	differences	among	samples	
(percent	 of	 explained	 variation	 is	 shown	 between	 brackets	 on	 each	 axis).	 Each	 sample	 is	
represented	by	the	overall	microbiota	composition	of	a	single	faecal	specimen.	Samples	are	
separated	into	four	categories:	before	and	after	probiotic	treatment	(panels	A),	and	before	
and	after	probiotic	treatment.	∑|v|,	the	sum	of	absolute	Euclidean	distances	of	paired	points	
calculated	as	the	sum	of	square	variances	of	the	coordinates	of	each	point	before	and	after	a	
treatment	 (|v|	 =	 √	 [(xi-xj)2+	 (yi-yj)2],	 where	 «i»	 indicates	 before	 treatment	 and	 «j»	 after	
treatment).	Paired	points	are	the	sample	before	and	the	sample	after	a	treatment	for	a	specific	
subject.	 For	 coordinates	 PC1	 vs	 PC2,	 absolute	 distances	 were	 not	 significantly	 different	
between	the	probiotic	and	the	placebo	treatments.	
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Figure	 S2.	 Analyses	 of	 enterotypes	 in	 samples	 of	 the	 PROBIOTA-Bb	 trial.	 A.	 Principal	
Coordinated	Analysis	 (PCA;	 the	 first	 two	 principal	 components	 are	 shown);	 clustering	was	
based	on	genus	relative	abundance	using	JSD	distance	and	the	Partitioning	Around	Medoids	
(PAM)	algorithm.	The	optimal	number	of	clusters	was	determined	through	Calinski-Harabasz	
(CH)	 index	 (59)	 and	 the	 Silhouette	 coefficient.	 B,	 shifts	 between	 enterotypes	 of	 faecal	
microbiota	compositions	in	a	single	subject;	red,	blue,	and	dotted-black	arrows	indicate	shifts	
that	 occurred	 across	 the	 probiotic,	 placebo,	 and	 wash-out	 phases	 respectively.	 C,	 Tukey	
boxplots	of	the	dominant	bacterial	genera	distribution	in	the	two	identified	enterotypes.	
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Figure	S3.	Tukey	boxplots	representing	bacterial	taxonomic	richness	of	enterotypes	assessed	
with	a	Chao1	estimator	of	α-diversity.	Ba,	Bacteroides-dominated	enterotypes;	Pr,	Prevotella-
dominated	enterotype.	Statistically	significant	difference	is	according	to	Mann	Whitney	test;	
***,	P	<	0.001.	
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ALL SUBJECTS p values baseline    post 
PROBIOTIC    
k_Bacteria;Other 0.030 1.536% 2.812% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;g_ 0.018 0.162% 0.364% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae 0.041 14.179% 11.973% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella 0.034 14.158% 11.963% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae 0.010 3.987% 5.919% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_undefined 0.013 3.823% 5.640% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;Other 0.015 0.120% 0.158% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_Alistipes 0.013 0.044% 0.122% 
p_Firmicutes;c_Bacilli;o_Bacillales;f_Staphylococcaceae;g_Staphylococcus 0.023 0.000% 0.005% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_;g_undefined 0.044 0.000% 0.000% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_;Tissierellaceae;g_Peptoniphilus 0.029 0.001% 0.002% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae 0.005 0.405% 0.838% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_undefined 0.006 0.389% 0.810% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;Other 0.006 0.016% 0.027% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_Christensenella 0.042 0.000% 0.001% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Dehalobacteriaceae 0.042 0.002% 0.005% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Dehalobacteriaceae;g_Dehalobacterium 0.046 0.001% 0.004% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae 0.039 12.212% 15.271% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Anaerotruncus 0.029 0.026% 0.031% 
p_Firmicutes;c_Clostridia;o_Clostridiales;Other 0.008 1.289% 1.794% 
p_Firmicutes;c_Clostridia;Other 0.030 0.107% 0.215% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_;Eubacterium; 0.010 0.023% 0.056% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;Other 0.038 0.004% 0.017% 
p_Proteobacteria;c_Deltaproteobacteria;o_Desulfovibrionales;f_Desulfovibrionaceae 0.014 0.133% 0.245% 
p_Proteobacteria;c_Deltaproteobacteria;o_Desulfovibrionales;f_Desulfovibrionaceae;g_Bilophila 0.010 0.051% 0.110% 
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PLACEBO    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;Other 0.036 1.095% 0.457% 
p_Firmicutes;c_Bacilli 0.012 0.030% 0.104% 
p_Firmicutes;c_Bacilli;o_Gemellales;f_Gemellaceae;g_undefined 0.038 0.000% 0.001% 
p_Firmicutes;c_Bacilli;o_Lactobacillales 0.030 0.027% 0.094% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Carnobacteriaceae;g_Granulicatella 0.008 0.000% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Lactobacillaceae;g_Lactobacillus 0.019 0.001% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Streptococcaceae;g_Streptococcus 0.019 0.022% 0.087% 
p_Firmicutes;c_Bacilli;o_Turicibacterales;f_Turicibacteraceae;g_Turicibacter 0.006 0.001% 0.008% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Peptococcaceae 0.025 0.001% 0.006% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_undefined 0.021 0.024% 0.010% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Veillonella 0.017 0.018% 0.038% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Holdemania 0.032 0.003% 0.015% 
p_Proteobacteria;c_Gammaproteobacteria;o_Pasteurellales;f_Pasteurellaceae;g_Haemophilus 0.012 0.002% 0.019% 
    
BEFORE TREATMENTS p values          V1  V3    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24;7;g_undefined 0.010 0.025% 0.033% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia 0.004 0.936% 0.413% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Bulleidia 0.012 <0.001% <0.001% 
	
Table	S1.	Bacterial	taxa	that	were	significantly	modified	by	probiotic	or	placebo	treatments.	Mean	bacterial	relative	abundances	are	
shown	at	baseline	(before	treatment)	and	post	(after	treatment),	and	at	visit	1	(V1)	and	3	(V3).	Visits	are	according	to	Figure	1.	p	values	
are	according	to	Wilcoxon-Mann-Whitney	test	with	Benjamini-Hochberg	correction	to	determine	statistically	significant	differences	
before	and	after	the	treatment.	Bacterial	taxa	with	a	relative	abundance	higher	than	1%	are	shown	in	bold.	The	taxonomic	lineage	of	
each	taxon	is	shown;	k,	kingdom;	p,	phylum;	c,	class;	o,	order;	f,	family;	g,	genus.	
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Table	S2.	Bacterial	taxa	that	were	significantly	modified	by	probiotic	or	placebo	treatments	in	enterotypes.	Mean	bacterial	relative	
abundances	are	shown	before	treatment	(baseline)	and	after	treatment	(post).	p	values	are	according	to	Wilcoxon	test	with	Benjamini-
Hochberg	correction	to	determine	statistically	significant	differences	before	and	after	the	treatment.	Bacterial	taxa	with	a	relative	
abundance	higher	than	1%	are	shown	in	bold.	The	taxonomic	lineage	of	each	taxon	is	shown;	k,	kingdom;	p,	phylum;	c,	class;	o,	order;	
f,	family;	g,	genus.
Bacteroides-dominated enterotype p values baseline    post 
PROBIOTIC    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;g_ 0.011 0.026% 0.072% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;Paraprevotellaceae;g_;Prevotella; 0.021 0.001% 0.367% 
p_Firmicutes;c_Clostridia;o_Clostridiales;Other;Other 0.039 1.169% 1.686% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;Other 0.005 0.012% 0.032% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_undefined 0.034 0.549% 0.655% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_Christensenella 0.022 0.001% 0.001% 
p_Proteobacteria;c_Deltaproteobacteria;o_Desulfovibrionales;f_Desulfovibrionaceae;g_Bilophila 0.044 0.061% 0.146% 
PLACEBO    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;Other;Other 0.036 1.657% 0.457% 
p_Firmicutes;c_Bacilli;o_Gemellales;f_Gemellaceae;g_undefined 0.038 0.001% 0.001% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Carnobacteriaceae;g_Granulicatella 0.008 0.001% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Lactobacillaceae;g_Lactobacillus 0.019 0.001% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Streptococcaceae;g_Streptococcus 0.019 0.025% 0.087% 
p_Firmicutes;c_Bacilli;o_Turicibacterales;f_Turicibacteraceae;g_Turicibacter 0.006 0.001% 0.008% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_undefined 0.021 0.032% 0.010% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Veillonella 0.017 0.017% 0.038% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Holdemania 0.032 0.003% 0.015% 
p_Proteobacteria;c_Gammaproteobacteria;o_Pasteurellales;f_Pasteurellaceae;g_Haemophilus 0.012 0.002% 0.019% 
 
Prevotella-dominated enterotype 
 
p values 
 
baseline 
 
   post 
PROBIOTIC    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;Other 0.024 0.051% 0.023% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella 0.014 34.416% 23.547% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;Other 0.002 0.057% 0.208% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_undefined 0.005 3.118% 6.478% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_Alistipes 0.024 0.063% 0.172% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;Barnesiellaceae;g_undefined 0.003 0.388% 1.092% 
PLACEBO    
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Veillonella 0.031 0.010% 0.084% 
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S02 
Before placebo 
- 0.14 20.48 0.77 5.37 2.19 1.25 1.59 1.51 
S03 0.40 0.78 39.45 1.72 9.91 5.16 - 2.77 2.73 
S04 0.26 0.47 18.12 1.71 14.82 8.51 - 2.29 2.62 
S05 - 0.47 160.15 19.39 39.77 57.22 32.31 0.59 2.49 
S07 0.44 0.95 47.04 1.73 14.18 2.41 - 3.19 3.25 
S08 0.25 0.55 6.59 1.97 2.72 3.22 - 1.51 1.85 
S13 0.25 0.35 21.65 1.47 16.16 - - 5.11 2.35 
S14 0.27 0.28 35.84 3.57 9.57 16.89 - 0.72 2.37 
S15 0.29 0.31 34.95 1.71 9.55 0.49 - 4.47 3.89 
S16 0.26 0.30 50.38 1.21 17.72 17.77 - 2.06 2.91 
S17 - 0.25 64.07 0.42 42.39 6.27 3.25 0.77 0.65 
S19 0.26 0.34 19.33 1.75 15.32 8.71 - 2.64 2.53 
S20 - 0.22 119.78 0.74 43.94 21.10 11.86 8.34 8.38 
S23 - 0.15 4.98 0.59 4.28 0.73 0.33 1.27 1.04 
S25 - 0.26 49.38 1.36 17.00 8.11 5.29 1.76 2.43 
S26 - 0.08 15.19 0.44 3.07 2.90 1.34 1.06 0.92 
S28 - 0.41 51.50 0.78 14.17 7.25 5.28 3.57 2.99 
S32 - 0.19 25.33 0.49 10.60 6.17 3.42 0.69 0.98 
S33 - 0.25 43.62 0.59 11.55 9.91 5.23 1.35 3.39 
S34 - 0.14 18.16 0.63 5.21 0.53 0.95 1.80 1.26 
S35 - 0.18 45.81 0.42 19.61 13.07 6.52 0.68 1.46 
S36 - 0.06 43.04 0.52 12.40 11.14 7.18 2.26 2.40 
S37 - 0.24 13.37 0.65 2.98 3.52 2.29 1.45 1.08 
S38 0.34 0.66 26.48 2.03 22.92 4.61 - 1.19 2.30 
S39 - 0.19 39.75 9.83 21.80 9.93 5.79 0.59 1.03 
S02 
After placebo 
- 0.14 12.89 0.72 2.37 - - 0.72 0.80 
S03 0.32 1.22 44.58 1.90 7.99 8.59 - 1.84 2.83 
S04 0.33 0.45 50.94 1.78 32.35 23.72 - 2.05 7.03 
S05 - 0.13 54.62 0.84 10.84 10.32 6.11 0.58 1.22 
S07 0.37 0.72 85.83 2.29 53.83 25.93 - 12.23 10.80 
S08 0.27 0.44 100.66 1.55 25.59 46.09 - 11.89 3.69 
S13 0.39 3.73 39.93 1.63 1.55 - - 1.00 1.98 
S14 0.23 0.25 26.11 2.74 13.60 12.94 - 1.37 3.02 
S15 0.26 0.43 13.30 1.34 7.44 3.08 - 2.29 3.13 
S16 0.27 0.25 29.15 1.47 6.75 6.30 - 1.18 1.87 
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S17 - 0.23 40.35 0.44 34.27 9.05 4.77 0.21 1.27 
S19 0.28 0.26 48.10 1.66 30.41 22.20 - 3.00 6.60 
S20 - 0.22 96.93 0.81 39.93 20.78 13.14 2.40 5.98 
S23 - 0.51 10.79 0.64 7.33 1.89 1.47 1.55 1.10 
S25 - 0.31 40.49 0.60 11.36 5.75 3.92 2.30 2.64 
S26 - 0.84 34.78 0.76 7.99 4.99 2.96 1.95 1.56 
S28 - 0.11 34.66 0.40 10.20 7.77 4.13 0.19 1.26 
S32 - 0.15 19.44 1.28 6.87 4.49 2.30 0.68 0.83 
S33 - 0.16 24.86 0.59 4.17 1.10 0.44 0.93 1.72 
S34 - 0.10 10.02 0.57 4.28 1.49 1.92 3.31 2.15 
S35 - 0.53 63.90 0.60 33.36 17.38 8.52 1.13 2.50 
S36 - 0.12 40.79 0.66 9.57 9.41 6.61 3.30 2.22 
S37 - 0.27 15.25 0.48 2.69 2.71 1.39 1.06 0.92 
S38 0.32 1.01 66.25 1.81 43.33 10.98 - 2.45 3.83 
S3 - 0.14 61.15 1.44 36.84 18.10 10.55 1.93 3.07 
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S02 Before Probiotic - 0.77 60.76 6.86 13.97 11.82 6.55 0.46 1.15 
S03 0.32 0.55 48.09 1.97 26.18 15.02 - 1.90 5.21 
S04 0.38 - 48.16 1.91 6.62 2.43 - 1.11 1.79 
S05 0.29 0.41 45.62 1.86 24.70 14.18 - 1.81 4.69 
S07 0.26 - 53.96 1.42 17.56 35.63 - 1.44 3.87 
S08 0.33 0.93 68.78 1.95 27.35 17.92 - 3.54 4.65 
S13 0.19 0.24 50.64 1.35 12.21 21.31 - 0.96 2.26 
S14 0.39 0.10 55.40 1.56 23.03 10.99 - 5.62 6.51 
S15 0.33 1.81 11.26 1.54 2.32 - - 1.55 2.00 
S16 0.25 0.74 34.82 1.29 13.21 7.53 - 5.21 4.18 
S17 - 0.23 23.95 0.85 9.09 3.71 2.60 2.19 2.62 
S19 0.27 0.22 19.41 1.62 9.52 5.82 - 1.78 2.64 
S20 - 0.23 33.17 0.86 18.85 8.09 4.46 1.06 1.63 
S23 - 0.28 103.38 0.72 38.66 18.21 11.16 2.37 6.07 
S25 - 0.44 2.77 0.39 1.00 0.67 - 0.43 0.60 
S26 - 0.56 53.49 1.25 25.25 22.22 13.35 2.05 2.66 
S28 - 0.19 40.23 0.39 16.29 6.60 3.70 0.42 0.97 
S32 - 0.95 38.44 0.55 11.18 9.18 4.93 0.96 2.29 
S33 - 0.18 17.55 0.45 6.14 1.61 1.86 2.74 1.46 
S34 - 0.15 44.40 0.90 9.68 4.51 2.73 1.67 1.56 
S35 - 0.24 44.48 0.46 5.07 10.21 5.44 0.94 2.61 
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S36 - 0.16 37.61 0.59 11.39 6.16 3.28 1.38 2.41 
S37 - 0.30 93.50 0.84 37.23 20.43 12.63 3.02 4.40 
S38 - 0.14 48.60 0.44 15.82 17.06 11.29 4.34 3.25 
S39 - 0.17 37.38 0.70 9.41 2.45 2.31 2.75 2.00 
S02 After Probiotic - 0.16 51.95 0.87 11.69 11.98 7.54 0.82 1.38 
S03 0.37 0.46 72.93 1.46 33.96 20.33 - 10.18 6.95 
S04 0.38 1.02 22.04 1.61 8.78 2.03 - 2.40 2.10 
S05 0.30 0.27 64.70 13.36 29.99 17.95 - 8.98 5.71 
S07 0.22 - 45.78 1.83 15.27 27.40 - 1.77 2.70 
S08 0.36 1.51 47.32 2.32 6.77 3.99 - 2.48 2.72 
S13 0.27 0.25 8.31 1.44 6.37 3.76 - 2.46 2.57 
S14 0.35 1.92 76.83 1.70 26.52 9.40 - 5.26 5.71 
S15 0.36 1.96 42.40 1.56 7.59 1.32 - 3.91 2.53 
S16 0.22 0.36 41.66 1.56 14.03 19.97 - 3.18 3.34 
S17 - 0.22 10.39 0.46 2.40 0.65 - 0.65 0.84 
S19 0.34 0.29 33.83 1.82 13.34 9.99 - 2.93 3.08 
S20 - 0.24 110.13 1.07 49.00 15.48 9.41 2.68 4.23 
S23 - 0.74 32.00 2.46 10.27 8.17 4.31 0.43 1.06 
S25 - 0.16 40.94 0.52 12.79 11.48 7.77 3.92 3.47 
S26 - 0.42 41.81 1.17 17.25 18.09 10.81 3.77 2.73 
S28 - 0.28 52.20 0.41 35.10 13.17 7.41 0.49 2.09 
S32 - 0.26 12.12 0.94 7.84 4.28 2.76 1.96 1.67 
S33 - 0.32 18.60 0.53 3.58 1.66 1.11 1.63 1.06 
S34 - 0.23 30.22 0.75 7.91 6.47 4.05 2.14 1.55 
S35 - 0.19 63.94 0.42 16.85 21.64 11.98 1.03 4.10 
S36 - 0.17 42.63 0.74 20.16 10.47 5.92 1.71 2.15 
S37 - 0.09 77.39 0.98 30.90 15.21 9.51 2.59 3.94 
S38 - 0.08 43.43 0.49 - 11.00 8.21 4.32 2.54 
S39 - 0.09 47.98 0.62 9.89 3.36 2.57 2.53 1.57 
	
Table	S3.	Levels	of	short	chain	fatty	acids	in	the	faecal	samples.	Data	are	reported	as	mg	per	kg	of	feces.	-,	not	detectable.	
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    All subjects  SCFA group L  SCFA group H 
 p values baseline post  p values baseline post  p values baseline post 
PROBIOTIC            
Acetate 0,833 101,44 106,58     0.268 30.97 40.65     0.365 62.02 51.13 
Butyrate 0,271 22,78 27,51  0.025 * 4.93 8.71  0.042 * 18.62 13.39 
Isovalerate 0,853 5,37 6,15  0.217 1.73 2.23  0.465 2.50 3.92 
Lactate 0,653 0,82 1,27  0.808 0.41 0.41  0.919 0.39 0.54 
Propionate 0,711 38,70 44,49  0.068 9.27 14.95  0.102 23.81 17.18 
Succinate 0,508 5,65 2,90  0.502 0.89 0.93  0.278 1.84 2.55 
Valerate 0,426 5,88 7,40  0.502 2.06 2.41  0.365 4.06 3.45 
            
PLACEBO            
Acetate 0,937 111,58 113,16  0.179 29.53 40.23  0.125 98.60 55.27 
Butyrate 0,916 27,38 26,92  0.083 5.97 10.89  0.375 25.59 11.61 
Isovalerate 0,120 5,1708 7,42  0.393 2.00 2.72  0.125 2.94 1.09 
Lactate 0,989 1,00 1,170  0.338 0.33 0.57  0.250 0.31 0.21 
Propionate 0,874 39,17 39,82  0.203 11.58 16.82  0.125 35.95 22.95 
Succinate 0,164 3,27 4,108  0.473 1.65 1.21  0.875 5.44 0.89 
Valerate 0,853 7,35 7,179  0.128 2.11 3.03  0.250 3.61 2.58 
	
Table	 S4.	 Effects	 of	 the	 probiotic	 and	 placebo	 treatments	 on	 faecal	 short	 chain	 fatty	 acid	 (SCFA)	 concentration.	 Mean	 SCFA	
concentration	at	baseline	(before	treatment)	and	post	(after	treatment)	are	reported	as	mg	per	kg	of	feces.	p	values	are	according	to	
Wilcoxon-Mann-Whitney	test	with	Benjamini-Hochberg	correction	to	determine	statistically	significant	differences	before	and	after	
the	treatments.	The	asterisk	(*)	indicates	statistically	significant	differences	(p	<	0.05).	
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3.2	Evidence	of	dysbiosis	in	the	intestinal	microbial	
ecosystem	 of	 children	 and	 adolescents	 with	
primary	 hyperlipidemia	 and	 potential	 role	 of	
regular	hazelnut	intake	
3.2.1	Introduction	
Hyperlipidemia	is	comprehensively	defined	as	a	lipoprotein	metabolism	disorder	mainly	manifested	
by	an	increase	of	total	cholesterol	(TC),	low-density	lipoprotein-cholesterol	(LDL-C)	and	triglyceride	
concentrations.	Hyperlipidemia	may	be	either	the	result	of	a	genetic	defect	in	the	lipid	metabolism	
pathways	 (primary)	 or	 secondary	 to	 underlying	 diseases.	 It	 may	 occur	 from	 pediatric	 age	 and	
represents	an	unquestioned	risk	factor	for	cardiovascular	diseases	(D'Adamo	et	al.	2015).		
Dietary	 interventions	 appear	 a	 promising	 strategy	 to	 manage	 premature	 hyperlipidemia.	 For	
instance,	the	intake	of	a	food	supplement	containing	fiber	was	shown	to	reduce	total	cholesterol,	
LDL-C	levels,	and	apolipoprotein	B	in	hypercholesterolemic	children	(Guardamagna	et	al.	2013).	In	
addition,	the	daily	consumption	of	yoghurt	supplemented	with	phytosterols	modulated	lipid	proﬁle	
by	reducing	LDL-C	(Guardamagna	et	al.	2011a).	In	another	trial,	a	probiotic	formulation	resulted	in	
the	 decrease	 of	 LDL-C	 and	 in	 the	 improvement	 of	 trygliceridaemia	 and	HDL-cholesterol	 (HDL-C)	
levels	 (Guardamagna	 et	 al.	 2014).	 Mechanisms	 supporting	 the	 potential	 efficacy	 of	 the	 above	
mentioned	interventions	include	the	suppression	of	liver	cholesterol	synthesis	(Guardamagna	et	al.	
2011b),	the	reduction	of	the	intestinal	cholesterol	absorption	(Guardamagna	et	al.	2011a),	and	the	
production	of	conjugated	linoleic	acid	in	the	gut	(Guardamagna	et	al.	2014).	
In	principle,	 the	modulation	of	the	gut	microbiota	could	represent	an	additional	strategy	for	the	
amelioration	 of	 the	 lipid	 profile.	 Expanding	 scientific	 evidence,	 in	 fact,	 indicate	 that	 the	 gut	
microbiota	mediates	physiopathological	mechanisms	that	alter	lipid	metabolism	and	other	related	
metabolic	traits	(Ghazalpour	et	al.	2016).	Particularly,	the	intestinal	microbiota	has	been	recognized	
as	a	metabolically	active	endocrine	organ	of	the	human	superorganism	that	can	be	a	therapeutic	
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target	for	hyperlipidemia	and	associated	cardiometabolic	diseases	(Brahe	et	al.	2016,	Ghazalpour	et	
al.	2016).	
Although	 altered	 microbiota	 composition	 (generally	 called	 “dysbiosis”)	 has	 been	 associated	 to	
diseases	that	are	characterized	by	hyperlipidemia	such	as	obesity	(Kobyliak	et	al.	2016),	diabetes	
(Yamaguchi	et	al.	2016),	metabolic	diseases	(Woting	and	Blaut	2016)	and	non-alcoholic	fatty	liver	
disease	 (Wang	et	al.	 2016),	 the	 intestinal	microbial	ecosystem	 (IME)	has	never	been	 thoroughly	
investigated	in	young	people	with	inherited	hyperlipidemia.	
Hyperlipidemic	 subjects	 could	 benefit	 from	 dietary	 patterns/food	 products	 able	 to	 affect	 lipid	
metabolism	 through	 the	 modulation	 of	 intestinal	 microbiota.	 In	 this	 context,	 nuts	 have	 been	
suggested	as	lipid-lowering	products	due	to	their	richness	in	unsaturated	fats	and	other	bioactive	
compounds	(such	as	L-arginine,	fiber,	minerals,	vitamin	E,	phytosterols	and	polyphenols),	which	may	
synergistically	contribute	improving	plasma	lipid	profile	and	providing	overall	cardiovascular	benefit	
(Ros	2015).	In	light	of	the	above	considerations,	in	this	study,	we	characterized	the	IME	of	children	
and	adolescents	with	primary	hyperlipidemia	by	means	of	16S	rRNA	gene	profiling	and	short	chain	
fatty	acids	(SCFAs)	quantification	in	faecal	samples.	Furthermore,	the	potential	modulatory	effects	
of	the	regular	intake	of	hazelnuts	on	microbiota	composition	and	SCFAs	was	investigated.	Finally,	
we	studied	the	potential	correlations	existing	between	the	IME	and	hyperlipidemia-related	clinical	
parameters.	
3.2.2	Materials	and	methods	
3.2.2.1	Ethics	approval	and	consent	to	participate		
The	study	protocol	conformed	with	the	principles	outlined	of	the	Declaration	of	Helsinki	and	was	
approved	by	the	Ethics	Committee	of	the	City	of	Health	and	Science	University	Hospital	of	Turin,	
Italy	(EC:CS377).	The	protocol	and	the	aim	of	the	study	were	explained	in	detail	to	all	participants	
and	their	legal	guardians,	who	signed	an	informed	consent	before	the	enrollment	into	the	study.	
3.2.2.2	Participants		
Volunteers	considered	in	the	present	study	derive	from	a	subgroup	of	children	and	adolescents	with	
primary	 hyperlipidemia,	 aged	 between	 6	 and	 17	 years	 old,	 participating	 to	 a	 project	 aimed	 to	
characterize	this	pediatric	population	(Deon	et	al.	2017b)	and	to	investigate	the	effect	of	the	regular	
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intake	of	hazelnuts	with	skin	for	eight	weeks	on	several	markers	related	to	lipid	metabolism	and	
oxidative	stress	(Deon	et	al.	2017a,	Deon	et	al.	2017b).	The	trial	was	registered	under	ISRCTN.com	
(identifier	 no.	 ISRCTN12261900).	 Subjects	participating	 to	 the	 intervention	 study	were	 recruited	
among	patients	cared	at	the	Department	of	Health	Science	and	Pediatrics	of	the	University	of	Turin	
(Italy)	after	a	screening	for	eligibility.	In	addition,	15	age-matched	normolipidemic	volunteers	(mean	
age	11,	median	10;	min	7,	max	17	years	old)	were	recruited	as	controls	for	the	microbial	ecology	of	
the	faecal	samples.	
The	 recruited	hyperlipidemic	subjects	were	asked	 to	collect	a	 stool	 sample	before	and	after	 the	
intervention.	Thirty-four	 stool	 samples	were	collected	 for	analysis	at	baseline,	but	only	15	were	
available	after	the	eight	weeks	of	hazelnut	with	skin	consumption	(mean	and	median	age:	11;	min	
5,	max	17	years	old).	The	effect	of	the	dietary	intervention	on	the	faecal	microbiota	composition	
was	analyzed	 in	15	subjects,	whereas	 the	 levels	of	SCFAs	were	evaluated	 in	 the	whole	group	of	
children	and	adolescents	with	primary	hyperlipidemia	who	collected	stools	at	baseline.		
To	be	eligible,	screened	children	and	adolescents	were	required	to	be	normal-weight	with	diagnosis	
of	 primary	 hyperlipemia	 including	 familial	 hypercholesterolemia	 (FH),	 familial	 combined	
hyperlipidemia	(FCHL)	or	polygenic	hypercholesterolemia	(PHC),	with	total	serum	cholesterol	(TC)	
and/or	triglycerides	(TG)	levels	higher	than	age-	and	sex-specific	90th	percentile.	Diagnostic	criteria	
of	primary	hyperlipidemia	were	based	on	accepted	international	standards	as	previously	reported	
(Guardamagna	et	al.	2009).	FH	was	diagnosed	in	presence	of	LDL-C	≥95th	percentile,	parental	LDL-C	
≥	 190	 mg	 dl-1,	 tendon	 xanthomas	 and/or	 cardiovascular	 disease	 (phenotype	 IIA).	 FCHL	 was	
diagnosed	in	children	showing	TC	and/or	TG	>90th	age-	and	sex-specific	percentile,	with	at	least	one	
parent	affected	by	hypercholesterolemia,	hypertriglyceridemia,	or	both	(IIA,	IV,	or	IIB	phenotype,	
respectively),	with	concomitant	individual	and	familial	lipid	phenotype	variability.	Children	with	LDL-
C	levels	>90th	percentile	and	a	family	history	of	dominant	inherited	hypercholesterolemia,	but	not	
fulfilling	the	biochemical	international	diagnostic	criteria	of	FH	or	FCHL	were	diagnosed	with	PHC.	
Subjects	 were	 excluded	 if	 they	 had	 food	 allergies	 or	 specific	 aversion	 for	 nut	 consumption,	
secondary	hyperlipidemias,	obesity	(body	mass	index,	BMI,	≥	90th	percentile,	age	and	sex	matched);	
renal,	endocrine,	liver	or	gastrointestinal	disorders	(e.g.,	diarrhoea,	inflammatory	bowel	disease,	or	
irritable	 bowel	 syndrome)	 or	 chronic	 diseases	 requiring	 drug	 treatment	 (i.e.,	 immunologic,	
neurologic,	or	oncohematologic	disorders).	Subjects	were	also	excluded	from	the	study	if	they	were	
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taking	lipid-lowering	treatments,	antibiotics,	probiotic	or	prebiotic	products	one	month	prior	to	the	
first	visit,	or	if	they	had	viral	or	bacterial	enteritis	two	months	before	the	first	visit.	
3.2.2.3	Experimental	design		
All	 patients	 enrolled	 were	 under	 nutritional	 recommendations	 suggested	 for	 pediatric	
hyperlipidemia	based	on	the	cardiovascular	health	integrated	lifestyle	diet	(CHILD-1)	(Expert	Panel	
on	Integrated	Guidelines	for	Cardiovascular	et	al.	2011).	Dietary	intervention	consisted	of	8-week	
intake	of	 hazelnut	with	 skin	 (HZN+S).	 Subjects	were	provided	with	pre-weighed	 vacuum	packed	
portions	of	Italian	roasted	Corylus	avellana	L.	(cultivar	‘Tonda	Gentile	delle	Langhe’	from	Piedmont,	
Italy).	The	quantity	of	hazelnuts	per	packet	was	calculated	by	considering	doses	generally	advised	
to	adults	and	adjusted	to	children	body	weight	(about	0.43	g	kg-1	body	weight	until	a	maximum	of	
30	 g,	 which	 is	 the	 recommended	 daily	 dose	 for	 an	 adult).	 All	 participants	 were	 encouraged	 to	
maintain	the	same	dietary	pattern	and	lifestyle	habits	throughout	the	8-week	intervention	study.	
Subjects	 had	 to	 exclude	 the	 intake	 of	 other	 nuts,	 dried	 fruits,	 probiotic	 or	 prebiotic	 foods	 or	
supplements	 from	 one	 month	 before	 the	 beginning	 of	 the	 study	 until	 the	 end	 of	 the	
experimentation.	 Traditional	 yogurt	 was	 allowed.	 To	 check	 the	 compliance	 to	 the	 dietary	
recommendations,	subjects	and	their	families	were	asked	to	fill	in	weekly	food	diaries.		
At	 baseline	 and	 at	 the	 end	 of	 the	 HZN+S	 intervention	 (0	 and	 8	 weeks),	 each	 study	 participant	
underwent	 a	medical	 examination	 after	 an	 overnight	 fast,	 during	which	 biological	 samples	 and	
physical	parameters	(including	height,	weight	and	blood	pressure	measurements)	were	obtained.	
The	 serum	 levels	 of	 TC,	 HDL-C	 and	 TG	 were	 directly	 determined	 by	 an	 automatic	 biochemical	
analyzer	 (Olympus	 AU2700,	 Japan),	 while	 the	 LDL-C	 concentration	 was	 estimated	 by	 using	 the	
Friedewald	 formula	 (LDL=TC-(HDL+TG/5)	and	non-high	density	 lipoprotein	cholesterol	 (non–HDL)	
was	calculated	subtracting	HDL-C	from	TC.		
The	faecal	samples	were	collected	from	each	participant	in	a	sterile	plastic	pot	within	24	h	before	
visits	at	baseline	and	following	the	HZN+S	intervention.	A	single	faecal	sample	was	also	collected	
from	the	15	age-matched	controls.	According	to	the	recommendations	for	“storage	conditions	of	
intestinal	microbiota	matter	 in	metagenomic	 analysis”	 (Cardona	 et	 al.	 2012),	 participants	 were	
asked	to	deliver	the	faecal	sample	to	the	laboratory	within	24	h.	Since	delivery,	stools	were	stored	
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at	-80°C	until	DNA	extraction.	Subjects	were	asked	to	give	back	any	uneaten	HZN+S	package	at	the	
visit.	Compliance	was	assessed	by	weighing	returned	packages	and	by	checking	weekly	food	diaries.	
3.2.2.4	Bacterial	profiling	of	faecal	microbiota		
The bacterial community structure of faecal samples	was	determined	by	16S	ribosomal	RNA	gene	
profiling	 with	 Illumina	 MiSeq	 System	 at	 the	 Center	 for	 life	 –	 Nanoscience,	 Istituto	 Italiano	 di	
Tecnologia	(Roma,	Italy).	Briefly,	metagenomic	DNA	was	extracted	from	200	±	10	mg	of	stool	within	
30	days	from	delivery	by	means	of	a	PowerFaecal	DNA	Isolation	Kit	 (Mo	Bio	Laboratories,	Cabru	
s.a.s.,	 Biassono,	 Italy)	 according	 to	 the	 manufacturer’s	 specifications.	 A	 DNA	 fragment	
encompassing	the	V3	and	V4	regions	of	the	16S	rRNA	gene	was	amplified	from	metagenomic	DNA	
with	the	primer	pair	selected	by	Klindworth	et	al.	(Klindworth	et	al.	2013).	The	sequencing	runs	were	
multiplexed	 and	 barcode	 sequences	 were	 used	 to	 discriminate	 the	 samples.	 16S	 rRNA	 gene	
sequence	 reads	 were	 analyzed	 through	 the	 bioinformatic	 pipeline	 Quantitative	 Insights	 Into	
Microbial	Ecology	(QIIME)	version	1.7.0	using	the	last	version	of	GreenGene	(gg_13_5)	as	reference	
taxonomic	 database.	 Bacterial	 abundances	 in	 each	 faecal	 sample	 were	 determined	 at	 the	
operational	taxonomic	unit	(OTU)	level.	Sequence	reads	from	16S	rRNA	gene	profiling	have	been	
deposited	in	the	European	Nucleotide	Archive	(ENA)	of	the	European	Bioinformatics	Institute	under	
accession	code	PRJEB10296.	
3.2.2.5	Quantification	of	faecal	short	chain	fatty	acids	(SCFAs)		
SCFAs	 were	 quantified	 in	 the	 faecal	 samples	 collected	 from	 34	 subjects,	 including	 the	 15	 who	
completed	 the	 intervention	 trial.	 SCFA	 quantifications	 were	 performed	 as	 previously	 described	
(Gargari	et	al.	2016).	In	brief,	stools	(200	±	10	mg)	were	extracted	in	10	ml	of	0.001%	HCOOH	by	
vortexing	for	1	min.	The	supernatant	was	then	recovered	through	centrifugation	at	1000	x	g	for	2	
min	at	4	°C.	All	extracts	were	stored	at	-20	°C	until	UPLC-HR-MS	analysis,	which	was	carried	out	on	
an	Acquity	UPLC	separation	module	(Waters,	Milford,	MA,	USA)	coupled	with	an	Exactive	Orbitrap	
MS	with	an	HESI-II	probe	for	electrospray	ionization	(Thermo	Scientific,	San	Jose,	CA,	USA).	The	ion	
source	and	interface	conditions	and	other	detailed	information	were	as	specified	in	(Gargari	et	al.	
2016).	The	eluents	were	0.001%	HCOOH	in	MilliQ-treated	water	(solvent	A)	and	CH3OH:CH3CN	(1:1,	
v/v,	solvent	B);	UPLC	elution	gradient:	0%	B	for	4	min,	0-15%	B	in	6	min,	15–20%	B	in	5	min,	20%	for	
13	min,	and	then	return	to	initial	conditions	in	1	min.	The	UPLC	eluate	was	analyzed	in	full-scan	MS	
68	
	
	
in	the	range	50–130	m/z.	The	resolution	was	set	at	50	K,	the	AGC	target	was	1E6,	and	the	maximum	
ion	 injection	 time	 was	 100	 ms.	 The	MS	 data	 were	 processed	 using	 Xcalibur	 software	 (Thermo	
Scientific).	 Five-point	 external	 calibration	 curves	 prepared	 with	 analytical	 grade	 SCFAs	 (Sigma-
Aldrich,	Milan,	Italy)	were	adopted	to	quantify	acetate,	butyrate,	isobutyrate,	isovalerate,	lactate,	
propionate,	 pyruvate,	 succinate,	 and	 valerate	 in	 faecal	 samples.	 SCFA	 concentrations	 were	
expressed	in	millimoles	per	kilogram	of	wet	feces.	
3.2.2.6	Statistical	analyses.		
Statistical	analyses	were	performed	using	R	statistical	software	(version	3.1.2).	The	numerical	value	
of	0	(zero)	was	given	to	any	taxon	that	was	not	detected	in	a	specific	sample	to	allow	comparison.	
All	 the	 statistical	 tests	 were	 performed	 considering	 three	 study	 populations:	 (i)	 hyperlipidemic	
subjects	 before	 HZN+S	 intake,	 (ii)	 hyperlipidemic	 subjects	 after	 HZN+S	 intake	 and	 (iii)	
normolipidemic	 subjects	 as	 controls.	 Differences	 in	 microbiota	 composition	 between	 these	
populations	were	determined	using	Wald	test	following	DESeq2	(paired	between	the	comparison	of	
hyperlipidemic	subject	populations)	read	counts	normalization.	After	DESeq2	normalization,	only	
OTUs	with	a	number	of	reads	higher	than	5	in	at	least	one	quarter	of	the	samples	were	considered	
for	the	statistical	analysis.	
Differences	 in	 SCFA	 concentrations	 were	 evaluated	 by	 analyzing	 the	 data	 with	 non-parametric	
Wilcoxon-Mann-Whitney	test	using	paired	data,	when	allowed.	
	The	correlation	analyses	were	carried	out	using	the	Kendall	and	Spearman	formulas	with	bacterial	
taxa	abundances	(DESeq2-normalized	data),	lipidemic	profile	data	and	faecal	SCFA	concentrations	
in	hyperlipidemic	subjects.	
Statistical	significance	was	set	at	P	≤	0.05;	the	mean	differences	with	0.05	<	P	≤	0.10	were	accepted	
as	 trends.	When	p-values	correction	was	applied,	 the	 false	discovery	 rate	 (FDR)	adjustment	was	
used.	
3.2.3	Results	
16S	 rRNA	 gene	 profiling	 and	 SCFAs	 quantification	 revealed	 significant	 differences	 in	 the	 faecal	
microbial	ecosystem	between	hyperlipidemic	and	control	subjects.	A	total	of	15’069’105	filtered	
high-quality	sequence	reads	was	generated	(an	average	of	334’869	reads	per	sample).	We	identified	
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a	total	of	109	bacterial	families	(100	in	hyperlipidemic	samples	and	89	in	controls)	and	269	bacterial	
genera	(244	in	hyperlipidemic	subjects	and	193	in	controls).	We	found	a	minimum	number	of	39	
families	 and	 69	 genera,	 and	 a	 maximum	 of	 63	 families	 and	 110	 genera	 per	 faecal	 sample	 in	
hyperlipidemic	subjects;	a	minimum	of	44	families	and	80	genera,	and	a	maximum	of	64	families	
and	113	genera	were	found	in	controls.	Only	about	15%	of	families	(n=16)	and	10%	of	genera	(n=26)	
were	detected	in	all	45	analyzed	faecal	samples;	the	same	16	families	and	26	genera	were	the	only	
detected	in	all	30	hyperlipidemic	faecal	samples,	whereas	30	families	and	46	genera	were	found	in	
all	 15	 control	 samples.	 These	 data	 suggest	 that	 the	 bacterial	 composition	 varied	 more	 among	
hyperlipidemic	than	control	faecal	samples,	as	also	evidenced	by	the	analysis	of	β-diversity	(Figure	
1).	
	
Figure	1.	Inter-sample	ecological	diversity	based	on	16S	rRNA	gene	profiling	data	of	faecal	samples	
from	hyperlipidemic	 subjects	participating	 to	 the	hazelnut	 intervention	 trial	and	normolipidemic	
controls.	Principal	coordinates	analysis	of	weighted	(A)	and	unweighted	(B)	UniFrac	distances	based	
on	the	medians	of	OTU	abundances.	The	first	two	coordinates	(PC1	and	PC2)	are	displayed	with	the	
percentage	of	variance	explained	in	brackets.	In	panel	B,	a	bi-plot	is	represented	showing	five	of	the	
genera	that	better	describe	the	diversity	among	samples.	
	
The	analysis	of	the	β-diversity	performed	with	the	unweighted	UniFrac	algorithm	evidenced	a	good	
segregation	of	controls	from	hyperlipidemic	samples,	which	was	principally	led	by	the	abundance	
of	Faecalibacterium	spp.	and	two	unidentified	Clostridiales	genera	(Figure	1B).	Also,	the	intrasample	
(α)-diversity	 analyzed	 through	 Chao1	 index	 evidenced	 a	 difference	 between	 hyperlipidemic	 and	
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control	 samples	 (Figure	 2).	 In	 specific,	 Chao1,	 which	 estimates	 the	 abundance	 of	 operational	
taxonomic	units	(OTUs)	in	a	single	sample,	was	significantly	higher	in	controls;	nonetheless,	we	did	
not	find	any	difference	between	groups	when	we	analyzed	the	α-diversity	with	the	inverse	Simpson	
index,	which	estimates	biodiversity	also	considering	OTUs’	evenness	(Figure	2B).	
	
Figure	2.	Intra-sample	ecological	diversity	based	on	16S	rRNA	gene	profiling	data	of	faecal	samples	
from	hyperlipidemic	 subjects	participating	 to	 the	hazelnut	 intervention	 trial	and	normolipidemic	
controls.	A,	rarefaction	curves	obtained	using	Chao1	index	fixing	a	maximum	of	50.000	reads	per	
sample.	B,	α-diversity	analysis	based	on	Chao1	and	inverse	Simpson	indexes.	T0,	samples	before	the	
hazelnut	intervention;	T1,	samples	after	the	hazelnut	intervention.	***,	P<0.001	according	to	Mann-
Whitney	U	(unpaired)	test.	
	
To	 infer	 taxonomic	 signatures	 distinguishing	 the	 faecal	 microbiota	 structure	 of	 the	 15	
hyperlipidemic	participants	 and	 the	15	aged-matched	normolipidemic	 controls,	we	performed	a	
comparative	analysis	at	OTU	level	through	the	DESeq	negative	binomial	distribution	method.	We	
found	229	OTUs	whose	abundance	 significantly	differed	between	 the	 two	groups	of	 subjects	 at	
baseline	(Figure	S1	and	Figure	3):	193	OTUs	were	increased	in	the	controls,	whereas	only	36	OTUs	
in	the	hyperlipidemic	samples	(Figure	S1).	Most	of	the	OTUs	belonged	to	the	phylum	Firmicutes	and,	
particularly,	to	the	families	Ruminococcaceae	and	Lachnospiraceae;	notably,	controls	were	enriched	
in	OTUs	belonging	to	well-recognized	butyrate	producing	bacteria	such	as	the	genus	Roseburia	and	
the	 species	 Faecalibacterium	 prausnitzii.	 We	 also	 observed	 a	 significant	 reduction	 of	 an	 OTU	
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ascribed	to	the	species	Akkermansia	muciniphila	in	hyperlipidemics.	In	addition,	23	OTUs	belonging	
to	 the	phylum	Bacteroidetes	were	 significantly	enriched	 in	 controls	 compared	 to	hyperlipidemic	
samples,	whereas	only	3	Bacteroides	OTUs	were	reduced	(Figure	S1).	
	
Figure	3.	 Taxonomic	units	 in	 faecal	 samples	distinguishing	hyperlipidemic	 from	control	 subjects.	
Heat	map	based	on	the	normalized	abundance	of	OTUs	(horizontal	axis)	for	individual	faecal	sample	
(vertical	 axis).	 The	 figure	 includes	 only	 the	 OTUs	 that	 were	 significantly	 different	 between	
hyperlipidemic	and	control	 samples	 through	 the	DESeq2	negative	binomial	distribution	method.	
Lachn.,	Lachnospiraceae;	R.,	Ruminococcaceae.	
	
Finally,	the	IME	of	enrolled	children	and	adolescents	was	characterized	by	quantifying	8	SCFAs	and	
lactate	 in	 faecal	samples	by	UPLC-HR-MS	(Table	S1).	Specifically,	we	analyzed	the	data	 from	the	
faecal	samples	of	15	hyperlipidemic	subjects	undertaking	the	hazelnut	intervention	together	with	
19	additional	 faecal	 samples	 from	hyperlipidemic	subjects	at	baseline.	We	 found	that	 the	 faecal	
levels	of	several	SCFAs	were	significantly	different	between	hyperlipidemic	and	control	subjects;	
specifically,	 hyperlipidemia	 was	 associated	 with	 significantly	 lower	 concentrations	 of	 acetate,	
butyrate	and	propionate,	whereas	 lactate,	 isobutyrate	and	pyruvate	were	significantly	 increased	
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compared	to	control	subjects	(Figure	4).	Notably,	the	faecal	levels	of	acetate,	propionate	and	(as	a	
trend)	butyrate	were	significantly	 lower	 in	hyperlipidemic	samples	also	when	we	 included	 in	the	
analysis	the	data	collected	in	a	previous	study	of	25	healthy	adult	volunteers	(Gargari	et	al.	2016)	
(Figure	S2).	The	levels	of	valerate,	isovalerate	and	succinate	were	not	significantly	different	between	
groups.	
	
0
1
2
3
4
5
Hyperlipidemic
Control add. T0 →   T1
**
Iso
bu
ty
ra
te
 (m
m
ol
/k
g)
0
2
4
6
Hyperlipidemic
Control add. T0 →   T1
Va
le
ra
te
 (m
m
ol
/k
g)
0
2
4
6
8
Hyperlipidemic
Control add. T0 →   T1
Is
ov
al
er
at
e 
(m
m
ol
/k
g)
0.0
0.5
1.0
5
Hyperlipidemic
Control add. T0 →   T1
Su
cc
in
at
e 
(m
m
ol
/k
g)
0
10
20
30
40
50
50
75
Hyperlipidemic
*** #
Control add. T0 →   T1
Ac
et
at
e 
(m
m
ol
/k
g)
0
10
20
30
T0 →   T1
Hyperlipidemic
**
Control add.
Bu
ty
ra
te
 (m
m
ol
/k
g)
0.0
0.5
1.0
7
14
Hyperlipidemic
Control add. T0 →   T1
*
La
ct
at
e 
(m
m
ol
/k
g)
0
10
20
30
Hyperlipidemic
** p=0.0785
Control add. T0 →   T1
Pr
op
io
na
te
 (m
m
ol
/k
g)
0.0
0.4
0.8
4
Hyperlipidemic
Control add. T0 →   T1
u.d.l.
Py
ru
va
te
 (m
m
ol
/k
g)
Fig. 4
73	
	
	
Figure	4.	Faecal	levels	of	short	chain	fatty	acids	and	lactate	in	hyperlipidemic	and	control	subjects.	
add,	hyperlipidemic	subjects	not	included	in	the	intervention	trial;	T0,	samples	before	the	hazelnut	
intervention;	T1,	samples	after	the	hazelnut	intervention.	u.d.l.,	under	detection	limit.	*,	p	<	0.05;	
**,	 p<0.01,	 ***,	 p<0.001	 according	 to	Mann-Whitney	U	 (unpaired)	 text.	 #,	 p<0.05	 according	 to	
Wilcoxon	(paired)	text.	
Overall,	 these	 data	 suggest	 that	 hyperlipidemia	 is	 potentially	 associated	 with	 gut	 microbiota	
dysbiosis,	which	 can	be	 characterized	by	 the	alteration	of	numerous	OTUs	associated	 to	 SCFAs-
producing	bacteria,	and	the	reduction	of	the	faecal	levels	of	acetate,	butyrate	and	propionate.	
3.2.3.1	Hazelnut	intake	induced	limited	changes	in	the	bacterial	
abundances	but	modulated	SCFA	levels	in	feces		
The	α-	and	β-diversity	of	faecal	samples	were	not	significantly	affected	by	the	eight-week	hazelnut	
intervention	(Figure	1	and	Figure	2).	Furthermore,	we	did	not	find	any	OTU	that	was	modified	with	
a	FDR	adjusted	P	value	lower	than	the	significance	limit	of	0.05	(Figure	S3).	Adopting	the	p	value	
without	adjustment,	the	0.05	threshold	was	reached	by	30	OTUs,	29	of	which	ascribed	to	the	order	
Clostridiales.	 Specifically,	 13	 OTUs	 decreased	 after	 the	 dietary	 intervention,	 whereas	 17	 OTUs	
increased,	 including	 one	 OTU	 ascribed	 to	 Faecalibacterium	 prausnitzii	 and	 one	 belonging	 to	 an	
undefined	species	of	the	genus	Roseburia	(Figure	S3).	
Subsequently,	we	quantified	the	faecal	level	of	8	SCFAs	and	lactate	after	hazelnut	consumption	in	
14	 hyperlipidemic	 subjects	 that	 concluded	 the	 intervention	 (Figure	 4).	 	We	 found	 that	 acetate	
increased	significantly	over	the	intervention.	A	trend	of	increase	(P=0.079)	was	also	observed	for	
propionate.	
Overall,	these	results	indicate	that	the	eight-week	intervention	with	hazelnut	may	induce	limited	
changes	in	the	faecal	microbiota	composition	but	can	significantly	modulate	the	faecal	levels	of	the	
predominant	intestinal	SCFAs	such	as	acetate.	
3.2.3.2	The	modification	of	several	taxa	of	the	faecal	microbiota	
correlates	with	changes	of	host’s	hyperlipidemia	biomarkers		
We	performed	correlation	analyses	between	the	variations	observed	in	the	abundance	of	bacterial	
taxa	and	the	changes	in	the	lipid	profile	of	hyperlipidemic	subjects.	Specifically,	we	considered	the	
serum	 levels	 of	 total	 cholesterol	 (TC),	 low-density	 lipoprotein	 cholesterol	 (LDL-C),	 high-density	
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lipoprotein	 cholesterol	 (HDL-C),	 non-HDL	 cholesterol,	 and	 triglycerides	 (TG).	 We	 found	 that	
lipidemic	parameters	changed	over	the	intervention	and	were	associated	to	variations	in	144	OTUs,	
19	of	which	were	significantly	different	between	dyslipidemic	and	control	samples	(Figure	5).	We	
found	 an	 inverse	 correlation	 between	 the	 changes	 of	 TC	 and	 the	 variation	 of	 several	
Ruminococcaceae	OTUs,	particularly	Faecalibacterium	prausnitzii.	The	changes	in	HDL-C	inversely	
correlated	with	the	fluctuation	of	the	abundance	of	several	Clostridiales	and	Collinsella	OTUs;	on	
the	contrary,	a	positive	correlation	for	HDL-C	was	observed	with	the	variation	of	a	smaller	number	
of	Clostridiales,	 and	mostly	Lachnospiraceae,	 including	an	OTU	ascribed	 to	 the	genus	Roseburia.	
Only	 15	OTUs	were	 found	 to	 be	 correlated	with	 LDL-C	 changes,	 13	 of	 them	 (7	 positively	 and	 6	
negatively	correlated)	ascribed	to	the	order	Clostridiales.	Notably,	 trygliceridaemia	was	 inversely	
correlated	with	the	change	of	about	20	OTUs	ascribed	to	the	genus	Bacteroides,	9	Lachnospiraceae	
OTUs	(including	3	OTUs	ascribed	to	the	species	F.	prausnitzii),	and	2	Akkermansia	muciniphila	OTUs.	
On	 the	 contrary,	 trygliceridaemia	 modifications	 were	 positively	 correlated	 with	 changes	 of	 5	
Coprococcus	OTUs.	
Overall,	these	results	indicate	that	lipid	profile	of	the	hyperlipidemic	subjects	here	investigated	is	
linked	to	the	modification	of	the	abundance	of	specific	taxa	in	the	intestinal	microbiota	such	as	the	
families	 Lachnospiraceae	 and	 Ruminococcaceae,	 and	 the	 genera	 Akkermansia,	 Bacteroides,	
Roseburia,	and	Faecalibacterium	
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743755 p_Actinobacteria_c_Actinobacteria_o_Actinomycetales_f_Corynebacteriaceae_g_Corynebacterium_s_ +
370225 p_Actinobacteria_c_Actinobacteria_o_Bifidobacteriales_f_Bifidobacteriaceae_g_Bifidobacterium_s_adolescentis ++
535707 p_Actinobacteria_c_Actinobacteria_o_Bifidobacteriales_f_Bifidobacteriaceae_g_Bifidobacterium_s_longum +
193436 p_Actinobacteria_c_Coriobacteriia_o_Coriobacteriales_f_Coriobacteriaceae_g_Collinsella_s_ +
363794 p_Actinobacteria_c_Coriobacteriia_o_Coriobacteriales_f_Coriobacteriaceae_g_Collinsella_s_aerofaciens +
4481613 p_Actinobacteria_c_Coriobacteriia_o_Coriobacteriales_f_Coriobacteriaceae_g_Collinsella_s_aerofaciens +
189294 p_Actinobacteria_c_Coriobacteriia_o_Coriobacteriales_f_Coriobacteriaceae_g_Collinsella_s_aerofaciens +
368175 p_Actinobacteria_c_Coriobacteriia_o_Coriobacteriales_f_Coriobacteriaceae_g_Collinsella_s_aerofaciens +
348304 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +++
589277 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ ++
3887769 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ ++
580629 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ ++
4060124 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ ++
340474 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ ++
4468234 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
2137001 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
271214 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
4424408 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
2599028 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
198185 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ + +
2134452 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
844375 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
157327 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
4358723 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
182854 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
171559 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
3426658 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
4455163 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_ +
187324 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_caccae +
344525 *** p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_eggerthii +
351231 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_fragilis ++
197072 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Bacteroidaceae_g_Bacteroides_s_uniformis ++
198866 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Porphyromonadaceae_g_Parabacteroides_s_ +
367977 p_Bacteroidetes_c_Bacteroidia_o_Bacteroidales_f_Rikenellaceae_g_s_ +
217109 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Christensenellaceae_g_s_ + +
330714 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Clostridiaceae_g_Clostridium_s_ + ++
3434021 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Clostridiaceae_g_Clostridium_s_ +
181466 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Clostridiaceae_g_s_ ++
359750 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Clostridiaceae_g_s_ +
2270605 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Clostridiaceae_g_SMB53_s_ +
509416 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ ++
174353 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
368203 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
350091 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
4396655 ** p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ + +
360890 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
180681 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
186510 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
365484 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ + +
190208 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
4385326 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
197427 p_Firmicutes_c_Clostridia_o_Clostridiales_f_g_s_ +
585480 ** p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Anaerostipes_s_ +
198636 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ +
196791 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ +
193041 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ +
370183 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ ++
295085 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ +
195769 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ +
525378 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ +
364274 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Blautia_s_ +
367688 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_ +
313387 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_ +
177754 *** p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_ +
197022 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_ ++
514272 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_ ++
547913 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_ +
3141342 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_ +
362501 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Coprococcus_s_eutactus +
524258 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Dorea_s_formicigenerans ++
370098 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Lachnospira_s_ +++
314095 ** p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Lachnospira_s_ ++
350865 *** p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Lachnospira_s_ + ++
1029949 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Lachnospira_s_ +
342375 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Lachnospira_s_ +
175612 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Roseburia_s_ +
181485 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Ruminococcus_s_ +
592866 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Ruminococcus_s_ +
199245 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_s_ ++ +
194415 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_s_ +
362767 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_s_ +
303274 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_s_ +
513767 *** p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_s_ + + +
168071 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_s_ +
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Figure	5.	Correlation	between	lipidemic	profile	and	the	changes	in	faecal	microbiota	composition.	
The	figure	only	includes	OTUs	whose	change	over	the	hazelnut	intervention	significantly	correlated	
with	at	least	one	lipidemic	parameter	according	to	Kendall’s	Tau	rank	correlation.	The	colors	in	the	
left	 panel	 represents	 the	 mean	 of	 DESeq2-normalized	 abundances	 of	 the	 OTUs	 in	 control	 and	
hyperlipidemic	 (HL)	samples	before	 (T0)	and	after	 (T1)	 the	 intervention.	p	values	on	the	 left	are	
according	to	Wald	test	on	DESeq2-normalized	data	to	indicate	significantly	different	OTUs	between	
control	 and	 HL-T0	 samples;	 *,	 p<0.05;	 **,	 p<0.01;	 ***,	 p<0.001.	 The	 colors	 in	 the	 right	 panel	
represents	R-value	of	Spearman’s	correlation	of	the	differences	over	the	intervention	trial	between	
OTU	 abundance	 and	 lipidemic	 parameters.	 Plus	 signs	 are	 according	 to	 Kendall’s	 Tau	 rank	
correlation:	+,	p<0.05;	++,	p<0.01;	+++,	p<0.001.	
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3.2.4	Discussion	
In	this	study,	we	show	for	the	first	time	that	young	individuals	with	inherited	hyperlipidemia	may	
possess	 a	 dysbiotic	 gut	 bacterial	 ecosystem.	We	 came	 to	 this	 result	 by	 comparing	 the	 IME	 of	
hyperlipidemic	children	and	adolescent	(from	7	to	17	years	old,	mean	age	of	17)	with	the	IME	of	
age-matched	normolipidemic	controls	(from	5	to	17	years	old,	mean	age	of	17).	Although	the	range	
of	age	considered	was	quite	wide,	spanning	from	early	school-aged	childhood	to	late	adolescence,	
we	did	not	observe	age-related	differences	in	the	IME	of	volunteers,	in	accordance	with	scientific	
literature	demonstrating	that	the	intestinal	microbiota	of	children	reaches	the	adult	state	already	
at	 around	3	 years	of	 age	 (Lozupone	et	al.	 2013;	Matamoros	et	al.	 2013;	Rodriguez	et	al.	 2015).	
Notably,	diet	can	play	a	leading	role	in	shaping	the	gut	microbiota	(Amato	et	al.	2015;	De	Filippo	et	
al.	 2010),	 therefore,	 possible	 differences	 in	 eating	 behavior	 between	 hyperlipidemic	 and	
normolipidemic	 counterparts	 could	 have	 been	 contributed	 to	 IME	 differences.	 However,	 we	
calculated	 through	 food	 diaries	 and	 food	 frequency	 questionnaires	 that	 the	 macronutrient	
contribution	 to	 the	 overall	 diet	was	 comparable	 between	 the	 two	 groups	 of	 subjects	 (data	 not	
shown).		
The	results	of	the	present	study	evidenced	that	the	faecal	microbiota	of	hyperlipidemic	subjects	is	
characterized	 by	 the	 alteration	 of	 numerous	 taxonomic	 units,	 many	 of	 which	 belong	 to	 the	
Clostridiales	order.	In	addition,	we	observed	in	hyperlipidemic	samples	a	reduced	representation	of	
several	 Bacteroidetes	 OTUs.	 Hyperlipidemia	 is	 a	 predisposing	 factor	 and	 an	 intrinsic	 feature	 of	
several	diseases	such	as	obesity,	in	which	a	similar	alteration	of	the	microbiota	has	been	observed.	
In	fact,	a	number	of	studies	showed	that	obesity	is	associated	with	dysbiosis	supposed	to	enhance	
energy	extraction	from	food	and	increase	low-grade	inflammation,	characterized	by	an	increase	of	
bacteria	 from	 the	 phylum	 Firmicutes	 (mainly	 Clostridiales)	 and,	 particularly,	 a	 decrease	 of	
Bacteroidetes	(Armougom	et	al.	2009,	Baothman	et	al.	2016,	Ley	et	al.	2006,	Santacruz	et	al.	2010).	
In	addition,	the	enhanced	Firmicutes/Bacteroidetes	ratio	has	been	associated	with	a	high-protein,	
high-fat	Western	 diet	 (Amato	et	 al.	 2015)	 and	 distinguished	 European	 from	African	 1–6	 y	 aged	
children	(De	Filippo	et	al.	2010).	
Data	 on	 type	 2	 diabetes,	 which	 can	 be	 a	 hyperlipidemia-associated	 disease,	 indicated	 only	 a	
moderate	degree	of	gut	microbial	dysbiosis	and	rather	reported	a	‘functional	dysbiosis’,	in	which	a	
decrease	 in	 the	 intestinal	 level	 of	 butyrate	was	 observed	 (Knip	 and	 Siljander	 2016).	 The	 loss	 of	
78	
	
	
butyrate-producing	bacteria	and	the	decrease	of	butyrate	 levels	 in	the	gut	have	been	also	often	
reported	 in	 intestinal	 inflammatory	 conditions	 (Sokol	 et	 al.	 2008,	 Van	 Immerseel	 et	 al.	 2010).	
Accordingly,	 in	 our	 study,	 compared	 to	 normolipidemic	 controls,	 we	 found	 in	 hyperlipidemic	
subjects	a	significantly	reduced	abundance	of	OTUs	ascribed	to	well-recognized	butyrate	producing	
bacteria,	such	as	Faecalibacteirum	prausnitzii	and	Roseburia	spp.	(Louis	and	Flint	2009),	together	
with	the	significantly	lower	concentration	of	faecal	butyrate.	
Butyrate	is	mostly	produced	by	Clostridiales	bacteria,	whereas	acetate	and	propionate	principally	
derive	 from	 the	 primary	metabolism	of	members	 of	 the	 phylum	Bacteroidetes	 (Macfarlane	 and	
Macfarlane	2003).	In	accordance	with	the	observed	lack	of	several	Bacteroidetes	OTUs,	we	found	
that	the	faecal	levels	of	acetate	and	propionate	were	significantly	decreased	in	the	hyperlipidemic	
subjects.	Acetate	and	propionate	produced	by	gut	microbiota	are	rapidly	absorbed	and	reach	the	
liver	via	the	portal	circulation,	where	they	are	used	as	an	energy	source	(Canfora	et	al.	2015,	den	
Besten	et	al.	2013)	and	participate	to	lipogenesis	and	gluconeogenesis,	respectively	(Canfora	et	al.	
2015).	 There	 is	 experimental	 evidence	 suggesting	 that	 acetate	 and	 propionate	 may	 regulate	
cholesterol	 metabolism	 by	 decreasing	 the	 activity	 of	 hepatic	 3-hydroxy-3-methylglutaryl-CoA	
synthase	 (HMGCS)	 and	 reductase	 (HMGCR)	 (den	 Besten	 et	 al.	 2013);	 in	 addition,	 acetate	 may	
increase	cholesterol	7-α-hydroxylase	(CYP7A1)	(Fushimi	et	al.	2006,	Rodwell	et	al.	1976).	Notably,	
HMGCS	and	HMGCR	are	involved	in	the	initial	steps	of	cholesterol	biosynthesis	(Rodwell	et	al.	1976),	
whereas	CYP7A1	participates	to	cholesterol-bile	acid	conversion	(den	Besten	et	al.	2013).	It	can	be	
then	argued	that	the	reduction	of	the	intestinal	levels	of	acetate	and	propionate	in	hyperlipidemic	
subjects	 may	 contribute	 to	 their	 altered	 cholesterol	 metabolism.	 Interestingly,	 in	 our	 study,	
following	the	dietary	intervention	with	hazelnut,	we	observed	a	significant	increase	of	acetate	and	
a	 trend	 to	 rise	 of	 propionate	 levels,	 with	 assumed	 potential	 benefit	 for	 individuals	 with	
hyperlipidemia.	
In	 addition	 to	 the	 lower	 abundance	of	 the	predominant	 intestinal	 SCFAs	 (acetate,	 butyrate	 and	
propionate,	representing	up	to	95%	of	the	SCFAs	present	in	the	colon),	we	found	in	hyperlipidemic	
faecal	samples	increased	levels	of	lactate,	isobutyrate	and	pyruvate.	Lactate	is	produced	by	several	
members	of	the	intestinal	microbiota,	such	as	lactic	acid	bacteria,	bifidobacteria	and	enterobacterial	
species	(e.g.	E.	coli).	However,	under	normal	physiological	conditions,	lactate	does	not	accumulate	
in	 the	 colon,	 since	 it	 is	 consumed	 by	 other	 intestinal	 microorganisms.	 Particularly,	 lactate	 is	
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converted	to	butyrate	by	several	gut	commensals	such	as	Eubacterium	hallii,	Anaerostipes	caccae	
and	 Roseburia	 intestinalis	 (Bourriaud	et	 al.	 2005,	Duncan	et	 al.	 2004,	 Flint	et	 al.	 2015,	Van	den	
Abbeele	et	al.	2013),	which	are	all	members	of	the	order	Clostridiales.	Therefore,	an	accumulation	
of	lactate	can	be	plausibly	considered	as	a	microbial	metabolic	signature	of	dysbiosis;	accordingly,	
the	shifts	of	bacterial	metabolism	from	short-chain	fatty	acid	to	lactate	production	and	the	resulting	
intraluminal	pooling	of	lactate	have	been	associated	to	pathological	conditions	(Bustos	et	al.	1994,	
Huda-Faujan	et	al.	2010,	Vernia	et	al.	1988).	Reportedly,	lactate	is	present	at	low	concentrations	(<3	
mmol	l-1)	or	not	detected	in	the	feces	of	healthy	individuals	(Duncan	et	al.	2007,	Vernia	et	al.	1988),	
whereas	concentrations	up	to	100	mmol	l-1	have	been	reported	in	gut	disorders	(Hove	et	al.	1994,	
Vernia	et	al.	1988).	Therefore,	considering	that	in	our	study	lactate	exceeded	the	level	of	1	mmol	
per	kg	of	 feces	 in	only	5	out	of	48	analyzed	samples,	 the	actual	physiological	 significance	of	 the	
faecal	lactate	here	detected	in	hyperlipidemic	subjects	is	questionable.	
Isobutyrate,	which	is	produced	in	the	gut	by	degradation	of	amino	acids	such	as	valine	(Zarling	and	
Ruchim	1987),	has	been	found	to	be	correlated	with	behavior	changes	induced	by	prebiotics	in	mice	
(Burokas	et	al.	 2017),	whereas	pyruvate,	which	 can	derive	 from	bacterial	 autolysis	or	exfoliated	
apical	enterocytes,	has	been	associated	to	inflammatory	bowel	disease	(Huda-Faujan	et	al.	2010).	
However,	 the	 actual	 importance	of	 the	modification	of	 these	 organic	 acids	 in	 the	 human	 gut	 is	
unclear,	and	literature	is	too	limited	yet	to	allow	a	complete	interpretation	of	our	results.	
Although	the	hazelnut	intervention	modified	significantly	the	faecal	levels	of	SCFAs,	the	abundances	
of	 the	 bacterial	 taxa	 in	 the	 faecal	 microbiota	 were	 only	 limitedly	 affected.	 The	 observed	
modifications	 of	 SCFA	 levels	 that	 occurred	 after	 the	 hazelnut	 consumption	 may	 be	 plausibly	
explained	by	the	intake	of	fiber	derived	from	the	overall	diet	including	the	contribution	of	hazelnuts.	
However,	the	elaboration	of	dietary	intake	did	not	support	such	a	hypothesis	since	fiber	intake	did	
not	change	following	the	intervention	(i.e.,	about	10	g	per	day	as	a	mean	in	this	target	population)	
(Deon	et	 al.	 2017a).	Moreover,	 despite	 the	 energy	 intake	 did	 not	 change	 following	 the	 regular	
consumption	of	hazelnuts,	it	should	be	underlined	that	an	increased	intake	of	total	fat	(about	+5%)	
and	monounsaturated	fatty	acids	was	observed	(Deon	et	al.	2017a).	Finally,	children	had	also	an	
increased	 intake	 of	 phytosterols,	 tocopherols	 and	 polyphenols	 following	 hazelnut	 consumption.	
Consequently,	in	light	of	the	recognized	activity	of	phenolic	compounds	as	potential	modulator	of	
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the	microbiota	(Valdes	et	al.	2015),	the	contribution	of	these	bioactives	on	bacterial	fermentation	
in	the	gut	cannot	be	excluded.	
Numerous	human	trials	in	recent	years	included	the	profiling	of	the	intestinal	microbiota,	identifying	
the	 expansion	 or	 depletion	 of	 specific	 taxa	 as	 potential	 markers	 for	 pathological	 conditions	 or	
dysfunctions	(Knip	and	Siljander	2016,	Miele	et	al.	2015,	Sokol	et	al.	2008).	Nonetheless,	only	few	
studies	associated	specific	gut	bacteria	to	defined	physiopathological	mechanisms	(e.g.,	(Devkota	et	
al.	2012)).	Such	restricted	knowledge	on	the	involvement	of	bacteria	in	host	physiological	processes	
greatly	limits	the	possibility	to	understand	the	actual	biological	meaning	(if	any)	of	several	significant	
correlations	 we	 found	 between	 specific	 taxa	 of	 the	 intestinal	 microbiota	 and	 lipidemic	 profile.	
However,	a	few	speculations	can	be	done.	Interestingly,	the	variation	of	OTUs	belonging	to	intestinal	
bacteria	with	recognized	anti-inflammatory	properties	such	as	Faecalibacterium	prausnitzii	(Sokol	
et	al.	2008)	and	Akkermansia	muciniphila	(Zhao	et	al.	2017),	correlated	inversely	with	the	change	of	
TG,	TC,	LDL-C,	and	non-HDL	cholesterol,	suggesting	the	potential	involvement	of	these	bacteria	in	
the	 link	 between	 inflammation	 and	 hyperlipidemia	 (Feingold	 and	Grunfeld	 2000,	 Tall	 and	 Yvan-
Charvet	 2015).	 Reportedly,	 Faecalibacterium	 prausnitzii	 is	 associated	 with	 inflammatory	 bowel	
diseases	 and	 its	 supplementation	 abolished	 inflammation	 (Sokol	 et	 al.	 2008).	 Furthermore,	 the	
abundance	of	Akkermansia	muciniphila	is	lower	in	obesity	and	diabetes	and	the	administration	of	
this	 bacterium	 has	 been	 shown	 to	 reduce	 obesity,	 fat	 mass	 inflammation	 and	 also	 plasma	
cholesterol	and	triglycerides	(Everard	et	al.	2013,	Plovier	et	al.	2017).	This	 last	example	is	also	in	
accordance	 with	 the	 present	 study,	 where	 the	 changes	 of	 some	 plasma	 lipids	 are	 inversely	
associated	with	this	intestinal	commensal.	In	addition,	the	change	of	Bacteroides	fragilis,	which	is	
another	species	with	a	reported	potential	anti-inflammatory	role	in	the	gut	(Troy	and	Kasper	2010),	
was	 inversely	 correlated	with	 the	modification	of	 trygliceridaemia.	On	 the	 contrary,	we	 found	a	
direct	correlation	between	the	variations	of	cholesterolaemia	and	an	OTU	ascribed	to	Veilonella	
dispar,	which	is	a	potential	pathobiont	associated	with	several	clinical	cases	of	infection	(Houston	
et	al.	1997,	Marchandin	et	al.	2001).	V.	dispar	was	also	found	to	be	enriched	in	colorectal	carcinoma	
in	adenoma	(Kasai	et	al.	2016).	
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3.2.5	Supplementary	material	
Figure	S1.	OTUs	distinguishing	control	and	hyperlipidemic	subjects	determined	by	using	the	DESeq2	
negative	binomial	distribution	method	on	16S	rRNA	gene	profiling	data	of	a	single	fecal	sample	per	
subject.	The	colors	in	the	heatmap	represents	the	mean	of	normalized	abundances	of	the	reported	
OTUs.	The	taxonomic	lineage	of	each	taxon	is	shown;	p,	phylum;	c,	class;	o,	order;	f,	family;	g,	genus;	
s,	species.	Positive	fold	changes	(shown	on	a	red	background)	indicate	OTU	overrepresentation	in	
normolipidemic	controls	compared	to	hyperlipidemic	samples;	negative	fold	changes	(shown	on	a	
green	background)	indicate	a	decrease	of	OTU	abundance	in	hyperlipidemic	samples	compared	to	
normolipidemic	controls.		
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OTU nr. Taxonomy C HL
198774 p_Actinobacteria;c_Coriobacteriia;o_Coriobacteriales;f_Coriobacteriaceae;g_Adlercreutzia;s_ 1.48 2.6E-03 1.75E-02
3013444 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;g_;s_ -2.42 5.4E-09 2.20E-07
183395 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Barnesiellaceae];g_;s_ -2.29 3.3E-03 2.03E-02
3500642 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Barnesiellaceae];g_;s_ -1.64 6.8E-03 3.58E-02
194395 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Barnesiellaceae];g_;s_ -1.54 1.0E-03 8.29E-03
208479 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Odoribacteraceae];g_Butyricimonas;s_ -2.02 1.3E-03 1.04E-02
177353 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Odoribacteraceae];g_Odoribacter;s_ -2.73 2.7E-09 1.36E-07
196947 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Paraprevotellaceae];g_[Prevotella];s_ -3.17 1.0E-14 2.80E-12
228601 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -2.84 2.6E-11 2.19E-09
4467447 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.86 1.9E-04 2.12E-03
326662 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.85 8.0E-06 1.55E-04
157748 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.57 1.4E-03 1.08E-02
1126638 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.14 6.2E-03 3.34E-02
195508 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_caccae -2.23 2.4E-03 1.62E-02
184567 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_caccae -2.23 1.0E-04 1.42E-03
320120 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_caccae -2.18 4.1E-03 2.37E-02
344525 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_eggerthii -2.87 9.1E-07 2.28E-05
4387250 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ovatus -1.50 2.2E-03 1.57E-02
585914 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromonadaceae;g_Parabacteroides;s_distasonis -2.88 1.8E-07 5.22E-06
4374084 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromonadaceae;g_Parabacteroides;s_distasonis -1.46 3.6E-04 3.51E-03
336214 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_;s_ -3.26 9.0E-15 2.80E-12
439437 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24-7;g_;s_ -2.72 2.9E-10 2.11E-08
208409 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24-7;g_;s_ -2.55 2.0E-09 1.13E-07
339905 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24-7;g_;s_ -2.02 1.1E-06 2.63E-05
188735 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ 1.35 3.1E-03 1.93E-02
583656 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ 2.47 1.4E-04 1.68E-03
356827 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ 2.77 9.0E-08 2.90E-06
1787644 p_Cyanobacteria;c_Chloroplast;o_Streptophyta;f_;g_;s_ -2.63 1.1E-09 6.79E-08
1136443 p_Deferribacteres;c_Deferribacteres;o_Deferribacterales;f_Deferribacteraceae;g_Mucispirillum;s_schaedleri -5.66 6.8E-42 7.47E-39
4431922 p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Streptococcaceae;g_Streptococcus;s_ -1.24 8.9E-04 7.57E-03
260890 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -3.50 6.6E-17 3.66E-14
848615 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -3.35 2.8E-07 7.79E-06
275139 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -3.18 8.2E-14 1.82E-11
345862 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.86 4.3E-12 5.97E-10
198200 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.80 6.5E-11 5.13E-09
277265 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.60 4.3E-10 2.94E-08
330460 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.48 2.8E-09 1.36E-07
272072 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.45 1.3E-08 4.96E-07
361727 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.45 1.9E-05 3.25E-04
356627 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.26 8.6E-08 2.90E-06
188861 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.92 3.4E-03 2.04E-02
180307 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.87 4.0E-05 6.15E-04
198119 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.86 3.3E-06 7.17E-05
192741 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.76 3.8E-03 2.24E-02
1040889 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.74 3.6E-03 2.17E-02
187081 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.73 3.0E-03 1.91E-02
201772 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.68 1.3E-05 2.27E-04
976470 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.64 5.9E-03 3.22E-02
4358921 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.62 1.1E-04 1.42E-03
185034 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.56 3.7E-03 2.18E-02
194095 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.55 7.4E-06 1.46E-04
389371 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.53 5.0E-03 2.81E-02
364736 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.51 8.1E-03 4.11E-02
195799 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.51 4.8E-04 4.40E-03
188832 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.43 2.4E-04 2.51E-03
188596 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.25 4.9E-03 2.77E-02
357389 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.21 4.5E-04 4.18E-03
322560 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_SMB53;s_ -1.19 8.2E-03 4.11E-02
524404 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.98 4.0E-09 1.69E-07
536910 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.77 1.1E-05 2.07E-04
561171 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.52 2.7E-04 2.77E-03
846141 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.50 1.8E-05 3.17E-04
185486 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.45 2.2E-06 4.91E-05
336830 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.38 8.2E-04 7.07E-03
177061 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.27 6.0E-05 8.83E-04
Media log2 Fold 
Change pvalue padj
Figure S1. OTUs distinguishing control and hyperlipidemic subjects determined by using the DESeq2 negative binomial distribution
method on 16S rRNA gene profiling data of a single fecal sample per subject. The colors in the heatmap represents the mean of
normalized abundances of the reported OTUs. The taxonomic lineage of each taxon is shown; p, phylum; c, class; o, order; f, family; g,
genus; s, species. Positive fold changes (shown on a red background) indicate OTU overrepresentation in normolipidemic controls
compared to hyperlipidemic samples; negative fold changes (shown on a green background) indicate a decrease of OTU abundance in
hyperlipidemic samples compared to normolipidemic controls.
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Table	 S1.	 Levels	 of	 short	 chain	 fatty	 acids	 in	 faecal	 samples	 at	 baseline	 and	 following	 hazelnut	
intervention.	Data	are	reported	as	mmol	per	kg	of	feces.	-,	not	detected.	
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Fig. S2. Fecal levels of short chain fatty acids in hyperlipidemic and control subjects. Black	
circles	refer	to	control	samples	analyzed	in	the	present	study;	white	circles	refer	to	data	obtained	
from	healthy	adults	 in	 a	previous	 study	 (Gargari	 et	 al.,	 2016,	doi:	 10.1128/AEM.01753-16);	 grey	
triangles	refer	to	samples	from	hyperlipidemic	subjects	not	included	in	the	intervention	trial.	***,	
P<0.001	according	to	Mann-Whitney	U	(unpaired)	test.	 
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Figure	 S3.	 OTUs	 changed	 during	 the	 hazelnut	 intervention	 trial	 in	 hyperlipidemic	 subjects	 as	
determined	using	the	DESeq2	negative	binomial	distribution	method	on	16S	rRNA	gene	profiling	
data	of	a	single	fecal	sample	per	subject.	OTUs	have	been	selected	adopting	the	p	value	without	
FDR	adjustment	with	a	significance	limit	of	0.05.	The	colors	in	the	heatmap	represents	the	mean	of	
normalized	abundances	of	the	reported	OTUs.	The	taxonomic	 lineage	of	each	taxon	is	shown;	p,	
phylum;	 c,	 class;	 o,	 order;	 f,	 family;	 g,	 genus;	 s,	 species.	 Positive	 fold	 changes	 (shown	on	 a	 red	
background)	indicate	OTU	increase	after	the	intervention;	negative	fold	changes	(shown	on	a	green	
background)	indicate	a	decrease	after	the	intervention.		
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3.3	The	faecal	microbial	ecosystem	reflects	bowel	
habits	in	irritable	bowel	syndrome	
3.3.1	Introduction	
Irritable	 bowel	 syndrome	 (IBS)	 is	 the	most	 prevalent	 functional	 gastrointestinal	 disorder	 in	 the	
Western	world.	Although	it	does	not	have	a	lethal	prognosis,	IBS	may	induce	a	significant	diminution	
of	the	quality	of	life	of	patients,	depending	on	the	severity	of	symptoms,	which	characteristically	
include	abdominal	pain,	bloating,	distension	and	altered	bowel	habits	(Mearin	et	al.	2016).	
IBS	is	a	widely	heterogeneous	condition	in	terms	of	etiology,	pathogenesis	and	clinical	presentation.	
In	particular,	 IBS	 is	conventionally	classified	 in	four	subtypes	according	to	bowel	habits:	 IBS	with	
constipation	(IBS-C),	IBS	with	diarrhoea	(IBS-D),	IBS	alternating	constipation	and	diarrhoea	(mixed	
IBS,	IBS-M),	and	unsubtyped	IBS	(IBS-U)	(Mearin	et	al.	2016).	
Elucidations	of	 the	diverse	mechanisms	underlying	 the	pathophysiology	of	 IBS	 subtypes	 are	 still	
lacunose;	furthermore,	conclusively	validated	biomarkers	are	not	available	(Kim	et	al.	2017).	In	a	
recent	paper,	Collins	S.	M.	proposed	to	explain	the	intestinal	dysfunctions	associated	to	IBS	through	
a	gut-microbiota-centered	model	 (Collins	2014).	According	to	this	model,	 triggers	 like	antibiotics	
use,	 infections	 and/or	 stress	 affect	 host	 functions	 such	 as	 mucin	 production,	 gut	 motility	 and	
hormone	 secretion,	 leading	 to	 dysbiosis	 (i.e.,	 compositional	 and	 functional	 alterations	 of	 the	
intestinal	 microbial	 ecosystem;	 IME),	 which	 in	 turn	 promotes	 chronic	 gut	 dysfunctions.	 Hence,	
Collins’	model	 highlights	 the	 central	 role	 of	 the	 intestinal	microbiota	 in	 IBS,	 in	 agreement	with	
clinical	evidences	of	the	benefits	generated	by	gut	microbiota-targeting	strategies	such	as	the	use	
of	antibiotics	(e.g.	rifaximin)	(Li	et	al.	2016)	and	probiotics	(Guglielmetti	et	al.	2011,	O'Mahony	et	al.	
2005).	 Accordingly,	 gut	 dysbiosis	was	 often	 observed	 as	 a	 common	 alteration	 associated	 to	 IBS	
(Taverniti	and	Guglielmetti	2014,	Zhuang	et	al	2017).	
Several	possible	bacterial	signatures	have	been	proposed	to	distinguish	IBS	patients	from	healthy	
controls,	such	as	the	increase	in	certain	Ruminococcus	phylotypes,	the	reduction	of	Bifidobacteria,	
or	 the	 expansion	 of	 Proteobacteria	 and	 Veillonella	 spp.	 (Shukla	 et	 al.	 2015,	 Taverniti	 and	
Guglielmetti	 2014).	 IBS-subtype	 specific	 alterations	 have	 been	 also	 reported.	 For	 instance,	 the	
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reduction	 of	 Bifidobacteria,	 lactobacilli,	 and	 the	 genus	 Desulfovibrio	 was	 observed	 in	 IBS-D	
compared	to	IBS-C	(Malinen	et	al.	2005);	the	same	study	also	showed	the	increase	of	Veillonella	in	
IBS-C	(Malinen	et	al.	2005).	The	IBS-C	subtype	was	also	associated	to	the	expansion	of	ruminococci	
(Kassinen	 et	 al.	 2007,	 Lyra	 et	 al.	 2009).	Moreover,	 higher	 aerobic	 counts	 in	 faecal	 samples	was	
observed	 in	 IBS-D	 by	means	 of	 a	 culture-based	 analyses	 (Carroll	 et	 al.	 2010).	 In	 addition,	more	
recently,	Tap	et	al.	 (Tap	et	al.	2017)	 reported	 that	 IBS-D	patients	had	more	Methanobacteriales	
compared	to	the	other	IBS	subtypes.	However,	data	concerning	the	differences	in	the	gut	microbiota	
composition	of	 IBS	subtypes	are	 inconsistent,	partly	contradictory,	and	often	based	on	methods	
with	low-discriminatory	power	(Ringel-Kulka	et	al.	2016,	Taverniti	and	Guglielmetti	2014).	
Besides	 the	 taxonomic	 identity	of	 the	bacteria	 constituting	 the	 IME,	a	predominant	 role	 for	 the	
intestinal	microbiota-host	interaction	is	played	by	bacterial	metabolites	in	the	gut	and,	among	them,	
particularly	 by	 the	 short	 chain	 fatty	 acids	 (SCFAs)	 (Koh	 et	 al.	 2016),	which	 are	 produced	 in	 the	
intestinal	lumen	by	bacterial	fermentation	in	copious	quantity	(exceeding	hundreds	of	mmol	per	kg	
of	feces	[Gargari	et	al.	2016]).	Reportedly,	acetate,	butyrate	and	propionate,	which	are	the	three	
most	abundant	 intestinal	SCFAs,	 in	 fact,	 contribute	 to	host	physiology	within	 the	gut	and	 in	 the	
periphery,	affecting	the	metabolism	of	several	organs	(Koh	et	al.	2016).	Although	not	diffusely	taken	
into	consideration	in	clinical	investigations	focusing	on	IBS,	available	scientific	data	already	indicate	
that	altered	levels	of	the	SCFAs	may	have	a	significant	role	in	this	disorder	(Camilleri	et	al.	2016),	
suggesting	that	these	metabolites	of	the	intestinal	microbiota	need	further	attention	in	IBS.	
Inspired	 by	 the	 above	 considerations,	 in	 this	 study,	 we	 aimed	 to	 characterized	 the	 IME	 in	 IBS	
subtypes	by	means	of	16S	ribosomal	RNA	(rRNA)	gene	profiling	and	SCFAs	quantification	in	faecal	
samples	collected	during	a	multicentre	intervention	trial	that	we	recently	performed	to	assess	the	
effect	 of	 a	 probiotic	 preparation	 on	 the	 IBS	 symptoms	 of	 40	 patients	 (Cremon	 et	 al.,	 2017).	 In	
addition,	the	clinical	and	immunological	data	collected	during	the	trial	were	used	to	investigate	the	
potential	correlations	existing	in	IBS	subtypes	between	the	IME	and	host	physiological	and	clinical	
parameters,	 including	 bowel	 habits,	 depression/anxiety	 scores,	 and	 faecal	 levels	 of	 IgA	 and	
cytokines.	
97	
	
	
3.3.2	Materials	and	Methods	
3.3.2.1	Patients	
Eligible	patients	with	symptoms	meeting	Rome	III	criteria	for	IBS	diagnosis	were	recruited	in	five	
Italian	 hospitals	 as	 previously	 described	 (Cremon	 et	 al.,	 2017).	 In	 brief,	 the	 inclusion	 criteria	
comprised	 a	 positive	 diagnosis	 of	 all	 IBS	 subtypes,	 age	 between	 18	 and	 65	 years,	 negative	
colonoscopy	 or	 barium	 enema	 examination	 within	 the	 previous	 2	 years,	 and	 negative	 relevant	
additional	 screening	or	consultation	whenever	appropriate.	Patients	were	excluded	 if	 they	were	
pregnant,	breast-feeding,	or	not	using	reliable	methods	of	contraception.	The	exclusion	criteria	also	
included	 intestinal	 organic	diseases,	 such	as	 celiac	disease	 ascertained	by	 the	detection	of	 anti-
transglutaminase	 antibodies,	 diverticular	 disease,	 or	 inflammatory	 bowel	 diseases	 (IBDs;	 e.g.,	
Crohn's	disease,	ulcerative	colitis,	infectious	colitis,	ischemic	colitis,	or	microscopic	colitis);	previous	
major	 abdominal	 surgery;	 untreated	 food	 intolerance,	 such	 as	 ascertained	 or	 suspected	 lactose	
intolerance	as	defined	by	anamnestic	evaluation	or,	if	appropriate,	lactose	breath	test;	consumption	
of	 probiotics	 or	 topical	 and/or	 systemic	 antibiotic	 therapy	 during	 the	 month	 before	 study	
enrolment;	frequent	consumption	of	contact	laxatives;	presence	of	any	relevant	organic,	systemic,	
or	metabolic	disease	as	assessed	by	medical	history,	appropriate	consultations,	and	laboratory	tests;	
or	abnormal	laboratory	values	deemed	clinically	significant	on	the	basis	of	predefined	values.	
3.3.2.2	Collected	data	and	missing	samples	
A	total	of	40	IBS	patients	(IBS-C,	n=12;	IBS-D,	n=14;	IBS-M,	n=3;	IBS-U,	n=11)	were	included	in	the	
study.	Classification	into	IBS	subtypes	was	according	to	the	Rome	III	criteria	and	based	on	Bristol	
Stool	Form	scale	characteristics	(Longstreth	et	al.	2006).	Information	and	biological	specimens	were	
collected	every	four	weeks	at	five	consecutive	time	points	(visits	V1-V5)	according	to	the	trial	design	
described	by	Cremon	et	al.	(2017)	and	registered	at	ClinicalTrial.gov	(Identifier	NCT02371499).	One	
participant	 (belonging	 to	 the	 IBS-D	subgroup)	dropped	out	after	visit	V3	and,	consequently,	198	
faecal	samples	were	collected.	16S	rRNA	gene	profiling	analyses	were	performed	on	all	samples,	
whereas	SCFAs	were	quantified	in	the	5	faecal	samples	of	37	patients	(i.e.	a	total	of	185	samples;	
IBS-C,	n=12;	IBS-D,	n=11;	IBS-M,	n=3;	IBS-U,	n=11)	due	to	insufficient	specimen.	Data	from	Bristol	
stool,	anxiety/depression	scales,	and	IgA	and	cytokine	data	were	available	as	described	in	Cremon	
et	al.,	2017.	Correlation	analyses	were	performed	using	data	from	150	samples	(30	patients).	
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3.3.2.3	Profiling	of	faecal	microbiota	composition	
Metagenomics	DNA	was	extracted	from	about	200	mg	of	feces	using	the	PowerSoil®	DNA	Isolation	
Kit	(MO	BIO	Laboratories)	according	to	the	manufacturer’s	instructions.	Subsequently,	the	bacterial	
community	structure	was	profiled	by	16S	rRNA	gene	profiling.	In	brief,	Probio_Uni	and	Probio_Rev	
primers	were	used	to	amplify	a	partial	region	of	the	16S	rRNA	encompassing	the	V3	variable	region	
(Gargari	et	al.	2016).	Next,	amplicons	were	sequenced	using	Illumina	MiSeq	System	and	the	resulting	
sequence	reads	were	managed	by	means	of	the	bioinformatic	pipeline	Quantitative	Insights	 Into	
Microbial	 Ecology	 (QIIME)	 version	 1.7.0	 (Caporaso	 et	 al.	 2010)	 with	 the	 GreenGenes	 database	
(version	13.5).	Metadata	have	been	deposited	 in	 the	European	Nucleotide	Archive	 (ENA)	of	 the	
European	Bioinformatics	Institute	under	accession	code	PRJEB18753.	
3.3.2.4	Quantification	of	faecal	short	chain	fatty	acids	(SCFAs)	
SCFAs	were	quantified	in	the	faecal	samples	as	previously	described	(Gargari	et	al.	2016).	In	brief,	
100	mg	of	stools	were	suspended	in	2	ml	of	0.001%	formic	acid,	vortexed	for	1	min,	and	centrifuged	
at	1000	x	g	for	2	min	at	4	°C.	Supernatant	was	recovered	and	pellet	was	extracted	again	as	described	
above.	Then,	the	two	supernatants	were	combined	and	the	volume	adjusted	to	5	ml	with	0.001%	
formic	acid	solution.	All	extracts	were	stored	at	-20	°C	until	analysis,	which	was	performed	by	UPLC-
HR-MS	on	Acquity	UPLC	separation	module	(Waters,	Milford,	MA,	USA)	coupled	with	an	Exactive	
Orbitrap	MS	through	an	HESI-II	probe	for	electrospray	ionization	(Thermo	Scientific,	San	Jose,	CA,	
USA).	Column,	ion	source	and	interface	conditions	were	reported	in	(Gargari	et	al.	2016).	Elution	
was	carried	out	at	a	flow-rate	of	0.2	ml/min	with	solvents	0.001%	HCOOH	in	MilliQ-treated	water	
(solvent	A)	and	CH3OH:CH3CN	(1:1	v/v,	solvent	B),	using	the	following	elution	gradient:	0%	B	for	4	
min,	0-15%	B	in	6	min,	15-20%	B	in	5	min,	20%	for	13	min,	and	then	return	to	initial	conditions	in	1	
min.	 Subsequently,	 the	 UPLC	 eluate	 was	 analyzed	 in	 full	 scan	 MS	 in	 the	 range	 50-130	m/z	 as	
described	elsewhere	(Gargari	et	al	2016).	External	calibration	curves	were	prepared	with	reagents	
from	Sigma-Aldrich	(Milan,	Italy)	to	quantify	acetic,	butyric,	isobutyric,	isovaleric,	lactic,	propionic,	
and	valeric	acids	in	faecal	samples.	SCFA	concentrations	were	expressed	in	mmol	per	kilogram	of	
wet	feces.	
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3.3.2.5	Statistical	analysis	
Data	concerning	the	intestinal	microbial	ecosystem	(16S	rRNA	gene	profile	and	SCFA	quantification)	
were	 analyzed	 using	 R	 statistic	 software	 (version	 3.1.2)	 and	 QIIME.	 Statistically	 significant	
differences	 were	 determined	 through	 the	 Wilcoxon-Mann-Whitney	 test	 for	 unpaired	 data.	
Statistically	significant	differences	at	OTU	level	between	IBS	subtypes	were	determined	by	using	the	
differential	 gene	 expression	 analysis	 based	 on	 the	 negative	 binomial	 distribution	 method	
(R/Bioconductor	DESeq2	package)	using	q-value	(FDR	adjusted	p-value)	for	the	threshold	(Love	et	
al.	2014).	Correlation	analyses	were	performed	using	the	Kendall	and	Spearman	formulas	with	the	
items	specified	in	the	text	as	predictors	and	dependent	variables.	Significance	was	set	at	P≤0.05;	
significance	 in	 the	 range	0.05<P<0.10	was	accepted	as	 trend.	UNIFRAC	algorithms	were	used	 to	
study	 inter-sample	diversity	of	 the	 faecal	microbiota	 composition.	 Subjects	have	been	 clustered	
using	the	Jensen–Shannon	divergence	(JSD)	distance	and	the	Partitioning	Around	Medoids	(PAM)	
clustering	algorithm	based	on	microbiota	proﬁling	data.	
3.3.3	Results	
3.3.3.1	The	overall	bacterial	diversity	of	the	faecal	microbiota	does	not	
discriminate	IBS	subtypes	
16S	 rRNA	 gene	 proﬁling	 was	 performed	 on	 198	 faecal	 samples	 collected	 from	 40	 IBS	 patients,	
generating	a	total	of	16’963’222	ﬁltered	high-quality	sequence	reads	(average,	138’413	reads	per	
sample).	Rarefaction	curves	demonstrated	that	most	faecal	microbiota	diversity	had	been	covered	
(not	shown).	Unifrac	algorithm	was	used	to	investigate	inter-sample	(β-)	diversity.	According	to	the	
two	main	components	extracted,	we	found	that	the	intra-patient	variability	observed	among	the	
five	 samples	analyzed	 for	each	 subject	was	mostly	higher	 than	 the	differences	occurring	among	
different	 subjects	 (Supplementary	 figure	 S1).	 For	 this	 reason,	 besides	 considering	 the	data	of	 a	
single	 16S	 rRNA	 gene	 profiling	 determination	 per	 subject	 (single	 profiling	 data;	 n=40),	 we	 also	
performed	the	analyses	with	data	corresponding	to	the	medians	of	 five	16S	rRNA	gene	profiling	
determinations	per	patient	 (median	profiling	data;	n=39)	 in	order	 to	attenuate	 the	effect	of	 the	
temporal	instability	of	patients’	faecal	microbiota.		
100	
	
	
Afterwards,	we	investigated	the	β-diversity	of	the	different	types	of	IBS.	This	analysis	revealed	that	
both	weighted	and	unweighted	Unifrac	cannot	distinguish	faecal	samples	on	the	basis	of	the	IBS	
subtypes	either	with	single	(Supplementary	Figure	S2)	or	median	(Figure	1)	profiling	data.	
	
Figure	 1.	 Ecological	 β-diversity	 of	 the	 faecal	 microbiota	 in	 IBS	 subtypes.	 Principal	 coordinates	
analysis	 of	 weighted	 (A)	 and	 unweighted	 (B)	 Unifrac	 distances	 based	 on	 the	 medians	 of	 OTU	
abundances	related	to	five	faecal	samples	per	IBS	patient	(n	=	39).	The	first	two	coordinates	(PC1	
and	PC2)	are	displayed	with	the	percentage	of	variance	explained	in	brackets.	
	
Next,	intra-sample	taxonomic	richness	and	evenness	(α-diversity)	were	analyzed	by	means	of	four	
algorithms,	namely	Chao1,	 Faith's	Phylogenetic	Diversity,	 Shannon	and	Simpson	 indexes.	 The	α-
diversity	indexes	of	the	IBS	subtypes	were	not	significantly	different	both	with	single	and	median	
profiling	data	(Supplementary	Figure	S3).	
Microbiota	proﬁling	data	were	then	stratiﬁed	by	enterotyping	based	on	the	relative	abundances	of	
the	 bacterial	 genera	 (Gargari	 et	 al	 2016).	 An	 optimal	 number	 of	 three	 groups	 of	 samples	 was	
generated,	nonetheless	the	Silhouette	coefficient,	which	validate	the	consistency	within	groups	of	
data,	was	 too	 low	 to	 consider	 reliable	 the	 clustering	 (Supplementary	 Figure	 S4A).	 Notably,	 the	
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taxonomic	 overview	 of	 all	 198	 IBS	 faecal	 sample	 analyzed	 revealed	 that	 the	 first	 seven	 most	
abundant	genera	belong	to	the	Firmicutes	Gram	positive	order	Clostridiales	(Supplementary	Figure	
S4B);	in	particular,	collectively,	whereas	the	Clostridiales	accounted	for	about	the	75	%	of	detected	
bacteria,	 the	 relative	 abundance	 of	 members	 of	 the	 order	 Bacteroidales	 was	 lower	 than	 10	 %	
(Supplementary	Figure	S4B).	On	the	contrary,	in	our	previous	studies,	we	found	that	Bacteroidales,	
and	 particularly	 the	 genera	 Bacteroides	 and	 Prevotella,	 were	 dominant	 genera	 of	 the	 faecal	
microbiota	of	the	healthy	volunteers	(Ferrario	et	al	2014,	Gargari	et	al	2016).	Therefore,	in	order	to	
assess	 if	 the	 observed	 expansion	 of	 Clostridiales	 compared	 to	 Bacteroidales	 is	 an	 actual	
microbiological	 feature	 of	 the	 investigated	 IBS	 patients,	 we	 analyzed	 additional	 faecal	 samples	
collected	from	16	healthy	adults	through	16S	rRNA	gene	profiling	adopting	the	same	protocol	used	
for	IBS	samples.	The	obtained	results	indicated	that	Clostridiales	are	largely	dominant	also	in	the	
feces	 of	 control	 subjects	 (Figure	 S4C),	 demonstrating	 that	 the	 alteration	 of	 the	
Clostridiales/Bacteroidales	 ratio	 observed	 in	 IBS	 samples	 depended	 on	 technical	 issues	 and,	
probably,	 on	 the	 protocol	 used	 for	 the	 extraction	 of	 metagenomic	 DNA	 from	 feces.	 In	 fact,	
differently	from	the	present	study,	in	our	previous	works	we	extracted	the	faecal	metagenomic	DNA	
with	a	commercial	kit	that	did	not	include	a	cell	breaking	step	with	a	bead	beater,	plausibly	resulting	
in	the	underestimation	of	the	Gram	positive	bacteria	(e.g.	Clostridiales),	which	have	a	stronger	cell	
wall	then	the	Gram	negative	cells	(e.g.	Bacteroidales).	
Overall,	these	data	indicate	that	the	bacterial	ecological	diversity	indexes	of	the	faecal	microbiota	
do	 not	 vary	 significantly	 among	 IBS	 subtypes.	 The	 results	 of	 this	 study	 evidenced	 a	 general	
dominance	 of	 Clostridiales	 bacteria	 in	 the	 faecal	 samples	 collected	 from	 both	 IBS	 and	 control	
subjects.	
3.3.3.2	IBS-C	and	IBS-D	faecal	samples	are	differently	enriched	of	OTUs	
ascribed	to	Clostridiales	
Subsequently,	microbiomic	data	were	examined	with	 the	DESeq2	negative	binomial	 distribution	
method	to	infer	differential	relative	abundances	at	the	OTU	level	between	IBS	subtypes.	The	analysis	
was	 performed	 both	 on	 single	 and	 median	 profiling	 data,	 excluding	 IBS-M	 subtype	 because	
constituted	 by	 a	 too	 low	 number	 of	 patients	 (n=3)	 to	 allow	 the	 identification	 of	 significant	
differences.	We	found	that	several	OTUs	discriminated	the	three	IBS	subtypes	considered	(Figure	2	
and	Supplementary	Figure	5).	A	summary	of	the	number	of	significantly	different	OTUs	is	shown	in	
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the	 Venn	 diagram	 of	 Figure	 2A.	 In	 specific,	 the	 analysis	 of	 median	 profiling	 data	 revealed	 26	
significantly	different	OTUs	between	IBS-U	and	IBS-C,	11	of	which	were	also	found	analyzing	single	
profiling	data	(Figure	2B	and	Supplementary	Figure	5);	19	OTUs	distinguished	IBS-U	from	IBS-D,	6	
of	which	were	also	found	analyzing	single	profiling	data	(Figure	2B	and	Supplementary	Figure	5).	
The	highest	number	of	dissimilarities	was	found	between	IBS-C	from	IBS-D:	85	OTUs	had,	in	fact,	a	
significantly	different	relative	abundance,	39	of	which	found	also	analyzing	the	single	profiling	data	
(Figure	 2B	 and	 Supplementary	 Figure	 5).	 Largely	 most	 of	 the	 discriminating	 OTUs	 were	
taxonomically	 ascribed	 to	 the	 order	 Clostridiales	 (Figure	 2B	 and	 Supplementary	 Figure	 5);	
particularly,	 IBS-C	 were	 distinguished	 from	 IBS-D	 by	 numerous	 Clostridiales-associated	 OTUs	
belonging	 to	 the	 families	 Ruminococcaceae	 (in	 particular,	 the	 genus	 Ruminococcus)	 and	
Lachnospiraceae.	In	addition,	two	OTUs	ascribed	to	Bifidobacterium	adolescentis	were	increased	in	
IBS-C	 whereas	 OTUs	 associated	 to	 the	 order	 Bacteroidales	 and	 to	 the	 Firmicutes	 species	
Eubacterium	biforme	were	enriched	in	IBS-D	samples	(Figure	2B	and	Supplementary	Figure	5).	
Overall,	these	results	indicate	that	the	faecal	microbiotas	of	IBS-C	and	IBS-D	are	characterized	by	a	
different	 distribution	 of	 Clostridiales	 taxonomic	 units,	 whereas	 the	 faecal	 microbiota	 of	 IBS-U	
samples	possesses	compositional	features	which	are,	in	general,	in	the	intermediate	between	IBS-C	
and	IBS-D.	
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Fig. 2B 
104	
	
	
	
Figure	 2.	 OTUs	 distinguishing	 IBS	 subtypes	 determined	 by	 using	 the	 DESeq2	 negative	 binomial	
distribution	method	on	16S	rRNA	gene	profiling	data	of	 five	 faecal	samples	per	patient.	A,	Venn	
diagrams	summarizing	the	number	of	OTUs	that	discriminate	IBS	subtypes	on	the	basis	of	16S	rRNA	
gene	profilig	data	of	a	single	sample	(single	profiling	data)	and	five	samples	(median	profiling	data)	
per	patient.	C,	IBS	with	constipation	(IBS-C);	D,	IBS	with	diharrea	(IBS-D);	U,	unsubtyped	IBS	(IBS-U).	
Overrepresented	OTUs	are	reported	with	the	same	color	of	the	letter	indicanting	the	IBS	subtype.	
B,	 IBS	subtype-discriminating	OTUs	according	to	median	profiling	data	and	their	correlation	with	
host	physiological	and	clinical	parameters.	OTUs	that	distinguished	IBS	subtypes	also	according	to	
single	profiling	data	analysis	are	reported	in	bold.	The	heatmap	on	the	left	represents	the	mean	of	
normalized	 relative	 abundances	 of	 the	 reported	 OTUs.	 The	 taxonomic	 lineage	 of	 each	 taxon	 is	
shown;	p,	phylum;	c,	class;	o,	order;	f,	family;	g,	genus;	s,	species.	Positive	fold	changes	(shown	on	
a	red	background)	designate	OTU	overrepresentation	in	the	IBS	subtype	indicated	in	the	column	on	
the	 left	 of	 the	 Normalized	 Base	Mean;	 negative	 fold	 changes	 (shown	 on	 a	 green	 background)	
designate	the	OTU	overrepresentation	in	the	IBS	subtype	indicated	in	the	column	on	the	right	of	the	
Normalized	 Base	 Mean.	 The	 heatmap	 in	 the	 right	 panel	 represents	 R-value	 of	 Spearman’s	
correlation	 between	 the	 OTU	 and	 host’s	 parameters.	 Plus	 signs	 are	 according	 to	 Kendall	 rank	
correlation:	+,	P<0.01;	++,	P<0.001.	
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3.3.3.3	IBS	subtypes	are	characterized	by	altered	faecal	levels	of	short	
chain	fatty	acids	
The	intestinal	levels	of	lactate	and	the	short	chain	fatty	acids	(SCFAs)	acetate,	butyrate,	isobutyrate,	
valerate,	 isovalerate	 and	 propionate	 were	 quantified	 in	 the	 IBS	 faecal	 samples	 and	 used	 to	
characterize	the	IBS	subtypes.	As	for	the	faecal	microbiota	composition,	the	analyses	of	the	SCFAs	
were	 carried	out	 considering	 the	 levels	determined	 in	 a	 single	 faecal	 sample	per	patient	 (single	
analysis	SCFA	levels,	n=37;	Supplementary	Figure	6)	and	the	median	values	of	five	measurements	
per	patient	(median	SCFA	levels,	n=37;	Figure	3A).	The	organic	acids	were	also	quantified	in	the	IBS-
M	 faecal	 samples,	 but	 this	 subgroup	 was	 excluded	 from	 statistical	 analyses	 due	 to	 the	 limited	
number	of	patients	(n=3).	
We	found	that	the	faecal	levels	of	SCFAs	clearly	distinguished	IBS-C	from	IBS-D	and	IBS-U	samples.	
In	detail,	the	levels	of	acetate,	butyrate,	propionate	and	valerate,	were	significantly	higher	in	IBS-D	
than	IBS-C.	In	addition,	faecal	concentrations	of	acetate,	butyrate	and	propionate	were	higher	in	
IBS-U	than	IBS-C.	Compared	to	all	IBS	samples	considered	together,	the	faecal	level	of	acetate	was	
significantly	 lower	 in	 IBS-C,	whereas	 the	 faecal	 level	of	valerate	was	 significantly	higher	 in	 IBS-D	
(Figure	 3A).	 No	 significant	 differences	 among	 IBS	 subgroups	 were	 observed	 for	 isobutyrate,	
isovalerate	and	lactate	(Figure	3A).	
Subsequently,	a	principal	component	analysis	(PCA)	was	performed	to	discriminate	samples	on	the	
basis	of	faecal	SCFA	levels.	As	evidenced	by	the	PCA	bi-plot	depicted	in	Figure	3B,	increased	levels	
of	acetate,	butyrate	and	propionate	characterize	IBS-D	samples	and	distinguish	them	from	IBS-C;	on	
the	other	hand,	IBS-U	samples	are	located	in	an	intermediate	area	of	the	plot	or	in	proximity	of	IBS-
D	samples.	
Overall,	these	results	indicate	that	IBS-C	patients	are	characterized	by	reduced	levels	of	the	most	
abundant	faecal	SCFAs	compared	to	IBS-U	and,	more	evidently,	IBS-D	subjects.	
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Figure	 3.	 Short	 chain	 fatty	 acids	 (SCFAs)	 in	 faecal	 samples	 of	 IBS	 patients.	 A,	medians	 of	 SCFA	
concentrations	in	five	faecal	samples	per	IBS	patient	(n=37).	Statistical	significances	are	according	
to	Mann-Whitney	test;	*,	P<0.05;	**,	P<0.01.	B,	Principal	component	analysis	(PCA)	biplot	of	SCFAs	
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(represented	by	arrows)	and	 IBS	patients.	The	first	 two	coordinates	 (PC1	and	PC2)	are	displayed	
with	the	percentage	of	variance	explained	in	brackets.	
3.3.3.4	The	intestinal	microbial	ecosystem	reflects	clinical	features	of	IBS	
subtypes	
Finally,	we	performed	correlation	analyses	between	the	data	of	faecal	microbial	ecology	and	clinical	
parameters	of	the	IBS	patients.	To	this	aim,	we	used	as	predictors	the	faecal	levels	of	SCFAs	or	the	
relative	abundances	of	the	OTUs	that	we	found	to	be	significantly	different	between	IBS	subtypes;	
on	 the	other	hand,	 the	dependent	 variables	 considered	were	 SCFAs,	 Bristol	 stool	 scale	data	 (to	
assess	bowel	habits),	abdominal	pain/discomfort	score,	faecal	levels	of	IgA	and	cytokines	(TGFβ,	IL6,	
IL8,	IL10,	IL12,	IFNγ,	and	TNFα),	and	HADS	and	SF-12	questionnaire	data	(to	evaluate	anxiety	and	
depression,	and	quality	of	life,	respectively)	(Cremon	et	al.,	2017).	
We	found	that	host	parameters	correlated	significantly	to	numerous	OTUs	(Figure	2B).	Notably,	we	
found	that	most	Clostridiales	OTUs	enriched	in	IBS-C	negatively	correlated	with	SCFAs	and	cytokines	
compared	to	the	Clostridiales	OTUs	increased	in	IBS-D	(Figure	2B).	In	specific,	the	Clostridiales	OTUs	
enriched	 in	 IBS-C	 samples	 were	 negatively	 correlated	 with	 the	main	 faecal	 SCFAs	 (i.e.	 acetate,	
propionate	 and	 butyrate),	whereas	many	Clostridiales	 OTUs	 overrepresented	 in	 IBS-D	 positively	
correlated	with	 the	 same	 SCFAs,	 particularly	 acetate	 (Figure	 2B).	Moreover,	most	 of	 the	 IBS-C-
enriched	OTUs	 that	were	 inversely	 linked	 to	SCFAs,	at	 the	 same	 time,	 correlated	positively	with	
several	cytokines	and	negatively	with	 IgA	and	 IFNγ.	Conversely,	great	part	of	 the	 IBS-D-enriched	
OTUs	that	were	positively	associated	to	SCFAs,	were	also	positively	correlated	with	the	faecal	type	
determined	 through	 the	 Bristol	 stool	 scale	 (Figure	 2B).	 Accordingly,	 we	 also	 found	 a	 positive	
correlation	between	 the	 faecal	 type	 and	acetate,	 propionate	 and	butyrate,	which	 also	 inversely	
correlated	with	IL10	and	IL12.	Furthermore,	acetate	and	propionate	were	positively	correlated	with	
IFNγ	and	depression	score	(Figure	4).	
Overall,	these	results	indicate	that	the	differential	representation	of	Clostridiales	OTUs	between	IBS	
subtypes	is	associated	with	altered	levels	of	intestinal	SCFAs;	then,	in	turn,	both	OTUs	and	SCFAs	
are	associated	with	faecal	cytokine	levels	and	stool	consistency.	
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Figure	4.	Short	chain	fatty	acids	(SCFAs)	in	IBS	subtypes	and	their	correlation	with	host	physiological	
and	clinical	parameters.	The	heatmap	on	the	left	represents	the	median	values	(reported	as	mmol	
per	kg	of	feces)	of	SCFAs	in	each	IBS	subtype.	The	heatmap	in	the	right	panel	represents	R-value	of	
Spearman’s	correlation	between	SCFAs	and	host’s	parameters.	Astericks	are	according	to	Kendall	
rank	correlation:	*,	P<0.05;	**,	P<0.01;	***,	P<0.001.	
	
3.3.4	Discussion	
The	primary	aim	of	the	present	study	was	to	characterize	the	gut	microbiota	in	IBS	subtypes.	To	this	
purpose,	we	carried	out	16S	rRNA	gene	profiling	and	SCFAs	quantification	 in	198	faecal	samples	
obtained	from	40	IBS	patients	enrolled	in	5	different	Italian	hospitals	(Cremon	et	al.,	2017).	
The	temporal	instability	is	a	distinguishing	feature	of	the	intestinal	microbiota	associated	with	IBS	
(Durban	et	al.	2013,	Matto	et	al.	2005,	Maukonen	et	al.	2006);	for	this	reason,	it	was	suggested	that	
studies	aimed	at	characterizing	the	gut	microbiota	in	IBS	should	include	multiple	time	points	(Collins	
2014).	Accordingly,	in	this	study,	we	based	microbiota	analyses	on	data	obtained	from	five	faecal	
samples	collected	at	4-week	intervals	from	each	patient.	These	samples	derive	from	a	randomized	
cross-over	intervention	trial	that	assessed	the	clinical	efficacy	of	a	probiotic	product.	Although	we	
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are	aware	that	treatment	may	have	affected	the	intestinal	microbiota	of	IBS	patients,	we	believe	
that	the	benefits	of	using	five	different	faecal	samples	per	subject	are	greater	than	the	possible	bias	
and	may	permit	a	more	 reliable	 identification	of	 gut	microbiota	biomarkers	 for	 IBS	 subtypes.	 In	
specific,	all	 the	analyses	have	been	carried	out	also	considering	the	only	data	at	baseline	 (single	
sample	data	analysis);	single	sample	data	analysis	implies	a	mistake	due	to	the	great	variability	of	
the	gut	microbiota	in	IBS	subjects,	whereas	the	analysis	with	the	median	data	of	five	samples	per	
subject	may	determine	an	error	due	to	the	subject-dependent	response	to	the	probiotic	treatment.	
The	 two	potential	errors	are	compensated	by	 the	combined	use	of	 the	 results	derived	 from	the	
analyses	of	single	and	median	data.	We	believe,	therefore,	that	those	OTUs	and	SCFAs	that	resulted	
significantly	different	between	IBS	subtypes	with	the	analysis	of	both	populations	of	data	can	be	
most	plausibly	considered	valid	biomarkers.	
Several	studies	focused	on	the	characterization	of	the	microbiota	in	IBS,	with	particular	attention	to	
the	 identification	 of	 microbial	 markers	 distinguishing	 this	 dysfunction	 from	 healthy	 condition	
(Zhuang	et	al.	 2017);	however,	much	 less	attention	has	been	 spent	 to	 compare	 the	 IMEs	of	 IBS	
subtypes.	 In	 this	 context,	 recently,	 Tap	 and	 collaborators	 reported	 that	 neither	 richness	 nor	
variability	of	the	intestinal	microbiota	differed	among	IBS	groups	(Tap	et	al.	2017).	Accordingly,	we	
did	not	find	significant	differences	in	both	α-	and	β-diversity	among	the	different	IBS	subtype.	In	a	
previous	 study,	 Jeffery	et	al.	 (Jeffery	et	al.	 2012)	used	pyrosequencing	of	 the	16S	 rRNA	gene	 to	
determine	 the	microbiota	 composition	 in	a	 faecal	 specimen	 from	37	 IBS	patients.	Notably,	 they	
identified	distinct	 IBS	patients’	subsets,	which	however	did	not	correspond	to	the	traditional	 IBS	
subtypes	 (Jeffery	et	al.	 2012).	On	 the	contrary,	 in	 the	present	 study,	we	 found	 that	 the	 relative	
abundance	of	numerous	OTUs	were	significantly	different	among	IBS	subtypes.	Particularly,	here	
we	 report	 that	 major	 differences	 exist	 in	 Clostridiales	 OTUs	 between	 IBS-C	 and	 IBS-D	 feces;	
conversely,	IBS-U	faecal	samples	differed	much	less	from	IBS-C	and	IBS-D	in	terms	of	OTUs.	
In	 light	of	 the	rapidly	expanding	 literature	demonstrating	the	clinical	efficacy	of	dietary	patterns	
based	 on	 drastically	 reduced	 "Fermentable,	 Oligo-,	 Di-,	 Mono-saccharides	 and	 Polyols"	 (low-
FODMAP	diet)	(Eswaran	et	al.	2016),	we	can	speculate	that	Clostridiales	bacteria	in	the	gut	of	IBS	
patients	 may	 represent	 a	 therapeutic	 target.	 FODMAPs,	 in	 fact,	 are	 preferential	 fermentation	
substrates	 for	 the	 intestinal	 Clostridiales	 bacteria	 (Flint	 et	 al.	 2012);	 accordingly,	 several	 trials	
demonstrated	that	these	bacteria	may	be	affected	by	reduced	FODMAP	intake	(Chumpitazi	et	al.	
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2014,	 Halmos	 et	 al.	 2015,	McIntosh	 et	 al.	 2016).	 Therefore,	 low-FODMAP	 diet	 can	 be	 properly	
considered	a	Clostridiales-modulating	intervention.	
Many	OTUs	 that	 discriminated	 IBS-C	 from	 IBS-D	 samples	 belonged	 to	 the	Clostridiales’	 families	
Ruminococcaceae	 and	 Lachnospiraceae.	 The	 importance	 of	 these	 gut	 bacteria	 in	 IBS	 was	 also	
evidenced	 by	 the	 study	 of	 Tap	 et	 al.,	 who	 defined	 a	 composite	 gut	microbial	 signature	 for	 IBS	
severity	 constituted	 by	 90	 OTUs,	 among	 which,	 at	 the	 family	 level,	 principally	 OTUs	 within	
Lachnospiraceae	 and	 Ruminococcaceae	 were	 found	 (Tap	 et	 al.	 2017).	 Lachnospiraceae	 and	
Ruminococcaceae	 are	 the	most	 commonly	 retrieved	 families	 in	 the	 active	 intestinal	microbiota	
(Peris-Bondia	et	al.	2011)	and	are	considered	the	principal	degraders	of	plant	carbohydrates	in	the	
human	colon	 (Flint	et	al.	 2012).	 For	 instance,	 inside	 the	Ruminococcaceae	 family,	Ruminococcus	
champanellensis	 is	 the	only	known	human	 intestinal	bacterium	that	can	degrade	microcrystaline	
cellulose	 (Chassard	 et	 al.	 2007),	 whereas	 certain	 strains	 of	 Faecalibacterium	 prausnitzii	 were	
reported	to	catabolize	apple	pectin;	furthermore,	bacteria	phylogenetically	related	to	Ruminococcus	
albus	were	demonstrated	to	utilize	galactomannan	(Salyers	et	al.	1977).	Pectin	can	also	be	degraded	
by	 the	 species	 Lachnospira	 pectinoschiza,	which	 belongs	 to	 the	 family	 Lachnospiraceae	 just	 like	
Bryantella	formatexigens,	reported	to	have	cellulolytic	activity	(Wolin	et	al.	2003),	and	Roseburia	
intestinalis	and	Butyrivibrio	fibrisolvens,	two	species	that	may	utilize	xylan	(Chassard	et	al	2007).	The	
degradation	of	plant	material	by	members	of	the	families	Ruminococcaceae	and	Lachnospiraceae	in	
the	human	colon	directly	brings	to	SCFAs	as	main	products	of	their	energy	metabolism		(Flint	et	al.	
2012).	It	is	well	known,	in	fact,	that	these	bacterial	families	include	the	most	important	butyrate-
producing	microorganisms	of	the	human	gut	such	as	the	genera	Faecalibacterium	and	Roseburia	
(Barcenilla	et	al.	2000,	Louis	et	al.	2010),	as	well	as	bacteria	that	can	produce	acetate	from	reductive	
acetogenesis	 (Bernalier	 et	 al.	 1996,	 Rey	 et	 al.	 2010),	 and	 butyrate	 or	 propionate	 from	 lactate	
utilization	(Duncan	et	al.	2004,	Rios-Covian	et	al.	2016).	
Considering	the	above-mentioned	 literature,	 the	observed	differential	OTU	distribution	between	
IBS-C	 and	 IBS-D	 let	 presume	 that	 the	 IBS	 subtypes	 may	 have	 dissimilar	 faecal	 levels	 of	 SCFAs.	
Accordingly,	we	found	significantly	lower	levels	of	acetate,	butyrate,	propionate	and	valerate	in	IBS-
C	samples.	Notably,	in	our	study,	such	differences	were	found	to	be	significant	also	considering	the	
data	 calculated	 as	median	of	 five	 determinations	 per	 subject	 over	 a	 period	of	 about	 4	months,	
demonstrating	that	the	observed	alterations	are	stable	over	time.	
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Scientific	 literature	 on	 intestinal	 SCFAs	 in	 IBS	 is	 quite	 limited	 and	 contradictory,	 showing	 no	
alteration,	 augmented,	 or	 decreased	 levels	 compared	 to	 healthy	 controls	 (Halmos	 et	 al.	 2014,	
Mortensen	 et	 al.	 1987,	 Rajilic-Stojanovic	 et	 al.	 2015,	 Tana	 et	 al.	 2010,	 Treem	 et	 al.	 1996).	
Nevertheless,	our	data	are	in	accordance	with	the	study	of	Ringel-Kulka	et	al.	(Ringel-Kulka	et	al.	
2015),	 in	 which	 IBS-D	 patients	 (n=42)	 were	 shown	 to	 have	 significantly	 higher	 faecal	 levels	 of	
acetate,	propionate	and	butyrate	than	IBS-C	patients	(n=26).	Interestingly,	in	this	study	the	authors	
also	found	that	faecal	SCFA	concentrations	negatively	correlated	with	colon	transit	time.	This	result	
is	potentially	in	agreement	with	the	positive	correlation	we	found	between	faecal	type	(determined	
through	the	Bristol	stool	scale)	and	acetate,	propionate	and	butyrate.	The	link	between	colon	transit	
and	intestinal	SCFAs	in	IBS	subtypes	can	be	explained	by	two	possible	opposite	mechanisms	(Ringel-
Kulka	 et	 al.	 2015):	 (1)	 compared	 to	 IBS-C,	 IBS-D	patients	 are	 characterized	 by	 increased	 colonic	
fermentation	 that	 leads	 to	 higher	 faecal	 levels	 of	 SCFAs,	which	 stimulate	 the	 intestinal	motility	
(Fukumoto	et	al.	2003)	and,	then,	reduce	transit	time;	or	(2)	decreased	transit	time	in	IBS-D	patients	
slows	down	SCFAs	absorption,	determining	higher	SCFAs	concentration	in	the	feces	compared	to	
IBS-C.	 Here,	 we	 showed	 that	 several	 OTUs	 significantly	 enhanced	 in	 IBS-D	 compared	 to	 IBS-C	
correlated	positively	with	the	faecal	levels	of	SCFAs	(especially	acetate)	and	faecal	type;	at	the	same	
time,	a	number	of	OTUs	expanded	in	IBS-C	resulted	inversely	correlated	with	SCFAs.	Nevertheless,	
both	explained	scenarios	are	valid.	On	one	hand,	in	fact,	it	is	possible	that	the	different	distribution	
of	intestinal	bacteria	is	responsible	for	the	dissimilar	concentration	of	SCFAs	in	IBS	subtypes.	On	the	
other	hand,	 it	 can	be	even	 speculated	 that	bacteria	 in	 the	 colon	may	be	differently	 affected	by	
modified	 intestinal	 transit	 (for	 instance	due	to	variable	adhesion	ability	and/or	cell	 reproduction	
rate)	 with	 the	 consequent	 modification	 in	 the	 relative	 distribution	 of	 bacterial	 taxa	 in	 feces.	
However,	a	few	facts	are	potentially	in	support	of	the	first	scenario:	(i)	most	of	the	bacteria	that	
distinguish	IBS-C	from	IBS-D	feces	belong	to	taxa	known	to	be	SCFA	producers;	(ii)	it	is	known	that	
SCFAs	are	stimulators	of	colonic	motility	and	may	also	increase	the	osmotic	load	leading	to	diarrhoea	
(Fritz	et	al.	2005);	 (iii)	we	found	that	faecal	 levels	of	SCFAs	are	not	positively	associated	to	stool	
frequency,	as	we	would	expect	if	the	altered	colon	transit	time	was	the	main	trigger	of	the	observed	
differences	 between	 IBS	 subtypes.	 In	 summary,	 we	 think	 it	 is	 plausible	 to	 hypothesize	 a	 self-
perpetuating	mechanism,	in	which	an	initial	modified	colon	transit	time	(determined	by	any	possible	
trigger)	gives	rise	to	intestinal	dysbiosis	which,	in	turn,	lead	to	to	altered	intestinal	levels	of	SCFAs	
that	may	exacerbate	or	maintain	the	altered	intestinal	motility.	 	
112	
	
	
3.3.5	Supplementary	material	
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Figure	S1.	Principal	coordinates	analysis	of	weighted	(A)	and	unweighted	(B)	Unifrac	distances	based	
on	16S	rRNA	gene	profiling	data.	Lines	connect	samples	belonging	to	the	same	patient.	The	first	two	
coordinates	(PC1	and	PC2)	are	displayed	with	the	percentage	of	variance	explained	in	brackets.	
 
Figure	S2.	Principal	coordinates	analysis	of	Unifrac	distances	based	on	16S	rRNA	gene	profiling	data	
of	a	single	faecal	sample	collected	from	40	IBS	patients.	The	first	two	coordinates	(PC1	and	PC2)	are	
displayed	with	the	percentage	of	variance	explained	in	brackets.	
A 
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Figure	S3.	Within-subject	(alpha)	diversity	of	faecal	samples	from	IBS	patients	determined	through	
four	different	estimators.	Scatter	dot	plots	show	data	from	a	single	faecal	sample	per	subject	(panel	
A;	n	=	40)	and	medians	of	the	data	from	five	faecal	samples	per	subject	(panel	B,	n	=	39).	Statistical	
significances	are	according	to	Mann-Whitney	test.	
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Figure	S4.	Analyses	of	enterotypes	in	IBS	faecal	samples.	A,	Principal	Coordinates	Analysis	(PCoA;	
the	first	two	principal	components	are	shown);	clustering	was	based	on	genus	relative	abundance	
using	JSD	distance	and	the	Partitioning	Around	Medoids	(PAM)	algorithm.	The	optimal	number	of	
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clusters	was	determined	through	the	Calinski-Harabasz	(CH)	index	and	the	Silhouette	coefficient.	B,	
Tukey	boxplots	of	the	dominant	bacterial	genera	and	orders	in	IBS	faecal	samples.
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Figure	S5.	OTUs	distinguishing	IBS	subtypes	determined	by	using	the	DESeq2	negative	binomial	distribution	method	on	16S	rRNA	gene	profiling	data	
of	a	single	faecal	sample	per	patient.	The	colors	in	the	heatmap	represents	the	mean	of	normalized	relative	abundances	of	the	reported	OTUs.	The	
taxonomic	 lineage	of	 each	 taxon	 is	 shown;	 p,	 phylum;	 c,	 class;	 o,	 order;	 f,	 family;	 g,	 genus;	 s,	 species.	 Positive	 fold	 changes	 (shown	on	 a	 red	
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background)	indicate	OTU	overrepresentation	in	IBS-U	(panels	A	and	B)	and	IBS-C	(panel	C);	negative	fold	changes	(shown	on	a	blue	background)	
indicate	an	increase	of	OTU	relative	abundance	in	IBS-C	(panel	A)	and	IBS-D	(panel	B	and	C).	
Figure	S6.	Levels	of	short	chain	fatty	acids	determined	in	a	single	faecal	sample	per	IBS	patient	(n=40).	Statistical	significances	are	according	to	
Mann-Whitney	test;	*,	P<0.05;	**,	P<0.01.	
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4.	Conclusions	
The	analysis	of	the	data	collected	during	the	three	studies	presented	 in	this	PhD	thesis	revealed	
significant	 correlations	 between	 the	 intestinal	 microbial	 ecosystem	 and	 specific	 physiological	
parameters,	characteristic	for	the	physiological	conditions	under	study.	Therefore,	these	findings	
suggest	that	the	differential	abundance	of	specific	OTUs	could	be	used	as	a	biomarker	for	a	specific	
host	condition.	
The	results	obtained	and	analysed	in	this	PhD	work	confirmed	the	interactions	among	the	human	
organism	(host),	its	microbiota	and	the	surrounding	environment,	which	form	the	so	called	“triangle	
of	 interaction”.	 Before	 the	 introduction	 of	 the	 concept	 of	 the	 holobiont,	 scientific	 research	
approached	 human	 health	 issues	 omitting	 to	 consider	 the	 intestinal	 microorganisms	 and	 their	
products.	However,	the	new	and	increasing	knowledge	on	the	gut	microbiota	and	microbiome	is	
clearly	demonstrating	the	importance	of	the	intestinal	microorganisms	as	mediators	of	the	effects	
that	foods	and	drugs	may	have	on	human	health.	Each	stimulus	coming	from	the	environment	and	
each	 kind	 of	 dietary	 intervention	 or	 pharmaceutical	 treatment	 does	 also	 have	 an	 impact	 on	
microbiota	 composition,	 and	 on	 the	 other	 hand	 the	microbiota	 can	 impact	 on	 the	 intervention	
effects.	This	“interfering”	activity	exerted	by	the	microbiota	cannot	only	amplify	or	minimize	the	
end	effect,	but	even	invert	or	annul	it.	The	discovery	and	characterization	of	these	processes	will	
provide	the	foundation	for	the	creation	of	new	treatments	or	new	behaviour	recommendations,	
and	permit	the	prediction	of	the	efficacy	of	specific	treatments	for	distinct	category	of	people.	
4.1	 Conclusion	 of	 the	 probiotic	 B.	 bifidum	 Bb	
crossover	intervention	trial	
The	 intervention	 trial	 based	 on	 the	 administration	 of	 B.	 bifidum	 strain	 Bb	 has	 shown	 that	 the	
probiotic	 treatment	 modified	 the	 relative	 abundances	 of	 bacterial	 taxa	 that	 have	 often	 been	
associated	 with	 healthy	 conditions.	 The	 treatment	 modulated	 the	 faecal	 levels	 of	 butyrate,	 a	
microbial	metabolite	exerting	multiple	effects	on	gut	health.	Therefore,	the	daily	consumption	of	B.	
bifidum	Bb	cells	may	positively	affect	human	health;	however,	as	for	most	dietary	interventions,	the	
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current	state	of	knowledge	does	not	allow	us	to	better	define	the	significance	of	any	taxonomic	or	
metabolite	changes	of	the	intestinal	microbial	ecosystem	on	the	host	health.	
In	a	wider	perspective,	the	PROBIOTA-Bb	trial	contributes	to	the	field	of	research	on	probiotics	in	
healthy	populations,	which	is	currently	attracting	significant	attention	in	the	context	of	probiotic	
health	 claim	 assessment	 by	 the	 EFSA.	 In	 particular,	 our	 study	 demonstrates	 that	 a	 single	 daily	
administration	of	one	bacterial	strain	approximately	at	the	minimal	recommended	dose	(1	billion	
CFU	[Ministero	della	salute	2013])	can	modify	the	human	 intestinal	microbial	ecology	of	healthy	
(not	diseased)	adults	 in	a	significant	 fashion.	These	 findings	emphasize	the	need	to	reassess	 the	
notion	that	probiotics	do	not	influence	the	complex	and	stable	intestinal	microbial	ecosystem	of	a	
healthy	 individual	 and	 the	 importance	of	 a	 proper	 intervention	 setting	 coupled	with	 the	 use	 of	
adequate	analytical	and	bioinformatic	tools.	
4.2	Conclusion	of	the	Children’s	dyslipidemia	single	
arm	intervention	trial	
The	results	of	this	study	support	the	hypothesis	that	young	individuals	with	primary	hyperlipidemia	
possess	 an	 dysbiotic	 intestinal	 microbial	 ecosystem,	 which	 could	 plausibly	 contribute	 to	 the	
abnormal	lipid	profile	of	these	subjects.	A	limitation	of	this	study	is	the	small	sample	size,	which	may	
reduce	the	potential	robustness	of	the	obtained	results.	Moreover,	further	studies	focusing	on	the	
mechanisms	involved	in	such	hypothesized	association	are	warranted.	
In	the	last	years,	several	in	vitro	and	in	vivo	studies	demonstrated	the	ability	of	nuts	to	modulate	
the	 abundance	 of	 specific	 microbial	 taxa	 of	 the	 gut	 microbiota	 and	 change	 the	 intestinal	
concentration	of	SCFAs	(Burns	et	al.	2016,	Liu	et	al.	2016,	Mandalari	et	al.	2010,	Schlörmann	et	al.	
2016,	Ukhanova	et	al.	2014).	Nonetheless,	the	research	mostly	focused	on	almonds	and,	to	the	best	
of	our	knowledge,	only	one	study	investigated	hazelnuts,	showing	the	increase	of	butyrate	through	
in	vitro	fermentation	by	a	human	faecal	sample	(Schlörmann	et	al.	2016).	In	conclusion,	our	study	is	
the	first	human	trial	investigating	the	potential	role	of	hazelnuts	as	IME	modulator	and,	in	specific,	
suggests	that	a	dietary	intervention	with	hazelnut	could	be	an	effective	and	practical	strategy	to	
positively	modulate	the	IME	of	hyperlipidemic	subjects.	
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4.3	 Conclusion	 of	 the	 IBS-subtypes	 observational	
study	
This	 descriptive	 study	 demonstrates	 that	 the	 altered	 distribution	 of	 bacteria	 within	 the	 Gram-
positive	 order	 Clostridiales	 distinguishes	 the	 intestinal	 microbial	 ecosystem	 of	 IBS	 subtypes,	
plausibly	 contributing	 to	 the	 observed	 altered	 faecal	 levels	 of	 the	 SCFAs	 acetate,	 butyrate	 and	
propionate.	 Our	 study	 proposes	 intestinal	 Clostridiales	 and	 colonic	 SCFAs	 as	 IBS	 subtypes	
biomarkers	that	can	also	potentially	represent	therapeutic	targets.	In	addition,	this	study	supports	
the	notion	that	distinct	therapeutic	approaches	should	be	developed	for	the	different	IBS	subtypes.
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lunghe	chiacchierate	su	Skype,	anche	se	separati	da	8	ore	di	fuso	orario.	Grazie	per	avermi,	più	di	
una	volta,	scaldato	in	un	caloroso	abbraccio	che	spesso	e	volentieri	non	avrei	meritato	di	accogliere.		
Un	pensiero	va	a	mio	fratello	Marco.	Vorrei	fargli	presente	che	non	studio	“Allevamento	dei	delfini”	
come	millantava	in	giro	(uso	il	passato	nella	speranza	che	tu	non	lo	faccia	ancora).	Spero	che	un	
giorno	tu	legga	l’introduzione	di	questa	tesi	così	da	convincerti	che	non	passo	le	giornate	in	vasca	
ad	 accarezzare	 mammiferi	 marini	 (per	 quanto	 potrebbe	 essere	 divertente	 e	 rilassante).		
	
	
	
	
		
	
	
